The cytochrome P450 complement of the myxobacterium Sorangium cellulosum So ce56 and characterization of two members, CYP109D1 and CYP260A1 by Khatri, Yogan
The cytochrome P450 complement of the myxobacterium 
Sorangium cellulosum So ce56 and characterization of two 
members, CYP109D1 and CYP260A1 
 
 
 
 
 
 
 
Dissertation 
zur Erlangung des Grades 
des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät III 
Chemie, Pharmazie, Bio- und Werkstoffwissenschaften 
der Universität des Saarlandes 
 
 
 
 
 
 
von 
 
Yogan Khatri 
(M. Sc. in Medical Microbiology) 
 
 
 
 
 
 
Saarbrücken 
2009 
 INDEX 
PUBLICATIONS RESULTING FROM THIS WORK 
DECLARATION 
ABBREVATIONS 
ABSTRACT 
Abstract (English version) 
Abstract (German version) 
SUMMARY 
Summary (English version) 
Zusammenfassung (German version) 
LIST OF FIGURES 
LISTS OF TABLES 
Table of content                                                                                                            Page nos 
GENERAL INTRODUCTION  
1. 1. Cytochrome P450  
1. 1. 1. General aspects  1 
1. 1. 2. Heme Structure in P450 2 
1. 1. 3. Structure of cytochrome P450 4 
1. 1. 4. Reactions and mechanism 5 
1. 1. 5. Electron transfer in cytochrome P450 systems 7 
1. 1. 6. Substrate binding properties of cytochrome P450 9 
1. 1. 7. Reactions catalyzed by P450 10 
1. 2. Myxobacteria  
1. 2. 1. Taxonomy 11 
1. 2. 2. Characteristic features of myxobacteria 13 
1. 2. 2. 1 Gliding motility 13 
1. 2. 2. 2. Fruiting body formation 13 
1. 2. 3. Application of myxobacterial secondary metabolites 14 
1. 2. 4. Sorangium cellulosum So ce56 15 
CHAPTER I   
The cytochrome P450 complement (CYPome) of Sorangium cellulosum So ce56 
1. Introduction 16 
2. Objectives 17 
 3. Materials and methods 
3. 1. Materials  
3. 1. 1. Bacterial Strains 18 
3. 1. 2. Proteins 18 
3. 1. 3. Oligonucleotides 18 
3. 1. 4. Vectors 20 
3. 2. Methods  
3. 2. 1. Bioinformatic study  
3. 2. 1. 1.   Bioinformatic analysis of P450s of So ce56  20 
3. 2. 1. 2. Phylogenetic analysis 21 
3. 2. 1. 3. Other bioinformatics studies related to P450s and 
neighboring ORF 
 
21 
3. 2. 2. Molecular biology methods  
3. 2. 2. 1. Isolation of genomic DNA  21 
3. 2. 2. 2. Plasmid isolation, purification and determination 
of the nucleic acid concentration 
 
22 
3. 2. 2. 3. Digestion of DNA with endonucleases 22 
3. 2. 2. 4. Ligation of DNA 22 
3. 2. 2. 5. Agarose gel electrophoresis and extraction of 
DNA from agarose gel 
 
23 
3. 2. 2. 6. Polymerase chain reaction and molecular cloning 23 
3. 2. 2. 7. Site-directed mutagenesis 26 
3. 2. 3. Microbiological Methods  
3. 2. 3. 1. Cultivation and storage of bacteria 27 
3. 2. 3. 2. Preparation of competent cells 27 
3. 2. 3. 2. 1. Preparation of electro-competent cells  27 
3. 2. 3. 2. 2. Preparation of chemical competent cells  27 
3. 2. 3. 3. Transformation of E. coli 28 
3. 2. 3. 3. 1. Heat shock transformation 28 
3. 2. 3. 3. 2. Electroporation 28 
3. 2. 4. Protein expression and purification  
3. 2. 4. 1. Heterologous gene expression of His6-cytochrome 
P450 
 
28 
3. 2. 4. 2. Cell lysis by sonication 29 
3. 2. 4. 3. Protein purification 29 
3. 2. 4. 4. Determination of the protein concentration 30 
3. 2. 4. 5. SDS (Sodium Dodecylsulfate) Polyacrylamide 
Gel Electrophoresis 
 
30 
3. 2. 5. Spectrophotometric characterization  
3. 2. 5. 1. Spectrophotometric characterization of P450s of 
So ce56 
30 
3. 2. 5. 2. Investigation of electron transfer partners 30 
3. 2. 6. Biophysical characterization 
3. 2. 6. 1. Circular dichroism (CD) measurement 31 
3. 2. 6. 2. Electron Paramagnetic Resonance (EPR) 
measurement 
31 
3. 2. 7. Mass measurement 33 
3. 2. 8. Screening of compound library 33 
4. Results  
4. 1. Bioinformatic analysis  
4. 1. 1. Cytochrome P450 complement of Sorangium 
cellulosum  So ce56 (CYPome of So ce56) 
35 
4. 1. 2. Phylogenetic relationship of So ce56 CYPome 37 
4. 1. 3. The relationship of P450s of So ce56  38 
4. 2. Genome mining of cytochrome P450  
4. 2. 1. P450 potentially involved in secondary metabolite 
formation 
41 
4. 2. 2. P450 with potential physiological role 42 
4. 2. 3. P450 clustered with regulatory elements 43 
4. 2. 4. P450 clustered with carbohydrate related 
regulatory elements 
 
45 
4. 2. 5. P450 clustered with a terpene cyclase 45 
4. 2. 6. P450 with unique cluster 46 
4. 2. 7. P450 clustered with hypothetical protein 47 
4. 3. Cloning, expression and purification of So ce56 cytochrome 
P450 
 
4. 3. 1. Amplification and cloning of Soce56 CYPome 48 
4. 3. 2. Heterologous expression of So ce56 CYPome 48 
4. 4. Spectrophotometric characterization 50 
4. 5. Biophysical characterization  
4. 5. 1. Circular Dichroism (CD) measurement of So ce56 
cytochrome P450 
55 
4. 5. 2. Electronic paramagnetic resonance (EPR) 
spectroscopy 
57 
4. 6. Mass determination and conformation of active form of P450  60 
4. 7. Determination of electron donors 62 
4. 8. Screening of compound library 63 
5. Discussion  
5. 1. Bioinformatic analysis 65 
5. 2. Genome mining of cytochrome P450  66 
5. 3. Expression, purifiation and characterization of 
cytochrome P450 
68 
6. Outlook 72 
7. Literature review 73-85 
 
 
CHAPTER II   
A. CYP109D1 from Sorangium cellulosum So ce56: A fatty acid hydroxylase 
 
A. 1. Introduction 86 
A. 2. Objective  87 
A. 3. Materials and methods  
A. 3. 1. Materials 88 
A. 3. 2. Methods 88 
A. 3. 3. Spin state shift and substrate dissociation constant 
determination 
88 
A. 3. 4. In vitro assay of fatty acid and derivatization 88 
A. 3. 5. Fatty acid hydroxylation and GC/MS analysis  89 
A. 4. Results  
A. 4. 1. Search for a fatty acid hydroxylating P450 of So ce56 91 
A. 4. 2. Spin state shift and substrate binding 93 
A. 4. 3. Characterization of different members of CYP109  
family of So ce56 94 
A. 4. 4. Fatty acid hydroxylation and characterization 95 
A. 3. 4. 1. Hydroxylation of saturated fatty acid by CYP109D1 96 
A. 4. 5. Comparison of hydroxylation patterns of saturated fatty 
acids obtained by other CYP109 families of So ce56 
 
102 
A. 4. 6. Hydroxylation of other fatty acids by CYP109D1  
A. 4. 6. 1. Hydroxylation of unsaturated fatty acid by CYP109D1 103 
A. 4. 6. 2. Hydroxylation of branched fatty acid by CYP109D1 105 
A. 5. Discussion 108 
 
 
B. CYP109D1 from Sorangium cellulosum So ce56: A terpenoid epoxidase/hydroxylase 
B. 1. Introduction  
B. 1. 1.  Terpenoid compound 112 
B. 1. 1. 1. Geraniol and nerol  113 
B. 1. 1. 2. Limonone 113 
B. 1. 1. 3. Ionone 114 
B. 1. 1. 4. Role of cytochrome P450 in preparation of ionone 
derivatives 
 
116 
B. 2. Objective  116 
B. 3. Material and methods  
B. 3. 1. Materials 117 
B. 3. 2. Synthesized compound 117 
B. 3. 3. Methods 117 
B. 3. 3. 1. In vitro assay  118 
B. 3. 3. 2. Gas chromatography coupled with mass spectrometry 
(GC-MS) analysis 
118 
B. 3. 3. 3. Thin layer chromatography (TLC) 119 
B. 3. 3. 4. Isolation of 3-hydroxy-α-ionone from reaction mixture 119 
B. 3. 3. 5. Computational methods 119 
B. 4. Results  
B. 4. 1. Expression and purification of recombinant CYP109D1 121 
B. 4. 2. Conversion of geraniol by CYP109D1 121 
B. 4. 3. Conversion of nerol by CYP109D1 122 
B. 4. 4. Conversion of limonene by CYP109D1 123 
B. 4. 5.  
B. 4. 5. 1. 
Conversion of ionone by CYP109D1 
Conversion of α-ionone 
 
125 
B. 3. 5. 2. Identification of the product of α-ionone oxidation 125 
B. 4. 6. Conversion of β-ionone 126 
B. 4. 7 Homology modeling and docking of CYP109D1 with 
α-ionone and β-ionone 
 
127 
B. 5. Discussion 129 
B. 6. Literature review 133-147 
 
 
CHAPTER III  
CYP260A1 from Sorangium cellulosum So ce56 
 
1. Introduction 148 
2. Objectives  149 
3. Materials and methods  
3. 1. Materials 150 
3. 2. Methods  
3. 2. 1. 
3. 2. 2. 
3. 2. 2. 1.  
3. 2. 2. 2. 
Screening of a compound library 
Analytical methods 
In vitro steroid assay 
In vitro nootkatone assay 
150 
 
150 
150 
3. 2. 2. 3. High performance liquid chromatography (HPLC) of 
steroids and nootkatone 
150 
3. 2. 2. 4. GC-MS analysis of nootkatone 151 
4. Results  
4. 1. Screening and validation of substrate/ligand 153 
4. 2. Selection of structural analogues of the Type I binding 
ligands  
153 
4. 3. Binding of steroids to CYP260A1 155 
4. 4. Conversion of steroids by CYP260A1 156 
4. 4. 1 Conversion of progesterone by CYP260A1 157 
4. 4. 2. Conversion of DOC by CYP260A1 159 
4. 4. 2. 1. Time dependent DOC conversion by CYP260A1 160 
4. 5. Conversion of nootkatone by CYP260A1  
4. 5. 1. 
4. 5. 2.  
4. 5. 3. 
4. 5. 4. 
Selection of nootkatone as a substrate 
Binding of nootkatone to CYP260A1 
Conversion of nootkatone 
GC-MS of nootkatone conversion 
163 
164 
165 
166 
5. Discussion  
5. 1. Substrate screening and conversion of analogues 
compound. 
167 
5. 2. Microbial conversion of progesterone and DOC  167 
5. 3. Triterpenoids and their biosynthesis in myxobacteria 172 
5. 4. Biotechnological application of CYP260A1  173 
6. Outlook 174 
7. Literature review 175-181 
Acknowledgment  
Appendix  
 
 
Publications resulting from this work 
 
A. Manuscripts 
 
1. Kerstin Maria Ewen, Frank Hannemann,Yogan Khatri,Olena Perlova, Reinhard 
Kappl, Daniel Krug, Jürgen Hüttermann, Rolf Müller and Rita Bernhardt (2009). 
Genome mining in Sorangium cellulosum So ce56 - identification and characterization 
of the homologous electron transfer proteins of a myxobacterial cytochrome P450. J. 
Biol. Chem., 284, 28590-8. 
2. Yogan Khatri, Marco Girhard, Anna Romankiewicz, Frank Hannemann, Vlada B. 
Urlacher, Michael C. Hutter and Rita Bernhardt (2009). Regioselective hydroxylation 
of sesquiterpenoids by CYP109D1 from Sorangium cellulosum So ce56 (submitted to 
Org. Biomol. Chem.) 
3. Marco Girhard, Tobias Klaus, Yogan Khatri, Rita Bernhardt and Vlada B. Urlacher 
(2009). Characterization of the versatile monooxygenase CYP109B1 from Bacillus 
subtilis. (under peer review in Appl. Microbiol. Biotech.) 
4. Yogan Khatri, Frank Hannemann, Kerstin M. Ewen, Olena Perlova, Alexander O. 
Brachmann, Dominik Pistorius, Rolf Müller and Rita Bernhardt (2009). The 
cytochrome P450 complement (CYPome) of Sorangium cellulosum So ce56 and 
identification of CYP109D1 as a new fatty acid hydroxylase (resubmitting to Chem. 
Biol).  
5. Yogan Khatri, Frank Hannemann, Marco Girhard, Vlada B. Urlacher and Rita 
Bernhardt (2009). Molecular cloning, expression and purification of P450 enzymes 
from the myxobacterium Sorangium cellulosum So ce56 and characterization of three 
fatty acid hydroxylases genes (in preparation)   
 
B. Patent application 
Yogan Khatri1, Rita Bernhardt1, Frank Hannemann1, Marco Girhard2 and Vlada B. 
Urlacher2. New biocatalyst for the epoxidation and hydroxylation of monoterpenes 
and sesquiterpenes (submitted). 
1Department of Biochemistry, Saarland University, D-66041 Saarbrücken, Germany 
2Institute of Technical Biochemistry, Universitaet Stuttgart, Allmandring 31, 70569 
Stuttgart, Germany. 
 
C. Presentaion 
 
1.        Yogan Khatri, Kerstin Ewen, Frank Hannemann, Olena Perlova; Rolf Müller and Rita 
Bernhardt (2008), The CYPome of myxobacteria (Sorangium cellulosum). Poster 
presentation - In 9th International Symposium on Cytochrome P450 Biodiversity and 
Biotechnology, June 8-12, Nice, France.  
DECLARATION 
 
I here by declare that this thesis is my original work and I have prepared it independently, 
except where specific reference is made to other sources. It has not been submitted in part 
either in German or in other country for any other degree. 
 
 
 
Yogan Khatri 
Place/date:  
Signature:  
  ABBREVIATIONS 
  
18-OH-B   18-hydroxy-corticosterone 
ACTH adrenocorticotrophic hormone 
ACP acyl carrier protein 
AdR adrenodoxin reductase 
Adx adrenodoxin 
Aldo aldosterone 
Amp    ampicillin 
APS ammonium persulfate 
ATP adenosine triphosphate 
CD circular dichroism 
CO carbon monoxide 
COD carbon monoxide difference spectra 
CYP cytochrome P450 
DMSO  dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxyribonucleotide triphosphate  
DOC deoxycorticosterone 
DTT dithiothreitol 
E. coli Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
EPR electron paramagnetic resonance 
ESI-TOF                    electron-spray ionization-time of flight 
Fad flavine adenine dinucleotide 
Fdx ferredoxin 
Fdr ferredoxin reductase 
FMN flavine mononucleotide 
GC-MS gas chromatography - mass spectrometry 
HPLC   high performance liquid chromatography 
IPTG isopropyl-β-D-thiogalactoside 
Kb kilobase 
kDa kilodalton 
KD   dissociation constant 
Mbp mega base pair 
NADPH nicotinamide adenine dinucleotide phosphate 
NMR     nuclear magnetic resonance 
OD optical density 
P450 cytochrome P450 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
Pfu Pyrococcus furiosus 
PKA protein kinase K 
PMSF   phenylmethylsulfonyl fluoride 
RT room temperature 
SDS sodium dodecyl sulfate 
Taq   Thermus aquaticus 
TEMED  N,N,N’,N’-tetramethylethylenediamine 
Tris tris(hydroxylmethyl)aminomethane 
UV     ultraviolet 
vis visible 
  
Standard abbreviations for amino acids 
 
A  Ala  Alanine     
L  Leu  Leucine 
R  Arg Arginine     
K  Lys  Lysine 
N  Asn  Asparagine     
M  Met  Methionine 
D  Asp  Aspartic acid     
F  Phe  Phenylalanine 
C  Cys  Cysteine     
P  Pro  Proline 
Q  Gln  Glutamine     
S  Ser  Serine 
E  Glu  Glutamic acid     
T  Thr  Threonine 
G  Gly  Glycine     
V  Val  Valine 
H  His  Histidine     
W  Trp  Tryptophan 
I  Ile  Isoleucine     
Y  Tyr  Tyrosine 
 
Units 
 
Current strength Ampere A 
Concentration Molar 
Micromolar 
M 
µM 
Length  Meter 
Centimeter 
M 
cm 
Mass Gram 
Micro gram                 
G 
µg
Molecular weight Dalton  
Kilodalton  
Da 
kDa 
Tension Volt V 
Electricity Watt W 
Temperature degree Celsius °C 
Volume Liter  
Mililiter  
Microliter  
L  
ml 
µl 
Wave length  Nanometer nm 
Time  Second (s) 
Minute (s) 
Hour(s) 
s  
min 
 hr 
      
       
       
ABSTRACT 
This is a very first systematic study of cytochrome P450s from Sorangium cellulosum So 
ce56. In chapter I, the open reading frames (ORFs) encoding twenty-one cytochrome P450s 
with nine novel families were identified, and a phylogenetic tree and a physical map were 
constructed. All P450 ORFs were cloned, expressed in Escherichia coli in a soluble form, 
purified and characterized. The heterologous redox partners for nine of the P450s were 
identified. A compound library (∼17,000 ligands) was screened with four P450s, and potential 
substrates and inhibitors were identified. In chapter II, CYP109D1 was shown as a new fatty 
acid hydroxylase. The GC-MS analysis of TMS-derivatized products of fatty acids showed 
sub-terminal ω-hydroxylation without any terminal (ω) product. In this chapter, CYP109D1 
was also shown as a new biocatalyst for the epoxidation and hydroxylation of monoterpenes 
like geraniol, nerol and limonene. Furthermore, the selective hydroxylation of 
sesquiterpenoids, α-ionone and β-ionone to 3-hydroxy-α-ionone and 4-hydroxy-β-ionone, 
confirmed by 1H NMR and 13C NMR, are also shown. The regioselective hydroxylation of the 
sesquiterpenes was also explained by docking models. In chapter III, steroids (progesterone 
and DOC) were identified as analogues of potential substrates found by the screening of the 
compound library with CYP260A1. HPLC analysis of the in vitro products demonstrated the 
hydroxylation of both the steroids. Moreover, nootkatone, a sesquiterpene, was also shown to 
be hydroxylated and/or epoxidated by this novel P450. 
 
ZUSAMMENFASSUNG  
Diese Arbeit ist die bislang erste systematische Untersuchung der Cytochrome P450 aus 
Sorangium cellulosum So ce56. In Kapitel I wurden die Offenen Leserahmen (ORF) für 21 
Cytochrome P450 mit neun neuen Familien identifiziert; ein phylogenetischer Baum und eine 
physikalische Genkerte wurden erstellt. Alle P450 ORFs wurden kloniert, in löslicher Form in 
Escherichia coli exprimiert, gereinigt und charakterisiert. Die heterologen Redoxpartner für 
neun der P450 wurden identifiziert. Eine Bibliothek (~17.000 Liganden) wurde mit vier P450 
gescreent und potentielle Substrate und Inhibitoren wurden identifiziert. Kapitel II beschreibt 
CYP109D1 als neue Fettsäurehydroxylase. GC-MS Analyse der TMS-derivatisierten 
Produkte der Fettsäuren zeigte ω-Hydroxylierung, aber kein terminales (ω) Produkt. In 
diesem Kapitel wurde CYP109D1 als ein neuer Biokatalysator für die Epoxidierung und 
Hydroxylierung von Monoterpenen gezeigt. Zudem wurden die Sesquiterpenoide α-ionon und 
β-ionon ebenso selektiv zu 3- Hydroxy-α-ionon bzw. 4-Hydroxy-β-ionon hydroxyliert, was 
mittels 1H NMR und 13C NMR Analysen bestätigt werden konnte. Die regioselektive 
Hydroxylierung der Sesquiterpene konnten auch durch Docking-Modelle erklärt werden. In 
Kapitel III wurden die Steroide Progesteron und DOC als physiologisch signifikante Analoga 
der Substrat-Hits für CYP260A1 identifiziert. HPLC Analyse der in vitro Produkte zeigte die 
Hydroxylierung beider Steroide. Darüber hinaus wurde auch das Sesquiterpen Nootkaton von 
diesem neuen Cytochrom wurde hydroxyliert und/oder epoxidiert. 
SUMMARY 
The cytochrome P450 superfamily plays a critical role in the bioactivation and detoxification 
of a wide variety of xenobiotics, in the biosynthesis of endogenous compounds and in the 
production of secondary metabolites. It also catalyzes late-stage stereo- and regiospecific 
oxidations when associated with polyketide biosynthetic gene clusters in bacteria. The 
presence of huge numbers of P450s in the genome of So ce56 high-light the potential role of 
P450s during the complex physiology of this microorganism. 
 
This work is a very first systematic study of cytochrome P450s done so far in myxobacteria. 
The open reading frames (ORFs) encoding twenty-one different cytochromes P450, eight 
ferredoxins and two reductases have been disclosed in the genome of Sorangium cellulosum 
So ce56. 
 
The chapter I deals with the bioinformatics analysis, cloning, expression, purification and 
characterization of the So ce56 cytochrome P450 complement (CYPome). The bioinformatic 
analysis of the P450s revealed nine novel P450 families (CYP259, CYP260, CYP261, 
CYP262, CYP263, CYP264, CYP265, CYP266, and CYP267). A phylogenetic tree and a 
physical map of the So ce56 CYPome was constructed. The genomic mining of the So ce56 
CYPome disclosed some important P450 features which could be useful for the prediction of 
potential substrates. We were able to find out that two of the P450s, CYP263A1 and 
CYP265A1, were clustered with a polyketidesynthase (PKS) and nonribosomal peptide 
synthetase (NRPS), respectively. Some P450s (CYP109C2, CYP110H1, CYP110J1, 
CYP260A1, CYP262A1, CYP262B1, and CYP261A1) are associated with regulatory 
elements. CYP264B1 was clustered with a terpene cyclase. Some of the other P450s 
(CYP124E1, CYP262A1 and CYP266A1) were clustered with neighbouring ORFs with 
potential physiological functions. In a unique cluster, two P450s (CYP109D1 and 
CYP259A1) were in close proximity and separated by only one ORF. The genomic mining 
also disclosed that none of the ferredoxins (Fdx) or ferredoxin reductases (FdR) was in an 
adjacent or neighbouring position with that of P450s. The ORFs of all the P450s of the 
CYPome were cloned, expressed in Escherichia coli in a soluble form and purified in an 
active form with a typical CO-difference peak at 448 or 450 nm. The characteristic apo- and 
holo-masses of some P450s were estimated and the biophysical properties (CD and EPR 
spectra) were studied for highly expressed P450s and for the representatives of new P450 
families (CYP109C1, CYP109C2, CYP109D1, CYP260A1, CYP264A1, CYP264B1, and 
CYP266A1). All measurements showed the typical nature of a P450 family member. 
Moreover, the absence of homologous redox partners was overcome for nine of the P450s 
(CYP109C1, CYP109C2, CYP109D1, CYP110J1, CYP124E1, CYP260A1, CYP264A1, 
CYP264B1, and CYP267B1) by heterologous electron donor partners from bovine adrenals, 
adrenodoxin (Adx) and adrenodoxin reductase (AdR). Furthermore, for four of the P450s 
(CYP109C1, CYP109C2, CYP260A1, and CYP266A1), potential substrates and inhibitors 
were screened with a compound library consisting of ∼17,000 substances.  
 
In the first part of Chapter II, considering the importance of fatty acids during the complex 
life cycle of myxobacteria, several potential fatty acid hydroxylases from So ce56 were 
identified. For the first time, a novel P450 enzyme, CYP109D1 was found to be a new fatty 
acid hydroxylase. The GC-MS analysis of the TMS-derivatized products of the fatty acids 
converted by CYP109D1 demonstrated the sub-terminal ω-hydroxylation without any 
terminal (ω) product for saturated fatty acids. The hydroxylation pattern of saturated fatty acid 
like, capric acid (C10) showed ω-1 and ω-2; lauric acid (C12) showed ω-1 to ω-3; tridecanoic 
acid (C13) and myristic acid (C14) showed ω-1 to ω-5, and palmitic acid (C16) showed ω-1 
to ω-6 hydroxylation. Furthermore, a unsaturated fatty acid, oleic acid (18:1cis9), was also 
tested and showed selective hydroxylation at ω-6 and ω-7 positions. The branched fatty acids, 
13-methyl myristic acid and 15-methyl myristic acid showed ω-2 to ω-6, and ω-2 to ω-5 
hydroxylation, respectively. The second part of chapter II illustrates the role of CYP109D1 as 
a new biocatalyst for the epoxidation and hydroxylation of monoterpenes and sesquiterpenes. 
CYP109D1 was able to catalyze the epoxidation of linear compounds like geraniol and nerol. 
The geraniol was converted into 2,3-epoxygeraniol, 6,7-epoxygeraniol and 2,3-,6,7-
diepoxygeraniol. In case of nerol, two epoxidated products, 2,3-epoxynerol and 6,7-
epoxynerol, were obtained. The epoxidated products of both the linear terpenoids were 
confirmed with the synthesized product as standards. Moreover, the conversion of the cyclic 
monoterpene, limonene, into hydroxylated and epoxidated products has also been shown. 
CYP109D1 also converted the sesquiterpenoids, α-ionone and β-ionone into the selectively 
hydroxylated products of 3-hydroxy-α-ionone and 4-hydroxy-β-ionone, respectively, which 
was confirmed by 1H NMR and 13C NMR. The regioselective hydroxylation of the 
sesquiterpenes was also studied by docking studies using a computer model of CYP109D1 
which gave a rational explanation for the observed selectivity and activities. All these data 
demonstrate not only the important role of CYP109D1 during terpenoid oxidation but also a 
potential biotechnological significance of this P450 for the production of selectively 
epoxidated and hydroxylated terpenoid derivatives with higher market values than the original 
substrates. 
 
The chapter III deals with the functional role of an additional novel member of the bacterial 
P450 family, CYP260A1. All the genes present in the close proximity of CYP260A1 in the 
genome code for hypothetical proteins. The individual homologue search done for each of the 
neighboring genes of CYP260A1 has no precise information for putative functions. 
Consequently, the potential putative substrates of CYP260A1 with respect to the genomic 
cluster could not be predicted. To overcome this, a compound library consisting of ∼17,000 
substances was screened with CYP260A1 and potential substrates as well as inhibitors were 
identified. Structural analogues of the Type I hits of the screening results were utilized and 
steroids as well as nootkatone were selected as potential substrates. The heterologous redox 
partners (Adx and AdR) were used for substrate (progesterone, DOC and nootkatone) 
conversion and the products were analysed in HPLC/GC-MS. CYP260A1 disclosed as a 
steroid hydroxylase and also sesquiterpene converter. CYP260A1 was able to hydroxylate 
progesterone and DOC. Progesterone was converted into more than three products, whereas 
DOC produced two major products during 1 hr of reaction time. One of the products has the 
same retention time as aldosterone and the other one was not identified. On successive 
increment of the incubation time of the in vitro assay, only the major product with the similar 
retention time of aldosterone was obtained. Since a steroid biosynthesis pathway in 
myxobacteria was already shown before, the steroid hydroxylation with CYP260A1 could 
have some physiological significance. Furthermore, CYP260A1 was also able to convert 
nootkatone, a sesquiterpene, into hydroxylated and/or epoxidated products. This gives new 
insights into the importance of CYP260A1 for steroid and terpenoid conversion having 
pharmaceutical and biotechnological applications. 
 
 
 
 
 
 
 
 
 
ZUSAMMENFASSUNG 
Die Cytochrom P450 Superfamilie spielt eine bedeutende Rolle in der Bioaktivierung und im 
Abbau einer großen Bandbreite von Xenobiotika, in der Biosynthese endogener 
Verbindungen und in der Produktion von sekundären Metaboliten. Darüber hinaus 
katalysieren sie, wenn sie in Bakterien mit Genklustern der Polyketidbiosynthese assoziiert 
sind, stereo- und regiospezifische Oxidationen. Die Anwesenheit einer großer Anzahl von 
P450 im Genom des So ce56 unterstreicht die wichtige Rolle innerhalb der seiner komplexen 
Physiologie dieses Mikroorganismus. 
 
Diese Arbeit repräsentiert die allererste systematische Untersuchung der Cytochrome P450 in 
Myxobakterien. Die offenen Leserahmen (OLRs) für 21 verschiedene Cytochrome P450, acht 
Ferredoxine und zwei Reduktasen wurden im Genom des Sorangium cellulosum So ce56 
identifiziert. 
 
Das erste Kapitel dieser Arbeit befasst sich mit der bioinformatischen Analyse, Klonierung, 
Expression, Reinigung und Charakterisierung des So ce56 Cytochrom P450 Komplements 
(CYPome). Die bioinformatische Analyse der P450 brachte neun neue P450 Familien 
(CYP259, CYP260, CYP261, CYP262, CYP263, CYP264, CYP265, CYP266 und CYP267) 
zum Vorschein. Davon ausgehend wurden ein phylogenetischer Baum und eine physikalische 
Genekarte der P450 erstellt. Die Gensuche des So ce56 CYPome lieferte einige wichtige P450 
Eigenschaften und könnte nützlich für die Substratvorhersage sein. Wir konnten zeigen, dass 
zwei der P450, CYP263A1 und CYP265A1, mit einer Polyketidsynthase (PKS) 
beziehungsweise mit einer nicht-ribosomalen Peptidsynthetase (NRPS) verbunden waren. 
Einige Cytochrome P450 (CYP109C2, CYP110H1, CYP110J1, CYP260A1, CYP262A1, 
CYP262B1, und CYP261A1) waren mit regulatorischen Elementen assoziiert. CYP264B1 
war in einem Cluster mit einer Terpenzyklase angeordnet. Einige andere CYPome 
(CYP124E1, CYP262A1, und CYP266A1) waren mit den benachbarten OLRs, die potentielle 
physiologische Funktionen besitzen, verbunden. In einem einzigartigen Cluster wurden die 
zwei CYPome (CYP109D1 und CYP259A1) identifiziert. Diese lagen in enger Nachbarschaft 
und wurden nur durch einen einzigen OLR voneinander getrennt. Die Gensuche zeigte auch, 
dass keine der So ce56 Ferredoxine (Fdx) oder Ferredoxin Reduktasen (FdR) benachbart oder 
näheren Umgebung eines der P450 war. Die OLR aller P450 wurden kloniert, erfolgreich in 
löslicher Form in Escherichia coli exprimiert und in aktiver Form mit einem typischen Peak 
bei 448/450 nm gereinigt. Die charakteristische Apo- und Holo-Massen der P450s wurden 
bestimmt und die biophysikalische Eigenschaften (mittels CD und EPR Messungen) für 
einige sehr gut exprimierte Cytochrome oder für Repräsentanten der neuen P450 Familien 
(CYP109C1, CYP109C2, CYP109D1, CYP260A1, CYP264A1, CYP264B1 und CYP266A1) 
untersucht. Alle Messungen zeigten die typischen Merkmale eines Mitgliedes der P450 
Familie. In Abwesenheit von homologen Redoxpartnern wurden die heterologen 
Elektronendonoren, bovines Adrenodoxin (Adx) und Adrenodoxin Reduktase (AdR) für neun 
der P450 (CYP109C1, CYP109C2, CYP109D1, CYP110J1, CYP124E1, CYP260A1, 
CYP264A1, CYP264B1 und CYP267B1) verwendet. Unterdessen wurde für vier dieser P450 
(CYP109C1, CYP109C2, CYP260A1 und CYP266A1) mittels einer Ligandenbibliothek mit 
17.000 Substanzen nach potentiellen Substraten und Inhibitoren gesucht. Dieses Kapitel 
befasst sich also mit den Grundlagen, Redoxpartnern und Substraten für die funktionale 
Untersuchung für einige dieser neuen Cytochrome P450. 
 
Da Fettsäuren während des komplexen Lebenszyklus der Myxobakterien von großer 
Bedeutung sind, beschäftigt sich der erste Teil von Kapitel II, mit der Identifizierung 
mehrerer potentieller Fettsäurenhydroxylasen aus So ce56. Darüber hinaus wurde ein 
Mitglied der CYP109D Familie, CYP109D1, zum ersten Mal als eine neue 
Fettsäurehydroxylase beschrieben. Die GC-MS Analyse der TMS-derivatisierten Produkte der 
durch CYP109D1 umgewandelten Fettsäuren zeigte ω-Hydroxylierungen ohne terminale (ω) 
Produkte der gesättigten Fettsäuren. Das Hydroxylierungsmuster gesättigter Fettsäuren wie 
Caprylsäure (C10) zeigte ω-1 und ω-2; Laurinsäure (C12) zeigte ω-1 bis ω-3; Tridecansäure 
(C13) und Myristinsäure (C14) zeigten ω-1 bis ω-5, und Palmitinsäure (C16) zeigte ω-1 bis 
ω-6 Hydroxylierung. Auch die ungesättigte Fettsäure Ölsäure (18:1cis9) wurde getestet und 
zeigte selektive Hydroxylierungen an den Positionen ω-6 und ω-7. Die verzweigten 
Fettsäuren 13-Methylmyristinsäure und 15-Methylmyristinsäure zeigten ω-2 bis ω-6 
beziehungsweise ω-2 bis ω-5 Hydroxylierungen.  
 
Der zweite Teil von Kapitel II zeigt die Rolle des CYP109D1 als einen neuen Biokatalysator 
für die Epoxidierung und Hydroxylierung von Monoterpenen und Sesquiterpenen. 
CYP109D1 war in der Lage, die Epoxidierung linearer Verbindungen, wie z.B. Geraniol und 
Nerol, zu katalysieren. Geraniol wurde in 2,3-Epoxygeraniol, 6,7-Epoxygeraniol und 2,3- 6,7-
Diepoxygeraniol umgewandelt. Im Falle des Nerols wurden zwei epoxidierte Produkte, 2,3-
Epoxynerol und 6,7-Epoxynerol, erhalten. Die epoxidierten Produkte der beiden linearen 
Terpenoiden wurden mittels eines synthetisierten Produktes als Standard bestätigt. Darüber 
hinaus konnte das zyklische Monoterpen Limonen in hydroxylierte und epoxidierte Produkte 
umgewandelt werden. Zudem hydroxylierte CYP109D1 die Sesquiterpenoide α-Ionon und β-
Ionon ebenso selektiv zu 3- Hydroxy-α-ionon bzw. 4-Hydroxy-β-ionon, was durch 1H NMR 
und 13C NMR Analyse bestätigt werden konnte. Die regioselektive Hydroxylierung der 
Sesquiterpene wurde auch mittels Dockingstudien an einem Computermodell des CYP109D1 
untersucht, welche eine logische Erklärung für die beobachteten Selektivitäten und 
Aktivitäten ergab. Alle diese Analysen zeigten nicht nur die bedeutende Rolle des CYP109D1 
während der Terpenoidoxidation, sondern auch eine mögliche biotechnologische Bedeutung 
dieses P450 für die Produktion von selektiv epoxidierten und hydroxylierten 
Terpenoidderivaten mit höherem Marktwert als den Ausgangssubstraten. 
 
Kapitel III dieser Arbeit behandelt die funktionale Rolle der neuen bakteriellen P450 Familie 
CYP260A1. Alle individuelle OLRs, die in nächster Umgebung zum CYP260A1 lagen, 
kodieren für hypothetische Proteine. Um den jeweiligen OLRs mögliche Funktionen 
zuzuordnen, wurde eine individuelle Homologiesuche durchgeführt. Diese lieferte aber keine 
genauen Informationen über putative Funktionen und somit waren alle OLRs hypothetische 
Proteine. Demzufolge konnten keine potentiellen, putativen Substrate für CYP260A1 
vorausgesagt werden. Daher wurde eine Bibliothek mit ~17,000 Liganden mit CYP260A1 
gescreent und sowohl potentielle Substrate als auch Inhibitoren identifiziert. Die strukturelle 
Analoga der Typ I Hits des Screenings und sowohl Steroide als auch Nootkaton wurden als 
potentielle Substrate ausgesucht. Die heterologen Redoxpartner (Adx und AdR) wurden zur 
Substratumwandlung von Progesteron, DOC und Nootkaton verwendet und die Produkte 
mittels HPLC/GC-MS analysiert. Es konnte zum ersten Mal gezeigt werden, dass CYP260A1 
nicht nur als eine Steroidhydroxylase, sondern auch als ein Sesquiterpen-Umwandler fungiert. 
CYP260A1 hydroxylierte sowohl Progesteron als auch DOC. Die Hydroxylierung von 
Progesteron führte zu mehr als drei Produkten, die Hydroxylierung von DOC während einer 
Stunde Reaktionszeit führte zu zwei Hauptprodukten. Eines dieser Produkte hatte die gleiche 
Retentionszeit wie Aldosteron, während das andere nicht identifiziert wurde. Mit steigender 
Inkubationszeit des in vitro Assays wurde nur noch das Hauptprodukt, welches die gleiche 
Retentionszeit wie Aldosteron besaß, erhalten. Da ein Steroidbiosyntheseweg in 
Myxobakterien bereits bekannt ist, könnte die Steroidhydroxylierung mittels CYP260A1 von 
physiologischer Signifikanz sein. Zusätzlich war CYP260A1 auch in der Lage, Nootkaton, ein 
Sesquiterpen, in ein hydroxyliertes und/oder epoxidiertes Produkt umzuwandeln. Dies erlaubt 
neue Einblicke in die Bedeutung von CYP260A1 für die Umwandlung einiger anderer 
Steroid- und Terpenoidverbindungen, die bereits pharmazeutisch und biotechnologisch 
angewendet werden.  
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THE CYTOCHROME P450 COMPLEMENT OF THE MYXOBACTERIUM 
Sorangium cellulosum So ce56 AND CHARACTERIZATION OF TWO MEMBERS, 
CYP109D1 AND CYP260A1 
 
GENERAL INTRODUCTION 
The cytochromes P450 are available in all from of life from prokaryotes to eukaryotes. The 
investigation of genome sequences has greatly facilitated the identification, classification and 
nomenclature of cytochrome P450 enzymes from different organisms. In plants, the P450s 
play a pivotal role for the production of secondary metabolites (Schuler and Werk, 2003). In 
yeast and fungi, a key P450 (CYP51) is essential for the production of sterols for membrane 
fluidity and integrity (Kalb et al., 1987). In insects, P450s are required for hormone synthesis 
(Helvig et al., 2004). Among 57 P450s in human, 15 P450s are involved in drug metabolism, 
14 primarily involved in the steroid metabolism, 6 involved in vitamin metabolism and 9 
P450s involved in the metabolism of fatty acids and eicosanoids, whereas the remaining 13 
human P450s are considered as orphans and their biological functions remain to be firmly 
established (Guengerich et al., 2005). In contrast, there is no cytochrome P450s in E .coli. 
Previously, it was presumed that bacteria would have less numbers of P450 but several 
genome sequence projects revealed the existence of higher numbers of P450s in some 
bacteria. Most recently, it was shown that the P450s are also available in virus and one of the 
P450 encoding genes, YP_143162, from Acanthamoeba polyphaga was heterologously 
expressed in Escherichia coli (Lamb et al., 2009).  
 
1. 1. CYTOCHROMES P450 
Cytochrome P450 proteins comprise one of the largest super-families of enzymes (Werck-
Reichhart and Feyereisen, 2000). They were first discovered in the 1950´s–60´s with 
simultaneous discovery of atmospheric oxygen incorporating into substrate molecules during 
metabolism catalyzed by metallo-proteins, which eventually lead to understanding the 
cytochromes having a part in oxidative metabolism (Estabrook, 2003). 
 
1. 1. General aspects  
The cytochrome P450s are a superfamily of heme b-containing monooxygenase enzymes, 
containing protoporphyrin IX as their prosthetic heme factor. P450 monooxygenases are 
‘mixed function oxygenases’, constituting the terminal components of electron transport 
chains where both substrate and NAD(P)H are oxidized. Irrespective of the substrate, the 
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general function of a P450 is the same - the activation of molecular oxygen and subsequent 
insertion of a single atom of molecular oxygen into an organic molecule (Figure 1). 
 
 
Figure 1: Cytochrome P450 catalyzed hydroxylation reaction. RH represents an 
oxidisable substrate and ROH the corresponding hydroxylated product. 
 
 
The first experimental evidence relating to cytochromes P450 was provided in 1955 (Axelrod, 
1955; Brodie et al., 1955) when an enzyme system oxidizing xenobiotic compounds was 
identified in the endoplasmic reticulum of the liver. In 1958, a carbon monoxide binding 
pigment with an absorption maximum at 450 nm was detected in liver microsomes (Garfinkle, 
1957; Klingenberg, 1958). The microsomal carbon monoxide-binding pigment was later 
demonstrated to contain iron-protoporphyrin IX (Omura and Sato, 1962; 1964), which was 
named cytochrome P450 after the primary characteristic feature in its absorption spectrum on 
complex formation with CO. The absorption peak of reduced P450 is still used for the 
estimation of the P450 content of a probe (Bernhardt, 2006). In cytochrome P450, P stands 
for pigment and 450 refers the maximum absorbance at 450 nm. Cytochrome stands for 
hemoprotein. The proteins of this family are commonly referred as CYPs, shorthand for 
cytochrome P450s. 
 
1. 2. Heme Structure in P450 
The heme structure found in P450s is a tetrapyrrole heme b (protoporphyrin IX) (Figure 2), 
which is a highly symmetrical and conjugated system, coordinated to an iron atom. The 
highly conjugated ring system leads to a strongly colored chromophore. The surrounding 
tetrapyrrole structure and axial ligands modulate the chemical properties of the heme iron. 
Heme electron transfer involves a single electron reversible oxidation/reduction of the iron 
between its 2+
 
and 3+
 
oxidation states, although the P450 catalytic cycle also involves other 
oxidation states of heme iron in the short-lived intermediates responsible for substrate 
oxidation (4+
 
and/or 5+). The properties of heme redox centers can be altered dramatically by 
changing the axial ligands. In P450s, four porphyrin central nitrogens provide the equatorial 
planar ligands for the heme iron, and the fifth ligand is usually a conserved cysteine 
sulphydryl bond (the ‘proximal’ distal ligand, typically considered to be in the deprotonated 
thiolate form). A 6th (displaceable) water ligand is generally found opposite the cystein(at)e as 
RΗ + Ο2 + ΝΑD(P)Η +Η+ 
P450  
RΟΗ +Η2Ο+ΝΑD(P)+ 
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the distal ligand. This ligand makes way for binding of oxygen in the catalytic cycle. The 
heme macrocycle is typically bound non-covalently to the protein. However, the studies of the 
mammalian CYP4 family of P450s indicate that covalent linkage of a peripheral heme methyl 
group via a glutamate residue is feasible (LeBrun et al., 2002a; 2002b). 
 
Changes in electronic spectral properties occur during catalytic cycles of heme proteins and 
on interactions with various ligands. Spectral perturbations of the P450 heme result from the 
ability of various ligands to perturb the spin equilibrium or alter the coordination state of the 
proximal cysteinate-ligated heme iron. Substrates of P450s frequently shift the equilibrium in 
favor of the high-spin form, which occurs by displacement of a water molecule at the 6th
 
ligand (distal axial ligand). Different spectral properties of the Soret band occur in the low-
spin and high-spin forms, with maxima close to 420 nm and 390 nm, respectively (Munro et 
al., 2000; Loew and Harris, 2000). The characteristic Type I binding spectra are represented 
by a decrease in an intensity of the Soret absorption peak at 420 nm coupled with a 
concomitant increase in the band intensity of 390 nm absorption (Gibson and Skett, 1994). 
The Type II binding spectrum is characterized by a decrease in absorption at around 390-405 
nm with a concomitant increase at about 425-435 nm (Schenkman et al., 1981). For several 
P450s (particularly certain well characterized bacterial isoforms), the change in spin-state 
facilitates the next step in their enzymatic cycle, one-electron reduction of heme iron from the 
redox partner.  
 
Alterations in spin-state are an integral part of the characteristic and functional properties of 
the P450s. The signature electronic properties of heme sites are primarily due to π-π* electron 
transitions within the protoporphyrin IX cofactor and the S→Fe ligand-to-metal charge 
transfer bands. Also, normally associated with substrate-induced shift in spin-state are 
changes in the mid-point reduction potential of the ferric heme iron. Electronic re-distribution 
that occurs in the low- to high-spin transition in the iron d-orbitals and changes in overall 
energy levels of the orbitals leads to a more positive heme iron reduction potential in the high-
spin state (Sharrock et al., 1973).  
 
The spectroscopic properties (i.e. UV-visible and other methods) of P450s provide a means to 
study and characterize a number of properties associated with these diverse biological 
catalysts. Accordingly, substrate dissociation constants (KD) can be determined by the extent 
of the spin-state shifts induced during titration with a substrate and by using optical 
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spectroscopy (Daff et al., 1997; Loew and Harris, 2000). Binding of inhibitory ligands (e.g. 
azoles) can also be analyzed by similar methods.  
 
1. 1. 3. Structure of cytochrome P450 
Cytochromes P450 share a common overall fold and topology despite less than 20% sequence 
identity across the gene super family (Hasemann, 1995). The typical crystal structure from the 
CYP102A is shown in Figure 3 (www.rcsb.org/pdb/results). The conserved P450 structural 
core is formed by a four-helix bundle composed of three parallel helices labeled D, L, and I 
and one antiparallel helix E (Presnell et al., 1989). The prosthetic heme group is confined 
between the distal I-helix and proximal L-helix and bound to the adjacent Cys-heme-ligand 
loop containing the P450 signature amino acid sequences FxxGx(H/R)xCxG. The absolutely 
conserved cysteine in the proximal side is the ‘fifth’ ligand to the heme iron. This sulfur 
ligand is a thiolate (Dawson et al., 1982) and is the origin of the characteristic name- giving 
450 nm Soret absorbance observed for the ferrous CO-complex. Typically, the proximal ‘Cys’ 
forms two hydrogen bounds with neighboring backbone amides. A further interaction with a 
side chain is observed in some P450, for example, with a ‘Gln’ in CYP152A1 or a ‘Trp’ in 
nitric oxide synthase (Chen et al., 2004, Ost et al., 2001).  The long I-helix forms a wall of the 
heme pocket and contains the signature amino acid sequences (A/G)Gx(E/D)T which is 
centered at a kink in the middle of the helix. The highly conserved ‘Thr’ preceded by an 
acidic residue is positioned in the active site and believed to be involved in catalysis (Imai et 
al., 1989, Kimata et al., 1995, Vidakovic et al., 1998). 
 
 
 
 
 
Figure 2: Schematic representation 
of the structure of heme b 
(ferriprotoporphyrin IX).  
 
 
Figure 3: Crystal structure of CYP102A1 
monooxygenase domain (www.rcsb.org/pdb/results). 
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1. 1. 4. Reactions and Mechanism 
Based on crystal structures with and without substrate, ESR and NMR studies and other 
physicochemical methods a reaction mechanism for P450 monooxygenases was proposed. 
The actual reaction cycle shown in Figure 4 is nowadays commonly accepted (Denisov et al., 
2005). 
(1) In the substrate free, inactive state the ferric heme iron Fe (III) is six times coordinated 
and in the low-spin state. The equatorial positions of the octahedral iron complex are 
coordinated with the nitrogens of protoporphyrin IX, while the cysteinate and a water 
molecule bind the axial positions. 
(2)The water at the distal site of the heme is displaced upon substrate binding. The substrate is 
not taking the place of the water but binds mostly by hydrophobic interaction in the vicinity of 
the heme. This results in the transition to the high-spin Fe (III) complex, where the iron is 
only five times coordinated and in a pronounced “out of plane” structure. While some amino 
acid side chains show distinctive conformational changes, substrate binding induces only 
marginal rearrangement of the protein backbone (Haines et al., 2001). More important than 
structural differences is the increase of the redox potential from around 300 to -170 mV. This 
is an important regulation mechanism, as after substrate binding the electron transfer guided 
by the potential gradient from NAD(P)H through the electron transfer chain to the heme iron 
is possible. The one electron transfer results in a high spin ferrous iron (Fe II) (3). 
(4) Due to its four unpaired electrons and its out of plane structure this complex is predestined 
to bind triplet oxygen with very high affinity, resulting in “in plane” coordination. This is the 
last stable (at low temperature) intermediate of this cycle.  
(5) The next step is again a one electron reduction to a very unstable postulated peroxo-iron 
(III) complex. 
(6) Due to their high reactivity the following intermediates can not be spectroscopically 
characterized but it can be assumed that after incorporation of one proton a hydroperoxo-
ferric intermediate is formed while through incorporation of the second proton the oxygen-
oxygen bond is cleaved under release of water. 
(7) The emerging reactive complex is often in literature termed “compound I” which most 
likely switches back to the initial state through a rebound mechanism (Figure I. 5). 
(8) The reaction of this iron-oxo complex with the substrate is in general formulated as a 
radical reaction. However carbo-cations as intermediates or direct addition of the substrate 
(to) (7) under insertion of oxygen into a C-H bond are also discussed. During the rebound 
mechanism the carbon centered intermediate should oscillate through the binding plane under 
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loss of the sterical information. Due to the often high enantioselectivity of the P450 catalysed 
oxidation the recombination of this radical state has to be extremely fast. The resulting 
alcohol (Figure 5) is probably shortly bound to the oxygen of the Fe (III) - porphyrin system 
before its dissociation. Next to the rebound mechanism heterolysis or addition of R-H as 
reaction mechanism can not be completely excluded. 
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Figure 4: Catalytic cycle of P450 monooxygenases. The numbers shown in the figure are as 
described above.  
 
 
 
Figure 5: Rebound mechanism of the P450 catalyzed hydroxylation. 
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At least three more ways for dissociation of the activated oxygen from the heme iron or for 
substrate hydroxylation apart from the already discussed one exist. These reactions are called 
shunt pathways. The most thoroughly investigated reaction is the peroxide shunt. In the 
presence of powerful oxidants like periodates, organic peroxides and hydrogen peroxide the 
peroxo-complex (6) can directly be formed from the substrate bound high spin complex (2). 
This reaction is interesting for synthetic processes because it enables product formation 
without the use of NAD(P)H. In auto-oxidation shunt complex (2) is formed by dissociation 
of the superoxide from complex (4). On the other hand complex (2) can be formed through 
the oxidase shunt where oxygen is reduced under consumption of two molecules of NAD(P)H 
to water. These two reactions as well as the reverse peroxide shunt are often consolidated as 
the uncoupling reactions because they are unproductive concerning substrate oxidation but 
nevertheless consume NAD(P)H. 
 
1. 1. 5. Electron transfer in cytochrome P450 systems 
P450 monooxygenases (mixed function oxidases) incorporate one atom of molecular oxygen 
into the substrate and are atom is reduced to water. For this process electron equivalents are 
needed (Figure 4). 
 
Regarding the electron transfer systems of P450, Chapmann et al. defined four classes 
(http:www.chem.edu.ac/champman/p450.html). This classification is further elaborated by 
Hannemann et al. (2007), into 10 classes, the details of which are illustrated in Figure 6. The 
class I P450 systems [NAD(P)H→FdR→Fdx→P450] are present in most bacterial 
cytochrome P450 systems along with the mitochondrial P450 systems from eukaryotes. The 
class II P450 systems are abundantly present in the endoplasmic reticulum with two integral 
proteins-cytochrome P450 and the NADPH-cytochrome P450 reductase (CRP) containing the 
prosthetic groups FAD and FMN. The class III P450 systems also contains a three 
components P450 system [NAD(P)H→FdR→Fldx→P450] as in Citrobacter braakii where 
the natural immediate electron donor of the cytochrome P450 (P450cin) is flavodoxin 
(cinodoxin). The class IV P450 system [pyruvate, CoA→OFOR→Fdx→P450] is present in 
Sulfolobus solfataricus, the extreme acidothermophilic archaeon, where the potential redox 
partners of CYP119, a ferredoxin and its corresponding partners, 2-oxo-acid: ferredoxin 
oxidoreductase (OFOR) from S. tokodaii strain 7 and also from S. solfataricus itself, are 
found to be an efficient redox partner. The class V P450 system is a novel class of P450 found 
in Methylococcus capsulatus having two separate protein components - a putative NAD(P)H-
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dependent reductase and a cytochrome P450-ferredoxin-fusion protein 
[NADH→FdR→(Fldx-P450)]. The class VI P450 system, present in Rhodococcus 
rhodochrous strain 11Y, has a putative NAD(P)H dependent flavoprotein reductase and a 
flavodoxin-P450 fusion protein [NAD(P)H→FdR→(Fldx-P450)]. In class VII P450 systems 
the cytochrome P450 is C-terminally fused to a reductase domain, which is usually not 
associate with P450 systems - a phthalate dioxygenase reductase domain [NADH→(PFOR-
P450)] and is present in Rhodococcus sp. The class VIII P450 system is catalytically self 
sufficient as monooxygenases in which the P450 is fused to its eukaryotic-like diflavin 
reductase partner, cytochrome P450 reductase (CPR), in a single polypeptide chain. In class 
IX P450 systems the nitric oxide reductase is involved which was identified in Fusarium 
oxysporum. The class X P450 systems include all independent cytochromes P450 which do 
not need NAD(P)H and redox partners like allene oxide synthase, fatty acid hydro-peroxide 
lyase, divinyl ether synthase, prostacyclin synthase and thromboxane synthase. 
 
 
 
 
Figure 6: Schematic organization of different cytochrome P450 systems. (A) Class I, bacterial 
system; (B) class I, mitochondrial system; (C) class II microsomal system; (D) class III, bacterial 
system; example P450cin; (E) class IV, bacterial thermophilic system; (F) class V, bacterial 
[Fdx]–[P450] fusion system; (G) class VI, bacterial [Fldx]–[P450] fusion system; (H) class VII, 
bacterial [PFOR]–[P450] fusion system; (I) class VIII, bacterial [CPR]–[P450] fusion system; (J) 
class IX, soluble eukaryotic P450nor; (K) independent eukaryotic system, example P450TxA. 
 9 
1. 1. 6. Substrate binding properties of cytochrome P450  
The heme prosthetic group of the cytochrome P450 often serves as a useful chromophore 
during substrate and inhibitor binding studies. The oxidation of P450 bound substrate occurs 
at the heme, as a result certain aspects of substrate binding can be monitored readily with a 
spectrophotometer. Most commonly, ligand titration experiments are carried out to determine 
a spectral dissociation constant (KD) for P450 substrates or inhibitors. 
 
Three specific types of substrate binding spectra have been identified, namely Type I, Type II 
and reverse Type I, the latter being sometimes referred as modified Type II (Schenkman et 
al., 1981). The characteristic Type I binding spectra (Figure 7) are represented by a decrease 
in the intensity of the Soret absorption peak at 420 nm coupled with a concomitant increase in 
the band intensity of 390 nm absorption (Gibson and Skett, 1994). Such spectrum is an 
indication of the substrate’s influence on the P450 heme iron spin-state equilibrium, because 
low-spin P450 absorbs at around 418 nm (though the range varies from 416-420 nm) whereas 
the high-spin form gives rise to the 390 nm absorption (though the range varies from 385-394 
nm). As a result, a Type I spectrum shows that the binding of substrate within the P450 heme 
locus brings about a shift in the Fe(III) spin equilibrium from low-spin to high-spin (Lewis, 
2001). In most of the cases, changes in the magnitude of the Type I spectra indicate both the 
extent and the rate of metabolism, especially as there can be tight coupling between spin and 
redox equilibria in both the microsomal and bacterial P450 systems (Sligar and Gunsalus, 
1976).  
 
Compounds which tend to act as P450 inhibitors via ligation of the heme iron generally show 
Type II spectra (Figure 7). The structures of such molecules usually posses atoms containing 
non-bounded electrons, such as a nitrogen lone pair and there is also an accessibility in the 
structure of the ligand so that it may bind freely at the heme locus. It appears that the pKa of 
the nitrogen is a factor in heme binding affinity of amines but the bond angle between the 
amine nitrogen and heme plane is also an important factor in those cases where steric 
hindrance can occur. The Type II binding spectrum is characterized by a decrease in 
absorption at around 390-405 nm with a concomitant increase at about 425-435 nm 
(Schenkman et al., 1981). As a result, there is a shift in the absorption maxima corresponding 
to low- and high-spin Fe (III) towards longer wavelengths coupled with a shift in spin-state 
equilibrium from high- to low-spin iron. 
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The reverse Type I spectrum is a ‘mirror image’ of the Type I spectral change, with an 
increase in the 420 nm band and a decrease in absorbance at 390 nm. This is similar to a Type 
II change, except that there is no shift in the location of the maxima. The exact nature of this 
interaction is not known and it may be that the ligand binds to a different site on the enzyme. 
 
 
 
Figure 7: The UV-difference spectra obtained by the addition of a substrate or inhibitor 
to cytochrome P450. The black and red lines represent Type I and Type II difference spectra, 
respectively.  
 
1. 1. 7. Reactions catalyzed by P450 
Despite cytochrome P450 being considered mainly as oxygenases, during their long period of 
evolution, 3.5 billion years, the P450 family has become very versatile and has a broad field 
of chemical activity (Rendic and di Carlo, 1997). Among P450s there are isomerases, 
reductases, dehydrases, NO-synthases and in addition to oxidation, they contribute to various 
other reactions listed in Table 1 (Guengerich, 2001; Danielson, 2003; Bernhardt, 2006). 
However, exceptions can be found among the listed reactions. 
 
 11 
Table 1: Chemical reactions catalyzed by cytochromes P450 (Guengerich, 2001; 
Danielson, 2003; Bernhardt, 2006). 
Reactions 
NO-reduction 
SO2-reduction 
Hydroperoxide reduction 
1-electron oxidation 
Aldehyde deformylation 
Coupling reactions 
Ring formation, expansion 
Hydrolysis 
1,2-shifts 
Mechanism-based heme inactivation 
Mechanism-based protein modification 
Reductive dehalogenation 
Dehydratations 
Hydrocarbon hydroxylation 
Aromatic hydroxylation  
Alkene epoxidation 
Epoxide reduction 
Isomerizations 
Oxidative C-C bond cleavage 
Alkyne oxygenation 
Arene epoxidation 
N-, S-, O-dealkylation 
N-hydroxylation 
N-oxidation 
S-oxidation 
Oxidative deamination 
Oxidative dehaloganation 
Dehydrogenation 
Steroid hydroxylation 
 
1. 2. Myxobacteria 
The myxobacteria are a group of gram-negative, mainly soil-dwelling bacteria belonging to 
the delta subdivision of proteobacteria and having a high G + C content (~70%) in their 
genomic DNA (McCudry, 1989; Reichenbach, 1999). Myxobacteria are usually isolated from 
soil, decaying plant material, animal feces and tree bark, and produce extracellular hydrolytic 
enzymes that are able to degrade proteins, nucleic acids and some polysaccharides. 
 
1. 2. 1. Taxonomy 
In 1809, the first myxobacterium, Polyangium vitellinum (today Kofleria flava), was 
discovered by the German botanist H. F. Link (Reichenbach and Dworkin, 1992). Due to its 
fruiting bodies, the bacteria were termed as “gasteromycete” (fungi). In 1857, the British 
mycologist M. J. Berkeley discovered two additional species, Stigmatella aurantiaca and 
Chondromyces crocatus, which were classified as hyphomycetes (fungi imperfecti) 
(Berkeley, 1857). The genera name “myxobacteria” was formed by the American botanist 
Roland Thaxter in 1892 who was the first scientist to describe their life cycle (Thaxter, 1892). 
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Contemporary, phylogenetic analyses, by comparison of the 16S rRNA reveal that 
myxobacteria belong to the delta branch of the proteobacteria (Ludwig et al., 1983). Based on 
morphological and physiological features and after several renaming, the order Myxococcales 
(myxobacteria) can be divided into three subgroups Cystobacterineae, Sorangineae, and 
Nannocystineae (Reichenbach, 2004; Shimkets et al., 2005), five families, 17 genera and 
about 50 species (Figure 8). 
 
 
 
Figure 8: Taxonomy of myxobacteria (Reichenbach, 2004; Shimkets et al., 2005). 
 
Myxococcus xanthus, Corallococcus sp., Archangium sp. and Stigmatella aurea are typical 
members of the first subgroup and mainly obtain nutritional substrates by proteolytic or 
bacteriolytic activities. They feed upon other bacteria, utilizing the protein and lipid fraction 
as carbon and energy sources. The vegetative cells are slender and have tapering ends up to 1 
µm in diameter and up to 20 µm in length. Myxococcus xanthus is the most extensively 
studied model organism among myxobacteria, and has a genome size of 9.14 Mb (Goldman et 
al., 2006).  
 
The Sorangineae like Sorangium (Polyangium) cellulosum and the Byssophaga genera are 
cellulose degraders and use inorganic nitrogen compounds while growing on cellulose and 
glucose (Reichenbach and Dworkin, 1992; Reichenbach, 2004). The vegetative cells of this 
suborder are mainly cylindrical rods with rounded ends up to 1 µm wide and 10 µm long. In 
contrast, other members of the Sorangineae subgroup like Haploangium and Chondromyces 
and the subgroup Nannocystineae show in feeding experiments no cellulolytic activity.  
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1. 2. 2. Characteristic features of myxobacteria 
The myxobacteria have two characteristics that distinguish them from other bacteria. At first, 
myxobacterial cells move by gliding motility in which cells move in the direction of their 
long axis on agar surfaces without the use of flagella. This gliding motility is utilized to 
accomplish swarming under vegetative conditions, during which cells of myxobacteria secrete 
hydrolytic enzymes that lyse other cells and convert their proteins into amino acids which are 
then metabolized. Secondly, myxobacteria can undergo complex cellular morphogenesis to 
form aggregates called fruiting bodies in which dormant myxospores are generated in 
response to starvation. The fruiting bodies can be very simple in shape and structure but also 
may occur as extremely complex designs. 
 
1. 2. 2. 1. Gliding motility 
One of the key elements in the development of M. xanthus is its gliding motility. The motility 
by gliding over a solid surface plays an important role in the developmental cycle of 
myxobacteria (Reichenbach and Dworkin 1992). In M. xanthus, wild-type gliding motility 
and cell swarming is the result of two separate systems. The S-, or social system, is 
responsible for the motility of groups of cells and is equivalent to twitching motility as seen in 
Neisseria and Pseudomonas (Connolly et al., 1999; Wall and Kaiser, 1999; Merz et al., 2000; 
Beatson et al., 2002). Twitching motility is mediated by the extension and retraction of type 
IV pili. The A-, or adventurous system, is responsible for the motility of single cells and is 
related to gliding motility. Secretion-mediated gliding displayed by some cyanobacteria is due 
to the expulsion of a polyelectrolyte gel through membrane pores and is proposed to provide 
the thrust for A- type gliding (McBride, 2001; Thomasson et al., 2002; Wolgemuth et al., 
2002). Many genes in M. xanthus have been shown to effect A- and S- type gliding 
separately, and a few have been shown to effect both systems. 
 
1. 2. 2. 2. Fruiting body formation 
The life cycle of myxobacteria consists of a vegetative growth cycle and a developmental 
cycle (Figure 9). The developmental cycle of myxobacteria, including fruiting body formation 
and sporulation, is triggered by the nutritional and physical changes of the environment. 
During fruiting body formation, myxobacteria sense the depletion of nutrient, move 
rhythmically (rippling), aggregate together on a solid surface, construct multicellullar fruiting 
bodies (ca. 105–107 cells/fruiting body) and convert the vegetative cells into stress resistant 
myxospores inside the fruiting body (Dworkin, 1985). These fruiting bodies are resistant to 
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several stress conditions such as desiccation, sonication and UV radiation. Additionally, 
sporulation can be induced independently from starvation by different chemical agents such 
as glycerol, DMSO, indole and its derivatives (Dworkin, 1994; Gerth et al., 1994; O'Connor 
and Zusman, 1997). Development of myxobacteria fruiting body requires intercellular 
communication. So far, at least five extracellular signals (Asg, Bsg, Csg, Dsg, and Esg) and a 
general starvation signal, (p)ppGpp, have been detected in M. xanthus (Downard et al., 1993; 
Dworkin, 1996; Hagen et al., 1978; LaRossa et al., 1983). The morphology of fruiting bodies 
varies between different myxobacterial species. Whereas the Stigmatella and Chondromyces 
sp. form sophisticated multiple tree-like sporangioles, Sorangium strains produce simple 
knobs consisting of slime and myxospores Figure 10. 
 
 
 
 
Figure 9: Diagram of the life cycle of 
myxobacteria (Dworkin, 1995). The fruting 
body of M. xanthus, in which myxospores are 
embedded in the slime mound, and the fruiting 
body of S. aurantiaca, which consists of a stalk 
and sporangioles, are illustrated.  
 
Figure 10: Fruiting bodies of different 
myxobacterial species. a). Sorangium 
cellulosum So ce56 (Gerth et al., 2003); b) 
Chondromyces apiculatus (Reichenbach and 
Dworkin, 1992); c and d) Chondromyces 
crocatus (Reichenbach and Dworkin, 1992). 
 
1. 2. 3. Application of myxobacterial secondary metabolites 
The secondary metabolites that are produced by myxobacteria display a wide diversity of 
structures and biological activities. Myxobacteria are known to be prolific producers of 
interesting and novel bioactive substances applied in biotechnology and pharmacology 
(Reichenbach and Höfle 1993, 1999, Gerth et al., 2003; Bode and Müller, 2006). About 7500 
different myxobacteria have been isolated and many of them were screened for secondary 
metabolites. The literature shows that nearly 500 derivatives from 100 core structures were 
found with several novel core structures (Gerth et al., 2003). Approximately, 50% of 
secondary metabolites are synthesized by different strains of Sorangium cellulosum (Figure 
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11). Different strains of Sorangium cellulosum produce several novel antimicrobial 
macrolides- thuggacins (Irschik et al., 2007), phoxalone (Guo et al., 2008), a new 
sesquiterpene- sorangiodenosine (Ahn et al., 2008) and a new free-radial scanvanger- 
soraphinol C (Li et al., 2008). Along with this, Sorangium cellulosum also synthesizes a novel 
class of antineoplastic agents- the epothilones and their analogs (Mulzer, 2008). 
Myxococcus 
20.70%
Polyangium
 5.20%
Chondromyces
10.30%
Sorangium
48.40%
Nannocystis
 1.70%
Stigmatella
 6.90%
Angiococcus 
1.70% Corallococcus 
1.70%
Melittangium
 1.70%
Crystobacter
 1.70%
 
Figure 11: Percentage distribution of the production of secondary metabolites from 
different myxobacterial strains (replotted from Gerth et al., 2003). 
 
1. 2. 4. Sorangium cellulosum So ce56 
The ~13.1 Mb genome of the model strain Sorangium cellulosum So ce56 is the largest yet 
discovered in bacteria (Schneiker, 2007). Varieties of biosynthetic gene clusters involved in 
natural product formation as well as numerous complex and unusual biosynthetic processes 
within Sorangium cellulosum have been identified (Wenzel and Müller, 2007). The selected 
strain So ce56 produces the natural secondary metabolites chivosazol, etnangien and 
myxochelin (Schneiker et al., 2007; Wenzel and Müller, 2007; Menche et al., 2008). The 
genomic sequence also revealed several additional regions of the chromosome encoding 
polyketide synthase (PKS) and/or nonribosomal polyketide synthase (NRPS) proteins, whose 
products have not been isolated till date (Schneiker et al., 2007). Sorangium strains provide 
no or less information concerning major biological processes like the gliding system, fruiting 
body formation and cell-to-cell interaction. 
 16 
CHAPTER I 
The cytochrome P450 complement (CYPome) of Sorangium cellulosum So ce56 
 
1. Introduction  
Cytochrome P450 monooxygenase systems are found throughout the biological kingdoms 
from eubacteria, archaebacteria to mammals. This gene superfamily plays a critical role in the 
bioactivation and detoxification of a wide variety of xenobiotics, in the biosynthesis of 
endogenous compounds and in the production of secondary metabolites (Gillam et al., 2007; 
Bernhardt, 1995; 2006). Cytochromes P450 also catalyze late-stage stereo- and regiospecific 
oxidations when associated with polyketide biosynthetic gene clusters in bacteria (Graziani et 
al., 1998; Zhao et al., 2008; Buntin et al., 2008).  
 
It has been observed that cytochrome P450 sequence information for various organisms is 
increasing during the last several years, especially as a result of various genome projects. 
Unfortunately, the functional study of the corresponding proteins is lagging far behind, even 
for the most heavily studied human forms, of which the complete substrate range is still 
unclear. Till date 110 P450 families are listed in animals, 95 in plants, 205 in bacteria, 10 in 
Archaea, 61 in protists and 310 families in fungi (http://drnelson.utmem.edu/p450stats. 
Feb2008. html).  
 
The investigation of P450s in Sorangium cellulosum So ce56 was started in parallel with the 
genome sequencing project. The recently completed genome sequence project of 
myxobacterum, Sorangium cellulosum So ce56 revealed 21 open reading frames (ORFs) of 
cytochromes P450 (Schneiker et al., 2007). As this was the very first attempt to study the 
cytochrome P450s in So ce56, at the beginning of this work only the sequence of the P450 
ORFs were in hand .The elucidation of the putative function of P450s can only be 
hypothesized after detailed theoretical study of all possible aspects.  
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2. Objectives  
1. To perform bioinformatics analysis of the P450s of So ce56. 
2. To clone, express and purify all 21 the P450s. 
3. To study the biophysical and biochemical characterization of selected P450s. 
4. To identify the heterologous redox partners for the selected P450s.  
5. To screen a compound library consisting of ∼17,000 substances as potential substrates for 
highly expressed P450s. 
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3. MATERIALS AND METHODS 
 
3. 1. Materials 
The instruments, chemicals, enzymes, kits, reagents and other accessories used in this work 
were of high grade. They are illustrated in Appendix I. 
 
3. 1. 1. Bacterial strains 
In this work several strains of E. coli were used for cloning and expression purposes. They are 
illustrated in Table I. 1. 
Table I. 1: E. coli strains and their genotypes. 
Strain Genotype Company 
BL21 (DE3)  E. coli B F- dcm ompT hsd S (rB-mB-) Novagen 
BL21 E. coli B F-dcm ompT hsd S (rB-mB-) gal Novagen 
TOP10F’ F’{lacIq, Tn10(TetR)} mcrA_(mrr-
hsdRMS-mcrBC)φ80lacZ_M15_lacX74 
recA1araD139 _(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG   
Invitrogen 
JM109 endA1, gyrA1, hsdR17(rk-mk+),mrcB+, 
recA1, relA1, supE44, thi-1, _(lac-proAB), 
F’[traD36,proAB, lacIqZ_M15 
Yanisch-Perron et al. (1985) 
 
 
3. 1. 2. Proteins 
Purification of bovine AdR and bovine Adx (4-108) (Uhlmann et al., 1994) was carried out 
by Wolfgang Reinle. AdR was purified according to a procedure published by Sagara et al. 
(Sagara et al., 1993). Adx (4-108) were purified following a protocol developed in our group 
(Uhlmann et al., 1994). Spinach ferredoxin and ferredoxin reductase were purchased from 
Sigma Aldrich Company.  
 
3. 1. 3. Oligonucleotides 
The designed oligonucleotides to amplify the P450 ORFs from the genomic DNA of So ce56 
were purchased from MWG Biotech. The list of the primers is illustrated in Table I. 2.  
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Table I. 2: List of the oligonucleotides.  
P450s of  
So ce56 
Oigonucleotide sequences 
CYP109C1 ccaatcat atgaaccttttcccggacgagat -3’  C7_NdeI_For 
cccttctagactagtgatggtgatggtgatgccccgggcacggcgt  C7_His.XbaI_Rev 
 
CYP109C2 ccaatcatatgaacctgt tctcggaaga gatgc  C6_NdeI_For 
ccaatctagatcagtgatggtgatggtgatggcccggggcaccgcc  C6_His.XbaI_Rev 
 
CYP109D1 ccaatcatatggaaaccgagaccgccccgagccc  C8_NdeI_For 
ccaatctagatcagtgatggtgatggtgatgggcggtggcgcggct  C8_His.XbaI 
 
CYP110H1 ccaatcatatgagccagttgccccgaggcccgc  C12_NdeI_For 
cccttctagatcaatggtgatggtgatggtgggcggcggcgtaaag  C12_His.XbaI_Rev 
 
CYP110J1 cccatcatatgggaaatc tgccgcccgg gc -5’  C11_NdeI_For 
ccaatctagatcagtgatggtgatggtgatgggagaagcccatggg  C11_His.XbaI_Rev 
 
CYP117B1 gggatcatatgaccaccg ccctccccgc t  C9_NdeI_For 
gccttctagatcagtgatggtgatggtgatggccgtcgaatcggac  C9_His.XbaI_Rev 
 
CYP124E1 ccaaccatatgacccctc aaaccgtcgatatcc  C3_NdeI_For 
agaattctagtg atg gtg atg gtg atg cctggcggggcgcgcgcaccgg  C3_His.EcoRI_Rev 
 
CYP259A1 ccaatcatatgctctccc tgggtcgaac cgacca  C10_NdeI_For 
ccgatctagatcagtgatggtgatggtgatggcaccggcgaaaggc  C10_His.XbaI_Rev 
 
CYP260A1 ccaacatatggcagacgagaaagcgccggagcgcg  C17_NdeI_For 
ccaaaagctttcagtgatggtgatggtgatggtgcaggagcacaggcag C17_His.HindIII_Rev 
 
CYP260B1 ccaacatatgctgcctcgtaaaaatctattttctt  C16_NdeI_For 
ccaaaagcttttagtgatggtgatggtgatgcacgagcagcgccggaa  C16_His.HindIII_Rev 
 
CYP261A1 ccaatcatatggagaccgccagagcagaagtcgcc C15_NdeI_For 
ccaaaagctttcagtgatggtgatggtgatggcggtggcggggggggaa  C15_His.HindIII_Rev 
 
CYP261B1 ccaatcatatg aaggggg gcatgaacgc cacgcccc C21_NdeI_For  
ccaaaagctttcagtgatggtgatggtgatgcgcgctcgcgcgcttcgt C21_His.HindIII_Rev 
 
CYP262A1 ccaatcatatggtggggctcctcccggcgctggcg C14_NdeI_For 
ccaaaagctttcaatggtgatggtgatggtgcacggcatggagcgtcat  C14_His.HindIII_Rev 
 
CYP262B1 ccaatcatatg cagccag atcttctctc cggcacac  C20_NdeI_For  
ccaaaagctttcagtgatggtgatggtgatgccttcccgggcgcggctc  C20_His.HindIII_Rev  
 
CYP263A1 ccaatcatatgagtgccacgctcgaacggcagcc C13_NdeI_For 
ccaataagctttcagtgatggtgatggtgatgggcccgggcgctgtacg  C13_His.HindIII_Rev 
 
CYP264A1 ccaatcatatgagcgagcgcgtggacatcatgac  C5_NdeI_For 
ccaaaagctttcagtgatggtgatggtgatgggccggcctgaagcggag  C5_His.HindIII_Rev 
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CYP264B1 
 
 
Mutagenic 
primers 
ccaatcatatgactcgacttaatctgttcgccc  C4_NdeI_For 
ccaataagctttcagtgatggtgatggtgatgccagatgccctggacga  C4_His.HindIII_Rev 
 
catcgctgatgacccacatggtcttgatcctcg  C4_Mut_For 
cgaggatcaagaccatgtgggtcatcagcgatg  C4_Mut_Rev 
 
CYP265A1 ccaacatatgtcgactcctcacacgctgcagccgg  C18_NdeI_For 
ccaaaagctttcagtgatggtgatggtgatggcgcgggcgcacgcggca  C18_His.HindIII_Rev 
 
CYP266A1 
 
ccttcatatggagacgcaagtggccgcgacgc  C2_NdeI_For 
ccaagaattctcagtgatggtgatggtgatggaatgatacagggagcgctctga  C2_His.EcoRI_Rev 
 
CYP267A1 
 
 
ccttcatatgaactcgcccgacgcaccgaagcc  C1_NdeI_For 
ccaagaattctcagtgatggtgatggtgatgggaggcggagctctgcgggccta C1_His.EcoRI_Rev 
 
CYP267B1 ccaatcatatggtcgacc aggacgcttt tccggagc C19_NdeI_For  
ccaaaagctttcaatggtgatggtgatggtggaacaccacaggcaccg C19_His.HindIII_Rev 
  
 CYP266B1P ccaacatatgggccaagctcccgccacctgcacagcc  C22_NdeI_For 
ccaaaagctttcagtgatggtgatggtgatggcggccagcggcgcgccg  C22_His.HindIII_Rev 
 
3. 1. 4. Vectors 
In this work the cloning vector PCR-Topo Blunt end (Invitrogen ), and the cloning vector 
pCWori+ and pET17b (Invitrogen) were used.  The expression vector pCWori+ was provided 
by Michael R. Waterman, Vanderbilt University School of Medicine, Nashville, USA. The 
details of these vectors are illustrated in Appendix V. 
 
3. 2. Methods 
3. 2. 1 Bioinformatics study 
3. 2. 1. 1. Bioinformatics analysis of P450s of So ce56 
The bioinformatics study of the P450s of So ce56 was done in collaboration with Dr. Olena 
Perlova and Prof. Dr. Rolf Müller, Pharmaceutical Biotechnology, Saarland University, 
during genome sequencing project of Sorangium cellulosum So ce56. 
 
Cytochrome P450s encoding open reading frames (ORFs) of Sorangium cellulosum So ce56 
were initially analysed in the genomic database based on the heme-binding domain signature, 
FxxGx(H/R)xCxG as query sequence. The ORFs possessing such motifs were further 
analyzed for the presence of the highly conserved threonine in the putative I-helix and the 
conserved EXXR motif in the K-helix (Nelson, 1996; Denisov et al., 2005). Amino acid 
sequences were deduced from the genes performed by ExPASy Translate tool 
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(http://www.expasy.org/tools/dna.html), and P450 family and subfamily assignments were 
made by Dr. David Nelson according to the P450 nomenclature 
(http://drnelson.utmem.edu/CytochromeP450.html). Briefly, P450s showing more than 40% 
identity was placed in the same family and P450ss exhibiting more than 55% identity were 
categorized in the same subfamily. New families were assigned for the P450s showing less 
than 40% identity to proteins from other organisms. 
 
3. 2. 1. 2. Phylogenetic analysis 
Translated ORFs of respective P450 genes of the Sorangium cellulosum So ce56 were aligned 
using Clustal W2 (Thompson, 1994) and analyzed by the Neighbour Joining Algorithm with 
boot strap analysis of 1000 times replicating to resample the data and displayed through Tree 
View (Page, 1996).  
 
3. 2. 1. 3. Other bioinformatics studies related to P450s and neighboring ORF 
The percentage similarity and identity of the P450s of So ce56 were studied by pairwise 
sequence alignment using EMBOSS Pairwise Alignment Algorithms. The closeness of So 
ce56 P450s with other bacterial strains was identified by using David Nelson’s P450s blast 
server (http://132.192.64.52/blast/P450.html). Comparison and analysis of the relatedness of 
each P450 gene of So ce56 and its neighboring genes were also studied by global NCBI 
protein BLAST and pfam (http://pfam.sanger.ac.uk/). The acquision of several P450s 
genes/proteins was accessed from EMBL/NCBI gene data bank or Protein Data Bank 
(http://www.rcsb.org/pdb/home).  
 
3. 2. 2. Molecular biology methods 
All standard DNA techniques were performed according to the standard methods as described 
previously (Sambrook and Russell, 2001), unless indicated.  
 
3. 2. 2. 1. Isolation of genomic DNA  
Genomic DNA from S. cellulosum So ce56 was isolated using the Puregene® Genomic DNA 
Purification Kit (Gentra, Minneapolis, USA) as per the manufacturer's instructions. The 
genomic DNA was provided from Prof. Dr. Rolf Müller, Institute for Pharmaceutical 
Biotechnology, Saarland University. All the P450s containing plasmid DNAs were purified 
using either the NucleoSpin Plasmid QuickPure Kit or the Nucleobond Plasmid Purification 
AX 100 Kit (Macherey-Nagel, Düren, Germany).  
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3. 2. 2. 2. Plasmid isolation, purification and determination of the nucleic acid 
concentration 
Plasmid purification was performed using a commercially available kit from Macherey-Nagel 
(Nucleobond® maxi or midi plasmid preparation kits) according to the manufacturer’s 
instructions. After purification, the plasmid DNA concentration was determined 
spectroscopically by measuring the absorption at 260 nm. The principle of this method is 
based on the absorption ability of UV light by the ring structure of purines and pyrimidines in 
the DNA or RNA where 1 AU260 corresponds to a dsDNA concentration of 50 µg/ml. 
(Hagemann, 1990). The concentration of nucleic acids was calculated by following the 
formula: C mg/ml = OD260*xε*f where C is the concentration in mg/ml, f = dilution factor 
and xε = 50 (double strand DNA) or 40 (single strand DNA and RNA). 
 
3. 2. 2. 3. Digestion of DNA with endonucleases 
Restriction endonucleases enzymes were purchased from Roche Diagnostics (Basel, 
Switzerland), NEB (New England Biolabs, Beverly, MA, USA), and from Promega 
(Madison, WI, USA). Digestion of the DNA was carried out according to the manufacturer’s 
instruction. Usually, 0.1-10 µg DNA were digested by 1-10 U of enzymes. Enzyme specific 
buffers provided with the enzymes were used to achieve the best results. Restriction 
digestions were performed in 20-50 µl volume. The incubation time and temperature were 
depended on the types of enzymes used, typically 1-4 hours to overnight at 37°C. The 
digested DNA was analyzed by agarose gel electrophoresis.  
 
3. 2. 2. 4. Ligation of DNA 
For the ligation purpose, new bonds between phosphate residues located at the 5’ termini of 
double-stranded DNA and adjacent 3’-hydroxyl moieties have to be formed in the digested 
and purified DNA stretches. DNA ligase enzyme can catalyzes these phosphodiester bonds 
between adjacent 5’-phosphate and 3’-hydroxyl residues.  
 
In this work, Fast-Link TM DNA Ligation Kit (Invitrogen) was used and the manufacturer’s 
instruction was followed with some modification. The ligation was done using the thermal 
cycler (16°C for 15 min, 20°C for 14 min and 70°C for 15 min) at different molar ratios of 
linker to insert (Sambrook and Russell, 2001).  
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3. 2. 2. 5. Agarose gel electrophoresis and extraction of DNA from agarose gel 
Agarose gel electrophoresis is an effective method to separate DNA fragments for analytical 
and preparative purposes by means of size (base pair) differentiation. The negative charges of 
DNA molecules help to migrate towards the anode in an electrical field. The migration 
depends on the size (base pair), the conformation of the DNA (either relaxed or super coiled) 
and also on the pore size of the gel. To visualize the DNA, ethidium bromide, a fluorescent 
dye, is often used. It intercalates between stacked base pairs and upon ultraviolet illumination 
makes DNA visible. 
 
Typically, for the DNA fragments between 1000 and 8000 bp length 1% melted agarose 
solution in 1 x TAE/TARE (Appendix II) was poured into the mould after addition of 0.01% 
ethidium bromide. The setted gel was transferred into the electrophoresis tank and was 
covered with 1 x TAE/TARE buffer. DNA samples (5-50 µl) with DNA loading buffer (5:1) 
were loaded on the gel. The Smart Ladder (Eurogentec Liège, Belgium) was used as reference 
DNA. Electrophoresis was performed at 80 V for 45 min. The gel was examined by 
ultraviolet light and documented. The extraction of DNA from agarose gel was done by using 
NucleoSpin (Macherey-Nagel) according to manufacturer’s instruction.  
 
3. 2. 2. 6. Polymerase chain reaction and molecular cloning 
Polymerase chain reaction (PCR) is the most common technique use in molecular cloning and 
analysis of DNA. It is used to amplify large copy numbers of a specific region of DNA using 
DNA polymerase which catalyzes the polymerization of deoxyribonucleotides alongside a 
DNA strand. PCR requires several basic components like DNA template, two oligonucleotide 
primers, DNA polymerase, dNTPs and buffer solution. The PCR usually consists of a series 
of 20 to 40 cycles involving the denaturation of template, the annealing of primer, and the 
extension of the annealed primers by DNA polymerase. 
 
In this work, the PCR reactions were carried out in the thermal cycler PT-100, MJ Research 
Inc. Each of the respective P450s from the high GC (71.38%) rich genomic DNA of 
Sorangium cellulosum So ce56 was amplified by using forward and reverse primers as 
described in Table I. 3. Direct or indirect cloning was done to design expression constructs in 
pCWori+. The insert possesses a Nde I site encoding the initiator codon ATG defining the 
5’end of the open reading frame and a hexa-histidine tag followed by a new stop codon and 
either restriction site for EcoRI, HindIII or XbaI. In two P450s, CYP266A1 and CYP262A1, 
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the originl initiating codon GTG in the genomic open reading frame (ORF) was replaced with 
ATG within the NdeI site.  
 
In case of CYP109C2, CYP109C1, CYP117B1, CYP259A1 and CYP110J1, the P450 
fragments were subcloned in pCR4 Blunt-Topo vector according to manufacturer’s 
instructions. All those cloned P450s have NdeI and XbaI site. But the XbaI site of those P450s 
inserts was methylated during transformation in normal E. coli and the restriction site was 
blocked. It was deactivated by transforming the plasmids into dam-negative E. coli GM1609 
and was subsequently digested and inserted into the NdeI and XbaI sites of expression vector 
(pCWori+). The typical reaction cocktail is illustrated in Table I. 4. 
 
Table I. 3: PCR programmes used for the amplification of the P450s from the genomic 
DNA of So ce56. 
P450s of 
Soce56 
GC %/ 
Tm value (°C) 
Thermal 
cycle* 
CYP109C1 45.2/66.8 
60.9/>75 
2 
CYP109C2 45.5/68.2 
60.9/>75 
2 
CYP109D1 61.8/>75 
58.7/>75 
3 
CYP110H1 63.6/>75 
56.5/>75 
4 
CYP110J1 63.3/73.6 
52.2/>72 
3 
CYP117B1 65.5/73.7 
54.3/>75 
1 
CYP124E1 50/69.5 
63.5/>75 
3 
CYP259A1 55.9/73.1 
56.5/>75 
1 
CYP260A1 62.9/>75 
53.1/>75 
3/1 
CYP260B1 34.3/64.8 
52.1/>75 
3a/2 
CYP261A1 57.1/74.2 
59.2/>75 
3a 
   
 
P450s of 
Soce56 
GC %/ 
Tm value (°C) 
Thermal 
cycle* 
CYP261B1 61.1/>75 
57.1/>75 
4 
CYP262A1 68.6/>75 
51.0/>75 
3 
CYP262B1 52.8/72.9 
59.2/>75 
3/2 
CYP263A1 58.8/74.3 
57.1/>75 
3a 
CYP264A1 52.9/71.9 
57.1/>75 
3 
CYP264B1 
 
Site directed 
mutagenesis 
45.5/68.2 
51/>75 
5 
 
 
6 
CYP265A1 60/>75 
61.2/>75 
3 
CYP266A1 
 
62.5/74.6 
49.1/>75 
2 
CYP267A1 59,4/73.3 
57.4/>75 
 
1 
CYP267B1 55.6/74 
53.1/>75 
3/2 
CYP266B1P 
 
 
64.9/>75 
63.3/>75 
3/2 
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*Thermal cycle:  
1: Initial denaturation 98°C for 2 min, denaturation 98°C for 10 s, annealing 50°C for 35 s,  
elongation 72°C for 2 min for 35 cycle, final elongation 72°C for 10 min with phusion 
polymerase, DMSO and GC buffer. 
2: Initial denaturation 98°C for 2 min, denaturation 98°C for 15 s, annealing 55°C for 30 s, 
elongation 72°C for 1:30 min for 35 cycle, final elongation 72°C for 10 min with phusion 
polymerase, DMSO and GC buffer. 
3: Two step PCR: Initial denaturation 98°C for 5 min, denaturation 98°C for 15 s, annealing 
and elongation 72°C for 40 s for 30 cycles, final elongation 72°C for 10 m with phusion 
polymerase, DMSO and GC buffer. 
3a:Two step PCR: Initial denaturation 98°C for 5 min, denaturation 98°C for 15 s, annealing 
and elongation 72°C for 40 s for 30 cycles, final elongation 72°C for 10 min with phusion 
polymerase and HF buffer. 
4: Modified Two step PCR: Initial denaturation 98°C for 2 min, denaturation 98°C for 10 s, 
annealing and elongation 72°C for 55 s for 30 cycles, final elongation 72°C for 10 min 
with phusion polymerase, DMSO and GC buffer. 
5: Initial denaturation 98°C for 2 min, denaturation 98°C for 15 s, annealing 55°C for 30 s, 
elongation 72°C for 1:30 min for 35 cycles, final elongation 72°C for 10 min with phusion 
polymerase and HF buffer. 
6: Site directed mutagenesis: Initial denaturation 95°C for 5 min, denaturation 95°C for 30 s, 
annealing 55°C for 1 min, elongation 70°C for 9 min for 16 cycles, final elongation 72°C 
for 10 min with Pfu polymerase. 
 
Table I. 4: Standard PCR reaction mix for genomic DNA amplification 
Components Volume 
Genomic DNA (100-400 ng) X µl 
5X buffer (GC/HF) 10 µl 
DMSO (only for GC buffer) 1.5 µl 
dNTPs (200 µM each) 2 µl 
Primer forward (0.5 µM) 1 µl 
Primer reverse (0.5 µM) 1 µl 
Water (ddH2O) Up to  50 µl 
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3. 2. 2. 7. Site-directed mutagenesis 
Site-directed mutagenesis was used to make point mutations, and delete or insert single or 
multiple amino acids. In this method, Pfu DNA polymerase replicated both plasmid strands 
with high fidelity. The procedure was performed using a recombinant vector with an inserted 
gene of interest and two oligonucleotide primers containing the desired mutation. The primers 
were extended during temperature cycling by Pfu DNA polymerase. This incorporation of 
primers generated a mutant plasmid containing staggered nicks. The treatment of the product 
with Dpn I resulted in the digestion of the parental DNA template.  
 
In this work site-directed mutagenesis was carried out for CYP264B1. In CYP264B1, the start 
codon (NdeI) was also present inside the ORF at 737 base pair towards 3’ end. The NdeI site 
in the ORF was removed by a point mutation maintaining the original amino acid sequence. A 
point mutation was done with Site-Directed Mutagenesis Kit (Stratagene Ltd, Cambridge, 
UK) according to the manufacturer’s instruction. For this, firstly, CYP264B1 encoding ORF 
was amplified from the genomic DNA of So ce56 with primers (Table I. 2) in a reaction 
cocktail (Table I. 4) and cloned into pCR4 Blunt-Topo vector according to manufacturer’s 
instruction. The positive clone of CYP264B1 was confirmed by automatic DNA sequencing 
at MWG Biotech. The positive clone of pCR4 Blunt-Topo_CYP264B1 was mutated my site 
directed mutagenesis with mutagenic primers (Table I. 2) in a reaction cocktail (Table I. 5) 
using programe ‘Thermal cycle 6’ (Table I. 4). The PCR product was digested with DpnI for 
4 hours at 37°C and 1µl was used for electro-transformation of competent E. coli TOP10F´. 
The positive mutated-clone of CYP264B1 in pCR4 Blunt-Topo vector was selected by 
restriction digestion and was confirmed by automatic DNA sequencing in MWG Biotech. 
Thus obtained positive mutated-insert was cut with NdeI and HindIII, and was finally cloned 
into expression vector pET17b at same restriction sites. 
 
Table I. 5: PCR reaction mix for site directed mutagenesis  
Components Volume Components Volume 
plasmid DNA (50 ng) X µl Primer 2 (0.2 µM) 1 µl 
10 x Pfu reaction buffer 5 µl Pfu DNA polymerase (2.5 u/µl) 0.5 µl 
dNTPs (100 µM each) 2 µl Water (ddH2O) 
Primer 1 (0.2 µM) 1 µl  
Up to 50 
µl 
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3. 2. 3. Microbiological Methods 
3. 2. 3. 1. Cultivation and storage of bacteria 
Unless otherwise stated, all the microbiological procedures for molecular cloning were carried 
out according to the standard methods as described previously (Sambrook and Russell, 2001). 
 
3. 2. 3. 2. Preparation of competent cells 
The process by which the foreign DNA is introduced into bacteria is known as bacterial 
transformation. When the bacteria grow under selective conditions (like antibiotic stress), the 
plasmid DNA remains stable in the cells, because of its resistance pattern to the selective 
antibiotic. The cells should be competent enough to incorporate the extra-chromosomal DNA. 
Depending upon the experimental purpose, chemical or electro-competent cells can be 
applied. In this work, both types of the competent cells were used. 
 
3. 2. 3. 2. 1. Preparation of electro-competent cells  
E. coli TOP10F’ competent cell was used for the cloning purpose. The overnight seed culture 
of 4 ml was prepared and was inoculated in 400 ml of LB-medium (Merck). The culture was 
grown at 37°C at 180 rpm, till the absorbance reached to 0.4-0.5 at 600 nm. The culture flask 
was incubated on ice for 30 min and was centrifuged at 4000 rpm for 15 min at 4°C. The 
bacterial pellet was dissolved in 400 ml of ice cold sterile distilled water and was centrifuged 
as before. The pellet was again resuspended in 200 ml of ice cold sterile distilled water and 
was centrifuged as before. Thus obtained bacterial cell pellet was resuspended in 20 ml of ice 
cold sterile 10% glycerol and centrifuged as before. The pellet was finally dissolved in 2 ml 
of ice cold sterile 10% glycerol and was divided into aliquots of 50 µl in microfuge tubes. The 
tubes were immediately frozen by liquid nitrogen and stored at -80°C. The cell count was 3 x 
1010 cells/ml.  
 
3. 2. 3. 2. 2. Preparation of chemical competent cells  
In this work, the competent cells were used for the protein expression and plasmid preparation 
purpose. The chemically competent cells were made from E. coli Top 10, BL21, BL21 (DE3), 
JM109 and Rosetta cells according to the need. Overnight cultures of each strain of E. coli 
cells were inoculated in 3 ml of nutrient broth (Merck) containing 10 mM Mg2+ either from 
2M MgSO4 or 2M MgCl2 and were grown at 37°C for 12-16 hours at 180 rpm. The culture 
was 100 fold diluted in 50 ml main culture volume of LB medium containing 10 mM Mg2+ 
and was incubated at 37°C on a shaker at 150 rpm. The cell density was monitored once per 
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hour until the optical density (A600) reached 0.3-0.5. The cell culture was harvested by 
centrifugation at 4000 rpm for 15 min at 4°C. The pellet was suspended in 14 ml TFP I buffer 
(Appenxidx II) and incubated on ice for 1 hour. After a further centrifugation, the cells were 
resuspended in 2 ml TFP II buffer (Appendix II). Aliquots of 100 µl volume of the competent 
cells were transferred into a chilled sterile microfuge tube. The cells were frozen with liquid 
nitrogen and were stored at -70°C.  
 
3. 2. 3. 3. Transformation of E. coli 
3. 2. 3. 3. 1. Heat shock transformation 
Heat shock transformation was applied to introduce the plasmid DNA into cells (Sambrook 
and Russell, 2001). The chemically competent cells were defrosted slowly on ice for 10 min 
and 1 µl (20-100 ng) plasmid DNA was added. It was incubated for 30 min on ice. The heat 
shock was performed at 42°C for 90 sec followed by incubation on ice for 5 min. Then 250 µl 
SOC medium (Appendix IV) was added to the cells and was incubated at 37°C for 1 h at 180 
rpm. 100 µl of the culture were plated on nutrient agar (Merck) plates containing appropriate 
antibiotic. The plates were incubated at 37°C overnight. 
 
3. 2. 3. 3. 2. Electroporation 
Higher transformation efficiency is generally required for cloning purpose so that the 
competent cells can have higher chance to incorporate the foreign plasmid. In this method, 
plasmid DNA was introduced into bacterial cells by dielectric breakdown of cell membranes. 
Electro-competent cells were thawed on ice and mixed with 3-5 µl of dialyzed ligation 
mixture. The suspension (~50 µl) was transferred to a chilled 0.1 cm electroporation cuvette 
and was jerked to remove air space. The cuvette was placed in EasyjecT Prima electroporator 
(Equibio) and an electric pulse of 18 kV/cm was applied. Cells were immediately resuspended 
in 400 µl of SOC medium, incubated at 37°C for 1 hour and plated on nutrient agar plates 
containing appropriate antibiotics. 
 
3. 2. 4. Protein expression and purification 
3. 2. 4. 1. Heterologous gene expression of His6-cytochrome P450 
E. coli strains BL21, BL21 (DE3), JM109 and Rosetta and were used as heterologous hosts 
for the expression of P450s from So ce56. A single colony was inoculated into 50 ml Terrific 
Broth (TB) (Appendix IV) containing ampicillin (100 µg per ml) and was grown overnight at 
37°C. The main culture was inoculated with 1:100 dilution of the overnight culture in TB with 
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the same concentration of ampicillin and incubated at 37°C in a baffled flask at 90-120 rpm. 
When the optical density (A600) of the culture reached 0.8 to 1.0, protein expression was 
induced with 0.8 mM isopropyl-β-D-thiogalactopyranoside (IPTG). In the mean time, 0.5 mM 
δ-aminolevulinic acid (δ-ALA) and ampicillin (50 µg/ml) were added and cells were further 
grown at lower temperature (25°C to 30°C) for 36 to 48 hours in a New Brunswick Inova 
Shaker, model Excella E25. Expression of the P450s was monitored by analyzing the cell 
extracts by SDS-polyacrylamide gel electrophoresis.  
 
3. 2. 4. 2. Cell lysis by sonication 
The expressed cell pellet of P450 was harvested by centrifugation at 4°C. It was resuspended 
in 50 ml (per liter cell culture) of lysis buffer A (Appendix III). Phenylmethylsulphonyl 
fluoride (PMSF) was added to a final concentration of 1 mM and the suspension was 
sonicated in an ice bath. Cell debris was removed by centrifugation at 6 x 104 x g for 30 min 
at 4°C. The soluble fraction was used to record carbon monoxide-reduced difference (CO-
difference or COD) spectra (Omura and Sato, 1964) to monitor the presence of P450. The 
parameters of the sonication are shown in Table 1.6.  
 
Table 1. 6. Parameteres for sonication of cell pellet 
Sonotrode type:  1 Pulse duration  30 sec 
Oscillation amplitude  25 µm Medium temperature 10°C 
Operating time  30 min Stirrer speed 200 rpm 
Pulse-duty factor  1 Pre-stir time 0 min 
 
3. 2. 4. 3. Protein purification 
Protein purification was carried out at 4°C using a purification unit (Äkta Prime, Amersham 
Pharmacia biotech) equipped with a flow cell UV/vis monitor and gradient mixer. The 
cytosolic fraction was applied to an immobilized metal ion affinity chromatography column 
(TALON, Clontech) that had been equilibrated with buffer B (Appendix III). The column was 
washed with 5 column volumes of buffer B. The tagged protein was eluted with buffer C 
(Appendix III). The fractions were collected and concentrated by ultra filtration (Centriprep 
30, Millipore) to less than 2 ml. The concentrated sample was finally passed over a Superdex-
75 column. The column was washed with 5 column volumes of buffer D (Appendix III). 
Fractions of highest purity (A416/A280>1.5) were retained, pooled and concentrated by ultra 
filtration (Centriprep 30, Millipore).  
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3. 2. 4. 4. Determination of the protein concentration 
Protein concentration was measured by using BC (Bicin-Choninic acid) Assay protein 
quantitation kit (Uptima Interchim, Montlucon, France) according to the manufacturer’s 
instructions. 
 
3. 2. 4. 5. SDS (Sodium Dodecylsulfate) polyacrylamide gel electrophoresis 
The discontinuous gel electrophoresis was used to monitor the status of protein expression 
and the purity of the P450s obtained during successive steps of heterologous protein 
expression and purification. Proteins are separated according to their charge and molecular 
mass. Laemmli discontinuous gel electrophoresis method (Laemmli, 1970) was followed. In 
this work, for several different P450s, a 10 or 12 or 15 % separating gel solution (Appendix 
III) with 5% stacking gel solution (Appendix III) were used. The sample buffer composition 
was as described by Sambrook and Russell, 2001. The gels were stored in soaked papers with 
water at 4°C until use. 
 
A portion of the protein sample was mixed with 2X SDS loading buffer (1:1 v/v) and heated 
at 100°C for 5 min. The samples were applied to the slots (wells) of the stacking gel and were 
run for 15 min at 120 V and then separated on a separating gel at 120 V until the 
bromophenol blue front, the tracking dye, reached to the bottom of the gel. The reference 
molecular weight marker, pre-stained broad range protein marker, from NEB (New England 
Biolabs, Beverly, MA, USA) was used. The gel was stained with Coomassie staining solution 
for 30 min at RT on shaker and then incubated in destaining solution until the protein bands 
become clearly visible. The gels were then slowly dried on a gel dryer (Model 583 gel dryer, 
BioRad) for storage. 
 
3. 2. 5. Spectrophotometric characterization  
3. 2. 5. 1. Spectrophotometric characterization of P450s of So ce56 
All absorbance spectra were measured using a UV-2101PC, SHIMADZU spectrophotometer 
at room temperature. The carbon monoxide difference spectra of purified P450s were 
analyzed by the spectral method of Omura and Sato (Omura and Sato, 1964). Briefly, the 
solution of P450 enzyme (2.5 µM) in 50 mM potassium phosphate buffer (pH 7.5) was 
reduced with few grains of sodium dithionite. It was split into two cuvettes and a base line 
was recorded between 400 and 500 nm. The sample cuvette was bubbled gently with carbon 
monoxide for 30 seconds and a spectrum was recorded. 
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3. 2. 5. 2. Investigation of electron transfer partners  
The native electron transfer partners of the Sorangium cellulosum So ce56 are not well known 
so far. The heterologous partners, spinach ferredoxin (Fdx)/ferredoxin reductase (FdR) and 
mammalian adrenodoxin (Adx)/adrenodoxin reductase (AdR) were used for this purpose. In 
this work, Adx (4-108) (Uhlmann et al., 1994) was used. The competency of Fdx/FdR or 
Adx/AdR to reduce So ce56 P450s was determined by recording the formation of peak 
maxima at 450 nm during COD measurement (Lei et al, 2004). Individual P450s with ratios 
of P450: Fdx/Adx: Fdr/AdR of 1:10:3 (200 pmol: 2 nmol: 600 pmol) were incubated with 
buffer E (Appendix III). After this NADPH was added to a final concentration of 1 mM. The 
spectrum of NADPH-reduced samples was recorded after bubbling with CO in the sample 
cuvette and was compared with the spectra of samples reduced with sodium-dithionite for 
each cytochrome P450.  
 
3. 2. 6. Biophysical characterization 
3. 2. 6. 1. Circular dichroism 
Circular dichroism (CD) is the differential absorption of the left- and right-circularly 
polarized components of plane-polarized electromagnetic radiation. The CD spectroscopic 
effect is observed when linear polarized light passes through a chiral (asymmetric) 
environment which absorbs the right and left circularly polarized vector components to 
different extents (Holtzhauser, 1996). When the beams recombine after passing through the 
sample, elliptically polarized light is produced. Dichroism is then expressed as the ellipticity 
in degrees. The chromophore may be either intrinsically chiral or placed in an asymmetric 
environment.  
 
In this work CD spectra were recorded at 25°C on a JASCO J715 spectrophotometer. 
Triplicate spectra of each were recorded and averaged. Far-UV spectra (195-260) were 
recorded with 5 µM P450 in 10 mM potassium phosphate buffer, pH 7.5. The near-UV 
spectra (300 to 450 nm) were recorded with 20 µM P450 in 10 mM potassium phosphate 
buffer, pH 7.5  
 
3. 2. 6. 2. Electron Paramagnetic Resonance (EPR) measurements 
An unpaired electron present in an atom has particular importance which will generate a net 
magnetic moment due to the spin and orbital magnetic moments of its unpaired electrons. The 
spin magnetic moments of unpaired electrons are randomly orientated in the absence of a 
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magnetic field, but the application of a field aligns the magnetic spin parallel or anti-parallel 
to the magnetic field orientation. In electron paramagnetic resonance (EPR) spectroscopy, the 
presence of an external magnetic field allows detection of unpaired electrons carrying an 
electron-spin magnetic moment. In a magnetic field each orbital energy level will be split into 
several energy levels and the transitions between them are associated with a net absorption of 
energy from the applied electromagnetic radiation (Hoff, 1989). This microwave absorption 
signal is also dependent on the orientation of the molecule bearing the unpaired electron with 
respect to the magnetic field, on the mobility of that molecule and on the presence of other 
unpaired electrons in the vicinity. The resulting resonance between the electron and a 
microwave field forms the basis of EPR, which is detected by a spectrometer to generate a 
signal. The frequency for EPR is calibrated in the dimensionless number called the g-factor 
which is defined in the following equation: ν = (gβB)/h where, ν = operating frequency of the 
spectrometer (constant), g = the g-factor, β = electron Bohr magnetron (9.273 x 10-23
 
Tesla), B 
= magnetic field (Tesla) at relevant point in EPR spectrum and h = Planck’s constant. In the 
equation, gβB describes interaction of electron spin with the magnetic field, characterized by 
the intrinsic g-factor (Zeeman interaction). The g-factor itself defines the centre of the 
resonance.  
 
In this work, the EPR spectra were recorded on a Bruker ESP300 spectrometer (X-band, 9.5 
GHz) equipped with a continuous flow helium cryostat ESR 900 and an ITC 4 temperature 
controller (Oxford Instruments) to allow measurements down to 5 K. The microwave 
frequency was measured by a HP 5350B frequency counter. Other parameters of 
measurements are given in the Figure legends in result. EPR measurements of oxidized P450s 
and the subsequent data analysis were done together with Dr. Reinhard Kappl, at the Institute 
of Biophysics, Universitätsklinikum, Universität des Saarlandes, Homburg.  
 
Prior to the measurement, the oxidized form of So ce56 P450 samples of 100-150 µM in 10 
mM potassium phosphate buffer (pH 7.4) were transferred in EPR quartz tubes (Wilmad) and 
frozen in liquid nitrogen. The spectral parameters (g-tensor, line width) of the heme-centers 
were obtained by accumulation of the spectra with the programs Simfonia or Xsophe 
(Bruker). Standard measurement parameters used in this work were: modulation frequency-
100 kHz, microwave strength-10 mW, modulation amplitude-10 G and time constant- 0.3 sec. 
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3. 2. 7. Mass determination 
In this work, seven of the P450s (CYP109C1, CYP109C2, CYP109D1, CYP260A1, 
CYP264A1, CYP264B1 and CYP266A1) were selected to determine the mass for both the 
apo- and holo-form. The mass of the P450s was measured in collaboration with Aurélie 
Même, Laboratoire de Dynamique et Structure Moléculaire par Spectrométrie de Masse, 
Institut de Chimie, Starsbourg, France.  
 
Prior to mass analysis, the samples were desalted on Vivaspin 500 (10 kDa) centrifugal 
concentrators (Millipore, Bedford MA, USA) in 20 mM ammonium acetate. Eight 
dilution/concentration steps were performed at 4°C and 10,000 rpm. Ammonium acetate 
enables native structures of proteins to be preserved and is compatible with ESI-MS analyses. 
 
Mass spectrometric studies were performed in the positive ion mode using an ESI-TOF 
(Time-of-flight) mass spectrometer (microTOF, Bruker Daltonics, Bremen, Germany). 
Calibration of the instrument was performed using protonated horse myoglobin (Sigma) 
diluted to 2 pmol/µl in a 1:1 water-acetonitrile mixture (v/v) acidified with 1% formic acid. 
Purity and homogeneity of the samples were estimated by mass analysis in denaturing 
conditions: samples were diluted to 5 µM in a 1:1 water-acetonitrile mixture (v/v) acidified 
with 1% formic acid. In these conditions the non-covalent are disrupted, which allows the 
measurement of the molecular weight of the protein with a good precision. In non-denaturing 
conditions, the mass measurement of native cytochrome P450 was performed in 20 mM 
ammonium acetate to preserve its native conformation in solution. Samples were diluted to 10 
µM. Great care was taken on instrumental parameters. Molecular species were assumed to be 
represented by series of peaks corresponding to multiply protonated ions. 
 
3. 2. 8. Screening of compound library  
In this work, four of the P450s (CYP109C1, CYP109C2, CYP260A1 and CYP266A1) were 
selected and a library consisting of ∼17,000 substances was screened at the Forschungsinstitut 
für Molekulare Pharmakologie in Berlin, in cooperation with Prof. Oschkinat/Dr. von Kries.  
 
The screening was done in 384 wells micro titer plate (MTPs) (3702 Corning) by an 
automated pipette robot cyclone ALH 3000 Workstation. This was equipped with plate-
photometer (Tecan-Safire) and an automated dispenser (EasySypense2). During screening, for 
each plate 12 ml of P450s solution of final concentration 2.4 µM was used. The stocks of the 
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P450s (CYP109C1, CYP109C2, CYP260A1 and CYP266A1) were diluted in assay buffer 
(AB) (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 20% glycerin, 0.05% Tween-20 and 1 mM 
DTT). At each time only one of the P450s was used for screening. During screening, firstly 
20 µl of 1X AB was added with the dispenser. As illustrated in Figure I. 1, row 23 and 24 
were used as controls. During screening, 0.5 µM of each compound from the ligand library 
were added in each well of the titer plate with Cyclone ALH 3000 Workstation. Wavelength 
of 350-450 nm with an interval of 10 nm was fixed with Tecan-Safire plate-photometer and 
the absorbance of the substances were recorded. P450 solution of 30 µl per well (1.5 µM final 
concentration) was added, centrifuged and the mixture was incubated for 15 min at room 
temperature in the dark. The measured values were transported in excel data-sheet and were 
plotted as absorbance vs wavelength to observe Type I or Type II binding spectra. During the 
measurements, the background due to cytochrome P450 was subtracted from the value of the 
substance spectrum. For the validation, the hits of the final concentration of 200 µM, 150 µM, 
100 µM, 50 µM and 16 µM were prepared in 1X AB and 30 µl per well of P450 (1.5 µM final 
concentration) were added and plotted as before. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
A s s s s s s s s s s s s s s s s s s s s s s RF d 
B s s s s s s s s s s s s s s s s s s s s s s RF d 
C s s s s s s s s s s s s s s s s s s s s s s RF d 
D s s s s s s s s s s s s s s s s s s s s s s RF d 
E s s s s s s s s s s s s s s s s s s s s s s RF d 
F s s s s s s s s s s s s s s s s s s s s s s RF d 
G s s s s s s s s s s s s s s s s s s s s s s RF d 
H s s s s s s s s s s s s s s s s s s s s s s RF d 
I s s s s s s s s s s s s s s s s s s s s s s P450 d 
J s s s s s s s s s s s s s s s s s s s s s s P450 d 
K s s s s s s s s s s s s s s s s s s s s s s P450 d 
L s s s s s s s s s s s s s s s s s s s s s s P450 d 
M s s s s s s s s s s s s s s s s s s s s s s P450 d 
N s s s s s s s s s s s s s s s s s s s s s s P450 d 
O s s s s s s s s s s s s s s s s s s s s s s P450 d 
P s s s s s s s s s s s s s s s s s s s s s s P450 d 
Figure I. 1: The representative diagram of the 384 wells Micro Titer Plate (MTPs) that 
used for screening. The representative diagram shows that 23 and 24 rows were fixed for 
control. The references and controls are shown as: RF = Reference, d = DMSO as a Blank, s = 
replicated substance form ligand library and P450 = individual P450 solution of 1.5 µM final 
concentration. 
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4. Results 
4. 1. Bioinformatics analysis 
4. 1. 1. Cytochrome P450 complement of So ce56 (CYPome of So ce56) 
The genome sequence project of So ce56 revealed 21 putative cytochrome P450s. These 
P450s are distributed all over the genome which is illustrated in the chromosomal physical 
maps in Figure I. 2. The genomic abundance of P450 is 0.15% of all coding sequences, which 
is relatively low because of the large genomic size in comparison with 0.2% and 0.4% as 
described for Streptomyces coelicolor A(3)2 and Streptomyces avermitilis, respectively 
(Lamb et al., 2003). All 21 P450s of So ce56 possess a conserved threonine in the I-helix, and 
glutamic acid and arginine in the EXXR motif of the K-helix. The heme-binding signature 
(FxxGxxxCxG) is absolutely conserved in 19 P450s. In CYP267A1 and CYP265A1, the 
aromatic amino acid phenylalanine in the heme domain is replaced by the neutral aliphatic 
amino acid leucine. The amino acid residues conserved in the I-helix, K-helix and the heme-
binding motif of individual P450 are illustrated in Table I. 7 with their respective amino acid 
positions. The details of the amino acids alignment of all 21 cytochrome P450s are illustrated 
in Appendix VIII. A. 
 
 
 
Figure I. 2: Physical map of the Sorangium cellulosum So ce56 chromosome and 
distribution of cytochrome P450, ferredoxin (Fdx), and ferredoxin reductase (FdR) 
genes. All 21 So ce56 P450s (red arrow) and one pseudo-cytochrome (CYP266B1P) with 
respective P450s annotation are assigned in the genomic location of the 13,033,779 base pairs 
genome. The distribution of 8 Fdx (brown arrow) and 2 FdR (in blue with blue arrow) are 
represented with respect to the gene number as annotated in NCBI. 
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Table I. 7: Conserved domains in Sorangium cellulosum So ce56 genome (So ce56 
CYPome). Residues conserved in the I-helix (Thr), the K-helix (Glu and Arg), and the heme-
binding motif (Phe, Gly and Cys) are highlighted in color. The unusual amino acid Leucine 
(L) is in italics-blue in heme-domain of CYP267A1 and CYP265A1. The numbers on the 
superscript of the starting and end of each domain represent the position of amino acids in 
P450 sequences.  
 
P450 of  
So ce56 
 
Gene  
name2 
I-helix K- helix Heme binding motif 
CYP109C1 sce0122 226AGTETA231 
 
264EEVLR268 
 
329FGHGIHFCIG338 
 CYP109C2 sce8913 226AGHETT231 
 
264EEVLR288 
 
329FGHGIHFCIG338 
 CYP109D1 sce4633 241AGNDTT246 
 
279EETLR283 
 
344FGQGTHFCIG353 
 CYP110H1 sce3065 251AGHETT256 
 
304KEALR308 
 
375FGGGHRRCIG384 
 CYP110J1 sce6424 255AGHETT260 
 
308LEALR312 
 
379FGGGARRCLG388 
 CYP117B1 sce5528 272AGHETS277 
 
326REALR330 
 
399FGGGAHFCLG408 
 CYP124E1 sce7867 239AGHDTT244 
 
277EEMLR281 
 
342FGIGPHVCLG351 
 CYP259A1 sce4635 250AGHETS255 
 
306REVLR310 
 
379FGGGPHFCLG388 
 CYP260A1 sce1588 279GGYETT284 
 
317EEGMR321 
 
331FGGGAHFCVG340 
 CYP260B1 sce4806 228GSYETT233 
 
266EESTR270 
 
331FGGGLHYCVG340 
 CYP261A1 sce0200 287AGEDTT292 
 
344QETLR348 
 
421FGSGPRVCPG430 
 CYP261B1 sce5725 299AGEDTT304 
 
355QETLR359 
 
431FGGGPRVCPG440 
 CYP262A1 sce2191 247AGNETT252 
 
302QEAMR306 
 
376FGGGPRQCIG385 
 CYP262B1 sce1860 279AGYETT284 
 
334QEALR338 
 
408FGIGQRQCVG417 
 CYP263A1 sce4885 263VGHETS268 
 
318NECLR322 
 
392FGAGQRICLG401 
 CYP264A1 sce6323 229GGLETT234 
 
267EEMMR271 
 
331FGHGAHFCLG340 
 CYP264B1 sce8551 235AGLETS240 
 
273EEVMR277 
 
338FGHGAHFCLG347 
 CYP265A1 sce8224 234GGLDTT239 
 
272EEILR276 
 
337LGAGPHHCLG346 
 CYP266A1 sce5624 249AGFETV254 
 
287DEMLR291 
 
353FGGGHHFCIG362 
 CYP267A1 sce0675 263GGHETT268 
 
301EELLR305 
 
366LGLGVHYCAG375 
CYP267B1 sce7167 243AGHETT248 281EEALR285 347FGGGIHFCLG356 
 
 
1 CYP names as annotated at website http://drnelson.utmem.edu/CytochromeP450.html 
2 Gene name as annotated in NCBI 
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4. 1. 2. Phylogenetic relationship of So ce56 CYPome 
The huge genome of S. cellulosum So ce56 contains nine new families of cytochrome P450s. 
This includes CYP259 (subfamily CYP259A1), CYP260 (subfamilies CYP260A1 and 
CYP260B1), CYP261 (subfamilies CYP261A1 and CYP261B1), CYP262 (sub-families 
CYP262A1 and CYP262B1), CYP263 (subfamily CYP263A1), CYP264 (subfamilies 
CYP264A1 and CYP264B1), CYP265 (subfamily CYP265A1), CYP266 (subfamily 
CYP266A1) and CYP267 (subfamilies CYP267A1 and CYP267B1). The remaining seven 
P450s sequences belong to the existing P450 families. Three of the P450s sequences 
(CYP109C1, CYP109C2 and CYP109D1), belong to the existing CYP109 family. Two 
enzymes (CYP110H1 and CYP110J1) are the members of the CYP110 family. CYP117B1 
and CYP124E1 belong to the already existing CYP117 and CYP124 families, respectively. 
The phylogenetic relationship of all P450s in So ce56 shows the relatedness of the different 
P450 families (Figure I. 3). CYP266A1, a new member of CYP166 family, was found to be 
distantly related to the rest of the So ce56 P450s.  
 
 
 
Figure I. 3. Phylogenetic tree of Sorangium cellulosum So ce56 cytochrome P450. The 
alignment was done with 10 gap setting and 1 gap extension having slow (very accurate) 
alignment input in CLC Workbench. The tree was constructed by using Neighbor Joining 
Algorithm with performing boot strap analysis of 1000 times replicate. Bootstrap values are 
shown at branch nodes. The bar in the left corner indicates 0.8 amino acid substitutions per 
amino acid for the branch length. 
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4. 1. 3. The relationship of P450s of So ce56  
The relatedness of P450s of So ce56 was studied and their similarities were compared with its 
own P450s members. Moreover, to study the phylogenetic relationship each of the P450s of 
So ce56 was compared with other bacterial P450s in the database of P450s. For this, the 
amino acid sequences of each of the P450s were used as a query for the local BLAST search 
of the GenBank using a recent non-redundant protein data base from NCBI and the closest 
homologues for the different myxobacterial P450s were identified and illustrated in Table I. 8.  
 
Among 21 P450s, only four families (CYP109, CYP110, CYP117 and CYP124) are 
belonging to the assigned P450 families. CYP109 family in So ce56 has 3 members 
(CYP109C1, CYP109C2 and CYP109D1). CYP109C1 has 68.1% sequence identity with 
CYP109C2 and 39.4% with CYP109D1 whereas CYP109C2 shows 38.8% sequence identity 
with CYP109D1 of Se ce56. These three members almost have 40% sequence identity with 
the members of CYP195A4 of Stigmatella aurantiaca, CYP113A1 of Saccharopolyspora 
erythraea, CYP107A1 of Streptomyces avermitilis and 30% identity with CYP105D5 of S. 
coelicolor A(3)2. (Table I. 8). This relatedness assumed the potential scope of CYP109D1 for 
xenobiotic and secondary metabolism as well as fatty acids hydroxylation as these 
homologues was performing such activities (www.drnelson.utmem.edu/cytochrome 
P450.html). CYP110H1 and CYP110J1 of So ce56 are the members of a larger family having 
nearly 40% identity with CYP110E1 and 44% identity with CYP110E4 of Nostoc sp and 
Gloeobacter violaceus, respectively, and the relatedness indicate the probability of having 
alkane affinity fatty acid hydroxylation (Torres et al., 2005). CYP117B1 of So ce56 shares 
41% sequence identity with CYP117A1 of Bradyrhizobium japonicum and CYP117A3 of 
Mesorhizobium loti, respectively, which suggested a probable role for terpenoid 
synthesis/conversion (Tully et al., 1998). CYP124E1 of So ce56 has 44% and 40% sequence 
identity with CYP124A1 of Mycobacterium tuberculosis and CYP124 of Rhodococcus sp 
(strain RHA1), respectively, but both of them were uncharacterized P450s and their 
experimental evidences were not know till now. As a result, the putative function of 
CYP124A1 was not speculated.  
 
The newly assigned P450 families (CYP259, CYP260, CYP261, CYP262 and CYP265) have 
30-39% sequence identity with several other bacterial P450 (Table I. 8). However, the 
experimental data for them were not existed and their functions were not predicted. Likely, 
the other new family (CYP264, CYP266 and CYP267) of So ce 56 exhibits 36-40% sequence 
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identity with CYP107 of Streptomyces sp. and other bacterial P450s (Table I. 8) which 
suggest the homologue to have a potential role for xenobiotic and secondary metabolism 
(Haydock et al., 1991; Jungmann et al., 2005).  
 
Table I. 8: Cytochrome P450s in Sorangium cellulosum So ce56 with their closest 
homologues. Pairwise sequence alignment was done to find the identity, similarity and the 
gaps of respective P450s.  
Match in databaseb  CYPa 
names Speices CYPa name Gene IDc % 
Identityd 
Gaps 
% 
CYP109C1  Solibacter usitatus 
Bacillus subtilis  
Saccharopolyspora 
erythraea 
- 
CYP109B1 
 
CYP107B1 
Q023S4 
yjiB 
 
M83110 
52 
43 
 
41 
1 
0 
 
8 
CYP109C2  Bacillus subtilis  
Saccharopolyspora 
erythraea 
Bradyrhizobium 
japonicum 
CYP109B1 
 
CYP113A1 
 
CYP107AA1 
yjiB 
 
eryK  
 
BAC51802 
43 
 
40 
 
40 
0 
 
3 
 
5 
CYP109D1  Saccharopolyspora 
erythraea 
Bacillus subtilis 
Streptomyces 
venezuelae 
 
CYP107B1 
CYP109A1 
 
CYP107L1 
 
CAL99581 
NP_389103 
 
AAC64105 
 
41 
39 
 
37 
 
1 
7 
 
5 
CYP110H1  Nostoc sp. 
Gloeobacter violaceus 
Myxococcus xanthus 
CYP110E1 
CYP110E4 
CYP209A1 
BAB76532 
AP006578  
CAB40542 
40 
44 
36 
2 
2 
7 
CYP110J1  Gloeobacter violaceus 
Nodularia spumigena 
Nostoc punctiforme 
CYP110E5 
CYP110D2 
- 
AP006578  
EAW43774.1  
ZP_00109203 
42 
39 
40 
4 
3 
3 
CYP117B1  Mesorhizobium loti 
Bradyrhizobium 
japonicum  
Burkholderia rhizoxina 
CYP117A3 
 
CYP117A1 
- 
NP_106891 
 
BJ-4 
CAL69892  
41 
 
41 
40 
0 
 
0 
0 
CYP124E1  Rhodococcus sp 
Mycobacterium 
tuberculosis 
Stigmatella aurantiaca  
CYP125 
 
CYP124A1 
- 
ABG96453 
 
Rv2266 
EAU6400 
45 
 
44 
42 
0 
 
3 
1 
CYP259A1*  Mesorhizobium loti 
Bradyrhizobium 
japonicum 
Pseudomonas 
fluorescens 
CYP117A3 
 
CYP117A1 
 
- 
NP_106891  
 
BJ-4 U12678   
 
AAY92264.1          
36 
 
34 
 
33 
1 
 
1 
 
1 
CYP260A1*  Saccharopolyspora 
erythraea 
Micromosospora 
griseorubida 
Streptomyces sp.  
 
CYP107B1 
 
CYP107E1 
CYP105D9 
 
M83110 
 
JP95  
AF509565  
 
35 
 
30 
33 
 
5 
 
4 
3 
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CYP260B1*  Streptomyces 
tubercidicus 
Rhodococcus sp.  
Pseudomonas 
aeruginosa 
 
CYP105S2 
CYP105 
 
CYP107S1 
 
AAT45294 
ABG94409 
 
ABJ12582 
 
31 
32 
 
32 
 
8 
4 
 
8 
CYP261A1*  Burkholderia 
phytofirmans  
Streptomyces 
avermitilis 
Magnetospirillum 
magnetotacticum 
 
- 
 
CYP184A1 
 
CYP173B1 
 
EAV04662 
 
cyp21 
 
AAP01002719 
 
44 
 
29 
 
30 
 
0 
 
5 
 
6 
CYP261B1*  Burkholderia 
phytofirmans  
Streptomyces 
avermitilis 
Streptomyces 
avermitilis 
 
- 
 
CYP184A1 
 
CYP102B2 
 
EAV04662 
 
cyp21 
 
cyp27 
 
44 
 
31 
 
30 
 
1 
 
5 
 
4 
CYP262A1*  
 
 
Myxococcus xanthus  
Bacillus halodurans 
Chloroflexus 
aurantiacus 
- 
CYP197A1  
 
- 
ABF92999 
BAB04298 
 
ABY34735 
37 
35 
 
41 
1 
4 
 
1 
CYP262B1*  Chloroflexus 
aurantiacus  
Streptomyces 
carzinostaticus  
Streptomyces 
avermitilis 
 
CYP205A1 
 
CYP208A2  
 
CYP184A1 
 
ABY34735 
 
AY117439 
 
cyp21 
 
40 
 
35 
 
35 
 
2 
 
4 
 
4 
CYP263A1*  Burkholderia 
thailandensis  
Streptomyces 
avermitilis 
Streptomyces 
globisporus 
 
CYP184A1 
 
CYP208A1 
 
- 
 
BTH_II2347. 
 
cyp21 
 
AAL06697 
 
34 
 
35 
 
35 
 
0 
 
5 
 
3 
CYP264A1*  Stigmatella aurantiaca  
Streptomyces sp. 
Streptomyces 
avermitilis 
CYP107B1 
CYP107AE1 
 
CYP107X1 
EAU64026 
BD133545 
 
cyp23 
58 
37 
 
37 
1 
5 
 
4 
CYP264B1*  Arthrobacter sp. 
Streptomyces 
avermitilis 
Bacillus licheniformis 
- 
 
CYP147B1 
- 
ABK03359 
 
cyp3 
yjiB 
39 
 
33 
32 
2 
 
3 
2 
CYP265A1*  Saccharopolyspora 
erythraea  
Streptomyces 
avermitilis 
Mycobacterium 
smegmatis 
 
CYP105P1 
 
CYP151A1 
 
- 
 
cypA 
 
pteC 
 
AF102510 
 
40 
 
38 
 
37 
 
1 
 
3 
 
1 
CYP266A1* Bradyrhizobium 
japonicum  
Streptomyces 
avermitilis 
 
CYP107AA1 
 
CYP147B1 
 
BAC51802  
 
cyp3 
 
40 
 
37 
 
1 
 
4 
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Bacillus subtilis CYP107H1 BioI  36 3 
CYP267A1* 
 
Roseiflexus sp.  
Streptomyces 
avermitilis 
Streptomyces 
venezuelae 
- 
 
CYP107P2 
 
CYP107L1 
ABQ89181 
 
cyp20 
 
pikC 
45 
 
41 
 
41 
1 
 
3 
 
6 
CYP267B1*  Stigmatella aurantiaca  
Streptomyces 
venezuelae  
Bacillus 
amyloliquefaciens 
CYP107B1 
 
CYP107L1 
 
CYP107K1 
EAU69748 
 
AF087022 
 
CAG23962 
51 
 
44 
 
42 
0 
 
3 
 
2 
 
Note: * = New members of P450 families found in So ce56 ; a = P450 names as annotated at 
the website: http://drnelson.utmem.edu/CytochromeP450.html; b = database search at NCBI; 
c = gene ID deposition in EMBL; d = the percentage identity represents the number of exact 
matches over the closed P450 length. 
 
4. 2. Genome mining of cytochrome P450 
Sequence alignment, homology modeling and spin-shift analysis are the existing theoretical 
and practical approaches for the prediction of potential substrates for several orphan 
cytochrome P450s. These approaches generally abolish the natural preponderance of 
corresponding neighboring genes of P450 in a genome. The study of proximal genes is more 
beneficial for those P450s which are in a cluster or in an operon with redox partners or with 
secondary metabolizing genes. The study of genomic organization of corresponding P450s 
may help to hypothesize some potential natural redox partners and/or potential 
natural/analogue substrates. Though various endogenous roles of P450s in several polyketide 
synthetase (PKS) gene cluster during secondary metabolite formation are already verified in 
some other strain of Sorangium cellulosum (Julien et al., 2000; Tang et al, 2000, Buntin et al., 
2008), the 13.1 Mbp genome of Sorangium cellulosum So ce56 has not been investigated so 
far. As this is the very first study of P450s in So ce56, a detailed genomic organization for 
each of the P450s with respect to the neighboring genes was studied .The genomic foot prints 
in accordance with the genome database of So ce56 with the direction of transcription (with 
arrow head of gene) were studied.  
 
4. 2. 1. P450s potentially involved in secondary metabolite formation 
It was observed that the genomic organization of P450s in So ce56 is different in comparison 
with other secondary metabolite producing strains like Streptomyces sp. In So ce56, though 
21 P450s are detected, none of them are directly organized in a cluster with ferredoxins or 
ferredoxin reductases. However, two of the P450s, CYP263A1 and CYP265A1, are found in 
 42 
a cluster with putative PKS and NRPS modules, respectively. The PKS module (sce4888) is 
detected downstream of CYP263A1 (sce4885). It is speculated that CYP263A1 potentially be 
involved in secondary metabolite biosynthesis (Figure I. 4).  
 
 
 
Figure I. 4: The genomic organization of CYP263A1. CYP263A1 (brown) and the PKS 
gene (sce4888 in green) are shown. The respective neighboring genes are - xynB4 (sce4884): 
xylan 1,4-beta-xylosidase, sce4885: CYP263A1, fabG9 (sce4886): 3-oxoacyl-(acyl-carier-
protein) reductase, sce4887: putative phospopantetheinyl transferase, sce4888: predicted PKS 
modules, sce4889: MarR family transcriptional regulator protein, sce4890: hypothetical 
protein, sce4891: protein kinase. 
 
Likely, CYP265A1 is found close to the putative NRPS module (sce8219) upstream in the 
genome which could have a potential role during secondary metabolite formation (Figure I. 
5). The neighboring genes of CYP265A1 (sce8224) also has several remarkable genes in 
upstream [a putative FkbH-protein (sce8221) which supposed to be involved in the 
methoxymalonyl-ACP biosynthesis] and downstream [a SAM-dependent methyl transferase 
(sce8225)].  
 
 
 
Figure I. 5: The genomic organization of CYP265A1. CYP265A1 (brown) and the NRPS 
gene (sce8219 in green) are shown. The respective neighboring genes are - sce8219: AMP-
dependent synthetase and ligase which function as non-ribosomal peptide synthetase (NRPS) 
modules and related proteins, sce8220: hypothetical protein, sce8221: putative FkbH-protein, 
sce8222: predicted acyl carrier protein, sce8223: hypothetical protein, sce8224: CYP265A1, 
sce8225: SAM-dependent methyl transferase, sce8226: acyl-CoA-ligase/synthetase, sce8227: 
putative acyl carrier protein. 
 
4. 2. 2. P450s with potential physiological role 
In the genomic organization of So ce56, three of the P450s (CYP124E1, CYP262A1 and 
CYP266A1) are clustered with other neighboring genes having some putative physiological 
functions. The P450s present in this cluster speculated to have some role to produce important 
derivatives having some physiological significance during the bacterial lifecycle in an 
ecological niche. Concerning this, a gene sce7866 in the adjacent upstream of CYP124E1 
(sce7867) has a putative function of protocatechuate catabolism. Furthermore, CYP124E1 
also has a putative phenylacetic acid (PA) degradation protein encoding gene (sce7863) in 
upstream (Figure I. 6. A). Similarly, in the upstream of CYP262A1 (sce2191), a putative 
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hydrolase encoding gene (xysA, sce2188) (Figure I. 6. B) is present. In CYP266A1 (sce5624), 
a gene encoding ubiquinone/menaquinone biosynthesis protein (ubiE4, sce5625) is present 
directly at an adjacent downstream. It was noticed that, CYP266A1 is the only P450 in So 
ce56 which has a NADH-flavin oxidoreductase (ferredoxin reductase, sce5629) within 4 
genes downstream (Figure I. 6. C). 
 
 
 
Figure I. 6: The genomic organization of P450s clustered with putative functional 
domain. The genes of P450s and the physiologically significant domains are shown in brown 
and green, respectively. A. Neighboring genes of CYP124E1.  The respective neighboring 
genes are - sce7862: sigma-54 dependent DNA-binding response regulator, sce7863: 
predicted penylacetic acid (PA) degradation protein in bacteria, alkA (sce7864): putative 
DNA-3-methyladenine glycoside, sce7865: hypothetical protein, sce7866: predicted 
protocatechuate catabolism protein, sce7868: hypothetical protein. The miscellaneous RNA 
(Misc_RNA) overlapped on sce7865 is shown in blue. B. Neighboring genes of CYP262A1. 
The respective neighboring genes are - xysA: endo-1-4-beta xylanase, sce2189: hypothetical 
protein, sce2190: putative hydrolase, sce2191: CYP262A1, sce2192: hypothetical protein, 
sce2193: hypothetical protein. C. Neighboring genes of CYP266A1. The respective 
neighboring genes are - sce5621: predicted iron-sulphur (Fe-S) oxidoreductase, sce5622: 
putative methyl transferases, sce5623: SAM dependent methyl transferases, sce5624: 
CYP266A1, ubiE4 (sce5625): ubiquinone/menaquinone biosynthesis protein, sce5626: 
transcriptional regulators, pta (sce5627): putative acyl transferases, sce5628: hypothetical 
protein, sce5629: NADH-flavin oxidoreductase. The ORFs of sce5628 and sce5629 are 
shown overlapped. 
 
4. 2. 3. P450 clustered with regulatory elements 
It was found that some of the P450s (CYP109C2, CYP110H1, CYP110J1, CYP260A1, 
CYP261A1 and CYP262B1) of So ce56 are found in a cluster with regulatory elements. 
CYP109C2 (sce8913) is clustered with the transcriptional regulator AraC family protein 
encoding genes (sce8912) adjacent upstream and protein kinase (sce 8916) downstream 
(Figure I. 7. A). CYP110H1 (sce3065) is clustered with two components hybrid system kinase 
(sce 3063) as a regulator towards 2 genes upstream. In an adjacent downstream of CYP110H1 
a conserved hypothetical protein encoding gene (sce3066) having identity with the DUF899 
thioredoxin family protein superfamily has been identified (Figure I. 7. B). The cluster of 
CYP110J1 (sce6424) has two regulators, transcriptional regulator (sce6423) upstream and 
protein kinase (sce6427) downstream. (Figure I. 7. C). The cluster of CYP260A1 (sce1588) 
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has a protein kinase regulator (sce1587) in an adjacent upstream along with a plethora of 
hypothetical protein encoding genes. (Figure I. 7. D). Likely, CYP261A1 (sce0200) clustered 
with two component sensor histidine kinase regulator (sce 0195) upstream. This P450 has 
several hypothetical protein (HP) encoding genes in both upstream and downstream (Figure I. 
7. E). Likely, CYP262B1 (sce1860) has a regulator encoding gene (sce1859) directly at an 
adjacent upstream position (Figure 7. F). It has been shown that these all kinds of regulators 
are generally the eukaryotic-like-regulators (ELR) which was recently studied in So ce56 
(Perez et al, 2008) The real significance of these regulators with respective to P450s has not 
been studied so far.  
 
 
 
Figure I. 7: The genomic organization of P450s clustered with regulatory elements. The 
neighboring genes of CYP109C2, CYP110H1, CYP110J1, CYP260A1, CYP261A1 and 
CYP262B1 are illustrated. The genes of P450s and the regulators are shown in brown and 
blue, respectively. A. Neighboring genes of CYP109C2. The respective neighboring genes 
are - sce8911: probable class-V aminotransferase, sce8912: transcription regulator, AraC 
family protein, sce8913: CYP109C2, sce8914: hypothetical protein, hisC4 (sce8915): 
histidinol-phosphate/aromatic aminotransaminase protein, sce8916: protein kinase. B. 
Neighboring genes of CYP110H1. The respective neighboring genes are - sce3063: two 
component hybrid system and regulator, sce3064: alpha-amylase catalytic region, sce3065: 
CYP110H1, sce3066: hypothetical protein, sce3067: hypothetical protein. C. Neighboring 
genes of CYP110J1. The respective neighboring genes are - sce6422: ArsR family 
transcriptional regulator, sce6423:  transcriptional regulator MarR family protein,, sce6424: 
CYP110J1, sce6425: hypothetical protein, sce6426: hypothetical protein, sce6427: protein 
kinase, sce6428: hypothetical protein. The pseudo-genes and the pseudo-P450 are shown in 
an adjacent downstream of CYP110J1 in green and brown, respectively. D. Neighboring 
genes of CYP260A1. The respective neighboring genes are - sce1586: hypothetical protein, 
sce1587: protein kinase, sce1588: CYP260A1, sce1589: hypothetical protein, sce1590: 
hypothetical protein. E. Neighboring genes of CYP261A1. The respective neighboring genes 
are - sce0195: two component sensor histidine kinase, pflA2: pyruvate formate lyase-
activating enzyme, sce0205: two component sensor histidine kinase. The genes, represented 
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by HP, in the upstream and downstream are all hypothetical proteins. F. Neighboring genes 
of CYP262B1. The respective neighboring genes are - sce1859: protein kinase with two 
component sensor domain, sce1860: CYP262B1, sce1861: hypothetical protein, sce1862: 
periplasmic surface binding protein, sce1863: putative ABC type permease protein, sce1864: 
hypothetical protein, sce1865: ABC transporter ATP-binding protein. 
 
4. 2. 4. P450s clustered with carbohydrate related regulatory elements 
Two of the P450s, CYP109C1 and CYP267A1, are identified in a cluster of carbohydrate 
related regulatory elements. CYP109C1 (sce0122) is clustered with a predicted universal 
stress protein (uspA, sce0123) in an adjacent downstream position and a beta-xylosidase 
(yagH, sce0125), the third gene downstream (Figure I. 8. A). Likely, CYP267A1 (sce0675) is 
clustered with a polyphosphate-glucose phospho transferase (ppgK, sce0674) adjacent 
upstream and a succinyl glutamic semialdehyde dehydrogenase encoding gene (sce0676) in 
adjacent downstream position (Figure I. 8. B). The miscellaneous RNA present in the 
downstream of both of these P450s, make them more complex to predict their physiological 
significance. 
 
 
 
Figure I. 8: The genomic organization of P450s clustered with carbohydrate related 
regulatory elements. The cytochrome P450s (CYP109C1 and CYP267A1) and the 
carbohydrate related genes are shown in brown and green, respectively. The miscellaneous 
RNA (Misc_RNA) is shown in blue. A. Neighboring genes of CYP109C1. The respective 
neighboring genes are - sce0119: putative cell surface protein, sce0120: putative ompA family 
protein, sce0121: hypothetical protein, sce0122: CYP109C1, sce0123: predicted universal 
stress proten (uspA), sce0124: putative sodium solute transport protein, yagH (sce0125): beta-
xylosidase protein. B. Neighboring genes of CYP267A1. The respective neighboring genes 
are - sce0672: hypothetical protein, sce0673: putative pectinacetylesterase, ppgK (sce0674): 
phosphate-glucose phosphotransferase, sce0675: CYP267A1, astD (sce0676): succinyl 
glutamic semialdehyde dehydrogenase, sce0677: putative phospoesterase, sce0678: 
hypothetical protein. 
 
4. 2. 5. P450 clustered with a terpene cyclase 
In So ce 56, only one P450, CYP264B1, is clustered with terpene cyclase gene. In the 
genome, CYP264A1 (sce8551) has a terpene cyclase gene, geoA (sce8552) adjacent 
downstream. It is observed that CYP264B1 and geoA are only separated by 63 bp (Figure I. 
9) which could possibly be arranged in an operon. CYP264B1 might have a potential role 
during biosynthesis of putative cyclase. 
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Figure I. 9: The genomic organization of P450 clustered with a terpene cyclase. 
CYP264B1, terpene cyclase gene and regulators are shown in brown, green and blue, 
respectively. The neighboring genes of CYP264B1 are - sce8548: ABC Transporter/ATP-
binding protein, sce8549: putative short-chain dehydrogenase, sce8550: transcriptional 
regulator, TetR family protein, sce 8551: CYP264B1, geoA (sce8552): putative terpene 
cyclase (geosmin), sce8553: protein kinase. 
 
4. 2. 6. P450s with unique clusters 
CYP109D1 (sce4633) and CYP259A1 (sce4635) are found in a gene cluster of So ce56 
genome. The P450 genes are in an anti-directional orientation in the genome and separated by 
a single gene, sce4634, encoding anti-anti sigma regulatory factor (Figure I. 10. A). The 
adjacent upstream gene (sce4632) of CYP109D1 belongs to the beta-CA superfamily protein 
and codes carbonate hydratases (CA) which are the zinc containing enzyme that catalyses the 
reversible hydration of carbon dioxide. This gene was found as a conserved gene in 
Myxococcus xanthus DK1622 (73% identity), Streptococcus sp N1 (52% identity) and in 
several Acinetobacter sp ADP1 (52% identity). The rest of the entire upstream gene clusters 
in the vicinity of this P450 codes for hypothetical proteins. The adjacent downstream gene 
(sce4636) of CYP259A1 (sce4635) has a conserved region of squalene cyclase (i.e. 343-416 
amino acids out of 511 amino acid sequence). This gene is also conserved in Rhizobium sp 
(40% identity), Mesorhizobium sp (39% identity), and several other actinomycetes like 
Mycobacterium tuberculosis CDC1551 (30% identity) as a putative cyclase  
 
 
 
Figure I. 10. A: The unique cluster of CYP109D1 and CYP259A1. The P450s (CYP109D1 
and CYP259A1) and the regulatory gene are shown in brown and green, respectively. The 
neighboring genes are - sce4630: hypothetical protein, sce4631: hypothetical protein, 
sce4632: hypothetical protein, sce4633 (cypA2): CYP109D1, sce4634: anti-anti sigma 
regulatory factor, sce4635: CYP259A1, sce4636: hypothetical protein. 
 
CYP267B1 also lies in a unique cluster. The neighboring region of CYP267B1 (sce7167) has 
a DNA repair exonuclease family protein (sce7166) in upstream and a hypothetical protein 
encoding gene (sce7168) in downstream position (Figure I. 10. B). A unique cluster of 
tymovirus analogue gene (sce7164), called as tymovirus 45/70 Kd protein, is present in the 
upstream of CYP267B1 in which a hypothetical protein encoding gene (sce7165) is 
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overlapped. Interestingly, several other genes encoding α-gluconotransferase (malQ4, 
sce7169), α-amylase family protein (sce7170) and ABC transporter ATP family protein 
(sce7171) were also present in downstream position of CYP267B1.  
 
 
 
Figure I. 10. B: The unique cluster of CYP267B1. CYP267B1 (brown) and the overlapped 
gene of sce7165 (green) on sce7164 are shown. The neighboring genes of CYP267B1 are - 
sce7165: hypothetical protein, sce7164: tymovirus 45/70Kd protein, sce7166: DNA repair 
exonuclease family protein, sce7167: CYP267B1, sce7168: hypothetical protein, malQ4 
(sce7169): 4-alpha gluconotransferase, sce7170: alpha amylase family protein, sce7171: ABC 
transporter ATP binding protein. 
 
CYP264A1 (cypA5) is also associated with other unique P450 clusters. CYP264A1 (sce6323) 
has a sigma-54 dependent transcriptional regulator (sce6324) in an adjacent downstream with 
a very unique signal domain XylR-N/v4r. This domain functions as an activator of aromatic 
catabolism (Jelsbak et al., 2005). The putative function of this P450 was not hypothesized as 
all the remaining genes in upstream and downstream are coding for hypothetical proteins 
(Figure I. 10. C). 
 
 
 
Figure I. 10. C: The unique clusters of CYP264A1 (cypA5). CYP264A1 (brown), the 
regulator (blue) and the structural (Str) RNA (deep blue) are shown. The neighboring genes of 
CYP264A1 are - sce6320: hypothetical protein, sce6321: ani-anti sigma factor protein, 
sce6322: hypothetical protein, cypA5: CYP264A1, sce6324: sigma-54 dependent 
transcriptional regulator, sce6325: hypothetical protein, sce6326: hypothetical protein. 
 
4. 2. 7. P450s clustered only with hypothetical protein 
The rest of the other P450s of So ce56 (CYP117B1, CYP260B1 and CYP261B1) were only 
clustered with hypothetical protein encoding genes. The adjacent and the neighboring genes 
of these P450s do not have any putative conserved domain to predict their potential function 
as a result, the putative functions of these P450s was not hypothesized.  
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4. 3. Cloning, expression and purification of So ce56 cytochrome P450 
4. 3. 1. Amplification and cloning of the Soce56 CYPome 
Amplification of all 21 cytochrome P450s from the GC (71.38%) rich genomic DNA of 
Sorangium cellulosum So ce56 was achieved by using several different combinations of 
reaction cocktail and thermal programs which is illustrated in Table I. 3-5. All P450 
expression constructs were created in the pCWori+ vector; except for CYP264B1 the 
expression vector pET17b was used. The expression constructs were preliminary sorted by 
colony PCR, restriction digestion, and the full frame of each ORF was confirmed by 
sequencing.  
 
4. 3. 2. Heterologous expression of cytochrome P450 
The yields of the heterologous expression of the various P450s of So ce56 with respect to 
time, temperature and shaking speed were not alike. Time course studies were done to 
determine the optimum heterologous expression for individual P450s, considering pH of the 
culture medium (pH 6.8-7.2) as an indicator, followed by the visibly observed confluent 
reddish brown color of the cell pellet. Depending on the P450, the expression time was 
between 24 to 36 hours. Each of the expression trails for the respective P450 was monitored 
by whole-cell SDS-PAGE. The crude cell supernatant was also used to measure the COD for 
the confirmation of active form of P450. All P450s were heterologously expressed in a 
soluble-form. As a model example, the whole cell SDS-PAGE for CYP109D1 is illustrated in 
Figure I. 11. All 21 P450s from So ce56 were successfully purified in an active from by 
affinity chromatography and gel-chromatography. The representative SDS-PAGE of purified 
So ce56 P450s is shown in Figure I. 12. The concentrations of purified P450s were variable 
and the maximum amount was up to 1400 nmol/L for CYP266A1. The details of the P450 
expression and characterization are illustrated in Table I. 9.  
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Figure I. 11. SDS-PAGE of CYP109D1. The expression and purification of 
CYP109D1 during heterologous expression in E. coli in soluble form are shown. Lane 
1- Prestained marker (BioLab), Lane 2- cell lysate before induction (-IPTG), Lane 3- 
cell lysate after 36 hours of expression, Lane 4- cell free supernatant after sonication, 
Lane 5- purified CYP109D1. 
 
A 
 
B 
  
 
Figure I. 12: SDS-PAGE of purified So ce56 P450s. The designated lanes denote the 
individual purified P450s. A. Lane 1- CYP260A1, lane 2- CYP266A1, lane 3- 
CYP124E1, lane 4- CYP265A1, lane 5- CYP264A1, lane 6- CYP109C1, lane 7- 
CYP109C2, lane 8- CYP259A1, lane 9-CYP109D1, lane 10- protein MW marker 
(pEQLab), lane 11- CYP263A1, lane12- CYP267B1, B. lane 1- CYP110J1, lane 2- 
CYP260B1, lane 3- CYP264B1, lane 4- 267A1, lane 5- protein MW marker (pEQLab), 
lane 6- CYP117B1. 
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Table I. 9. Expression yield and characterization of So ce56 cytochromes P450. 
Individual cytochromes P450 were purified by affinity chromatography followed by size 
exclusion chromatography and the expression yields of the purified P450s were tabulated. 
The absorption maxima of each of the P450s are also shown.  
 
P450s of 
So ce56 
 
number of 
amino acids 
P450 conc. 
nmol/L 
Absorption 
maxima 
CYP109C1 405 1333 450 
CYP109C2 397 1300 448 
CYP109D1 408 205 450 
CYP110H1 444 5 450 
CYP110J1 477 60 448 
CYP117B1 459 5 448 
CYP124E1 402 15 450 
CYP259A1 442 8 450 
CYP260A1 444 850 448 
CYP260B1 392 100 448 
CYP261A1 482 5 448 
CYP261B1 493 2 450 
CYP262A1 435 25 448 
CYP262B1 470 2 450 
CYP263A1 493 900 450 
CYP264A1 390 440 448 
CYP264B1 412 4 450 
CYP265A1 398 21 450 
CYP266A1 409 1400 448 
CYP267A1 429 23 450 
CYP267B1 405 70 450 
 
4. 4. Spectrophotometric characterization  
UV-visible absorption spectroscopy provides the primary technique for the recognition and 
characterization of P450 enzymes. The oxidized form of purified P450s of So ce56 followed 
typical spectral properties of the P450 enzyme class. The major Soret (γ) band of all 21 P450s 
coincided at 415-422 nm and the smaller α band at 532-537 nm and  β band at 563-574 nm. 
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The reduced spectra, of all the P450s, showed diminished absorption maxima at Soret band 
with or without a slight shift of the peak and gave a single peak at 537-556 instead of the 
smaller α and β bands (Table 1. 10). The representative spectra of oxidized, reduced and the 
CO-complexed spectra for CYP109D1 are shown in Figure I. 13. A. The carbon monoxide 
bound form gave a typical peak at 448 or 450 depending on the individual P450s (Figure I. 
13. B). Some of the P450s, CYP259A1, CYP260A1, CYP261A1, CYP264B1 and 
CYP265A1, gave a dominating P420 shoulder which was increased during time interval. The 
representative spectra for CYP264B1 are shown in Figure I. 13. C. All other CO difference 
spectras are illustrated in Figure I. 14.  
 
Table I. 10: Optical characteristics of So ce56 cytochromes P450. Soret maxima, α and β 
peaks during oxidation and reduction as well as CO complexed peak for all 21 Sorangium 
cellulosum So ce56 are shown. 
 
Oxidized form Reduced form  
 
So ce56 
P450s 
 
 
Soret 
(nm) 
 
α 
(nm) 
 
β 
(nm) 
 
Soret 
(nm) 
single peak at 
α and β 
regions 
(nm) 
CO-
difference 
(COD) 
Peak 
(nm) 
CYP109C1 418 535 563 417 540 448 
CYP109C2 417 533 566 417 535 448 
CYP109D1 420 535 565 417 546 450 
CYP110H1 418 534 566 418 554 450 
CYP110J1 418 532 565 416 538 448 
CYP117B1 416 534 568 416 552 448 
CYP124E1 422 537 574 422 537 448 
CYP259A1 420 535 565 418 550 452 
CYP260A1 416 534 566 412 546 448 
CYP260B1 418 535 560 416 548 448 
CYP261A1 420 536 565 420 550 448 
CYP261B1 420 534 570 420 DA* 450 
CYP262A1 417 534 566 417 556 448 
CYP262B1 418 534 568 416 552 450 
CYP263A1 418 535 560 420 DA* 450 
CYP264A1 415 535 566 415 DA* 450 
CYP264B1 417 532 568 417 DA* 450 
CYP265A1 419 535 568 415 552 448 
CYP266A1 415 535 567 407 540 448 
CYP267A1 418 535 570 417 548 448 
CYP267B1 420 534 565 416 548 450 
 
Note: DA*: Single peak at α and β regions was not obtained. Same absorption peaks as that 
of oxidized form at α and β bands were observed with diminished absorbance (DA).  
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Figure I. 13: Representative UV-visible characterization of So ce56 P450s. A. Typical 
UV-visible spectra of purified CYP109D1. The oxidized (black line), dithionite reduced 
(blue line) and reduced CO-complexed from (red line) of CYP109D1 are illustrated. B. The 
typical COD spectra of CYP109D1 and CYP266A1. CYP109D1 (red line) and CYP266A1 
(blue line) have peak maxima at 448 and 450 nm, respectively. C. CO-difference spectra of 
CYP264B1. The unstable P450 (CYP264B1), in absence of substrate, is shown with multiple 
spectra. The time dependent increment of the peak at 420 nm and a collapsing peak at 450 nm 
are shown. P420 form of CYP264B1 during the measurement of CO-difference spectrum (red 
line) is shown to be increased after 1 min (black line), 2 min (blue line), 3 min (pink line), 4 
min (light green) and 5 min (dark green line). The P450 peak was almost collapsed at 8 min 
(brown line).  
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Figure. I. 14. CO-difference spectra of Sorangium cellulosum So ce56 P450s. Respective 
P450s are indicated in each spectrum. The unstable P450 (CYP264B1) is represented with 
multiple spectra with time dependent increment of the peak at 420 nm and a collapsing peak 
at 450 nm  
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4. 5. Biophysical characterization  
Seven of the highly expressed, stable and the representative of the novel P450 enzymes 
(CYP109C1, CYP109C2, CYP109D1, CYP260A1, CYP264A1, CYP264B1 and CYP266A1) 
were selected for detail biophysical characterization. Circular Dichroism (CD) and Electron 
paramagnetic resonance (EPR) spectroscopy were recorded for them.  
 
4. 5. 1. Circular Dichroism (CD) of So ce56 cytochrome P450  
In the CD measurement, the spectra in the far-UV region (typically from 260 nm to 195 nm) 
and near-UV/visible region (typically from 300 nm to 500 nm) were measured. The 
representative far-UV spectra of CYP109C1, CYP109C2, CYP109D1, CYP260A1, 
CYP264A1, CYP264B1 and CYP266A1 are illustrated in Figure I. 15. The far-UV CD 
spectra for these P450s virtually look similar with a negative dichroic double band with 
minima at 208 and 220 nm. This indicates the typical α-helical protein characteristics and 
shows no significant change in the secondary structure. The trough at 208 nm corresponds to 
a weak but broad n→pi* transition (Munro et al., 1999 and Kelly et al., 2005). 
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Figure I. 15: CD spectra of P450s in far-UV region. CD spectra recorded in the far-UV 
region are shown. The individual P450 concentration was 5 µM in 10 mM potassium 
phosphate buffer, pH 7.4. The spectra were recorded in the absence of substrate at 20°C. A. 
The comparative CD spectra of CYP109C1 (red line), CYP109C2 (blue line) and CYP109D1 
(brown line). B. CD spectra of CYP260A1. C. The comparative CD spectra of CYP264A1 
(blue line) and CYP264B1 (red line). D. CD spectra of CYP266A1.  
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The near-UV/visible CD spectra provide information on the heme cofactor environment as 
well as on the tertiary structure of the protein. The spectrum in the near-UV region arises 
predominantly from the aromatic amino acids (phenylalanine, tryptophan and tyrosine) along 
with possible contributions from disulfide bonds. Aromatic CD spectral intensities are 
affected by protein flexibility, with the more highly mobile side-chains having lower CD 
intensities. In addition, interactions between aromatic side-chains in close proximity 
contribute to stronger signal intensity. Although the isolation of a heme chromophore exhibits 
no optical activity, because of the high symmetry, when bound in an asymmetric protein 
environment optical activity in the visible region may arise (Myer and Pande, 1978). 
 
The representative CD spectra for near-UV region of typical P450s (CYP109C1, CYP109C2, 
CYP109D1, CYP260A1, CYP264A1, CYP264B1 and CYP266A1) of So ce56 are shown in 
Figure I. 16. All tested P450s have displayed two large signals of negative peaks both at the 
delta and the Soret band. The near-UV CD spectra of the CYP109 family (CYP109C1, 
CYP109C2 and CYP109D1) showed similar delta band (peak at 350 nm), Soret band (peak at 
408 nm) and environment of the heme group (350-450 nm). Both of the new P450 families of 
So ce56, CYP260A1 and CYP266A1, were characterized with distinct transitions at 350 and 
403 nm, delta and Soret bands, respectively. In the case of CYP264A1 and CYP264B1, the 
delta bands centered at 348 and 350 nm, respectively, and the Soret bands were at 408 and 
420 nm, respectively. It was found that the environment of the heme group (350-450 nm) of 
CYP264A1 in resting ferric form is slightly different with respective to CYP264B1.  
 
A 
 
B 
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Figure I. 16: CD spectra of P450s in near-UV region. CD spectra recorded in the near-UV 
region are shown. The individual P450 concentration was 20 µM in 10 mM potassium 
phosphate buffer, pH 7.4. The spectra were recorded in absence of substrate at 20°C. A. The 
comparative CD spectra of CYP109C1 (red line), CYP109C2 (blue line) and CYP109D1 
(brown line). B. CD spectra of CYP260A1. C. The comparative CD spectra of CYP264A1 
(blue line) and CYP264B1 (red line). D. CD spectra of CYP266A1.  
 
4. 5. 2. Electron paramagnetic resonance (EPR) spectroscopy  
The EPR measurements of the cytochrome P450 are of particular interest. The EPR signal 
cannot be detected for the low-spin ferrous form, as there are no unpaired electrons. 
Therefore, the low-spin cytochrome P450 must be in the oxidized ferric state to exhibit an 
EPR spectrum. However, in the high-spin form, the unpaired electrons exist in both the 
reduced (ferrous) and oxidized (ferric) states, and can generate EPR signals in both states. 
Discrete EPR signals are produced for different spin-states and conformations of heme. Thus, 
obtained g-values differ depending on the ligation and environment of the heme iron (Hoff et 
al., 1989; Mansuy and Renaud, 1995). The two most common types of spectra for iron-
containing cytochromes are axial high spin and rhombic low spin. Axial high-spin systems 
have characteristic g-values of ~2 and ~8, whereas rhombic low-spin systems have three 
distinct g-values between 1.0 and 3.8.  
 
The X-band EPR spectra of the substrate free oxidized forms of the members of CYP109, 
CYP260, CYP264 and CYP266 of So ce56 were examined. The major signals generated in 
the EPR spectrum of those P450s constitute a rhombic trio of g-tensor elements gz, gy, gx 
(Figure I. 17-18). The occurrence of the three major peaks indicates a nuclear spin state of ½ 
(2I + 1). The resulting g-values of gz, gy and gx (Table I. 11) illustrated the typical low-spin 
ferric (FeIII) heme (Mansuy and Renaud, 1995).  
 
C D  
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Figure I. 17: X-band EPR spectra of the CYP109 family (CYP109C1, CYP109C2 and 
CYP109D1). The individual P450 concentration was 150 µM in 10 mM potassium phosphate 
buffer, pH 7.4. Substrate free P450s were used and the spectra at broad and narrow ranged 
were scanned. The g-values are indicated in each spectrum. On the panel A (the left side), the 
EPR spectra (broad range) for the CYP109 family are shown. It was measured with a field 
central of 2400 G and a sweep width of 4000 G. On the panel B (the right side), the expanded 
narrow range of the EPR spectra of panel A with a field central of 3140 G and a sweep width 
of 1440 G are shown for better resolution. In panel B, CYP109C1 (red line), CYP109C2 
(black line) and CYP109D1 (blue line) are shown. 
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Figure I. 18: X-band EPR spectra of cytochrome P450s (CYP260A1, CYP260B1, 
CYP264A1, CYP264B1 and CYP266A1) of So ce56. The individual P450 
concentration was 150 µM in 10 mM potassium phosphate buffer, pH 7.4. Substrate free 
P450s were used and the spectra of broad and narrow range were scanned. The g-values 
are indicated in each spectrum. The respective P450s are shown in each spectrum. A. 
The EPR spectra (broad range) were measured with a field central of 2400 G and a 
sweep width of 4000 G. B. The EPR spectra (narrow range) of A with a field central of 
3140 G and a sweep width of 1440 G are shown for better resolution. In panel B, 
CYP260A1 (black line), CYP260B1 (red line), CYP264A1 (red line), CYP264B1 (black 
line) and CYP266A1 (black line) are shown with respective P450 names. 
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Table I. 11: EPR spectral values of representative P450s of So ce56.  
P450s of So ce56  gz gy gx 
CYP109C1 2.470/2.408 2.259 1.922 
CYP109C2 2.546/2.411 2.261 1.917/1.864 
CYP109D1 2.469 2.270 1.897 
CYP260A1 2.516/2.419 2.264 1.191/1.871 
CYP260B1 2.453 2.269 1.892 
CYP264A1 2.411 2.250 1.918 
CYP264B1 2.507/2.411 2.201 1.911/1.879 
CYP266A1 2.535 2.268 1.867 
 
Firstly, a broad range EPR spectrum was recorded to check the presence of any high spin 
form. After this the narrow range was scanned for better resolution for gz, gy and gx. In this 
study, the signals at g = 3.826 and 3.206 were observed for CYP109C1, CYP109D1, 
CYP260B1 and CYP264A1 (Figure 27 and 28. A). This heterogeneity was supposed due to 
the purity of the sample (McLean et al., 2002a). In case of CYP109C2 minor splitting of the 
g-value at g = 4.325 was observed and indicates some heterogeneity of the heme species and 
could be due to the trace amounts of high spin ferric heme and adventitious FeIII or may even 
indicate a very low degree or rhombic splitting of the S = 5/2 high ferric state (Lipscomb, 
1980; Dawson, 1983). In this study only the oxidized form of substrate free EPR was 
recorded.  
 
The heterogeneity of low-spin heme was observed for CYP109C1, CYP109C2, CYP260A1 
and CYP264B1 at gz and gx (Table I. 11). The signal shifts at gz were also reported in the 4-
phenylimidazole-bound form of P450cam (2.45/2.5, 2.25. 1.89) (Uchida et al., 2004). The 
signals at gz 2.43/2.41 and gx 1.92 indicate a proportion of the sample retains a distal water 
ligand (Girvan et al., 2004; Lawson et al., 2004). In previous studies, some heterogeneity of 
the low-spin heme gx signal has also been obtained in P450cam with signals at both g = 1.970 
and 1.191 (Green et al., 2001; Lawson et al., 2004).  
 
4. 6. Mass determination and conformation of active form of P450 of So ce56 
The presence of the target band of corresponding P450s in correlation with the theoretical 
molecular weight in SDS-PAGE confirmed the successful expression. Sometimes the 
molecular weight obtained from SDS-PAGE was not identical with the theoretical values. 
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Seven of the P450s (CYP109C1, CYP109C2, CYP109D1, CYP260A1, CYP264A1, 
CYP264B1 and CYP266A1) were chosen to determine the masses using ESI-TOF for both 
the apo- and holo-forms. The experimental and theoretical masses are illustrated in Table I. 
12-13 and corresponding spectras are shown in Appendix VI. A. The theoretical and the 
experimental masses of apo- and holo-forms as well as the measured cofactor were nearly 
identical. 
 
Table I. 12: Comparison of theoretical and experimental apo-protein mass and relative 
spectra of different cytochrome P450s. 
P450 
of So ce56 
Apo-protein 
theoretical MW (Da)* 
Apo-protein 
measured mass (Da) 
Spectrum 
(Appendix VI. A) 
CYP109C1 45802.64 45799.54 ± 0.44 O7380AM 
CYP109C2 44924.15 44923.43 ± 0.45 O7379AM 
CYP109D1 45213.81 45213.84 ± 0.52 O7382AM 
CYP260A1 49746.75 49616.03 ± 0.65 O7392AM 
CYP264A1 43337.64 43205.66 ± 0.43 O7377AM 
CYP264B1 47414.64 47281.95 ± 0.38 O7374AM 
CYP266A1 46673.87 46672.66 ± 0.45 O7373AM 
 
Note: * The calculated theoretical apo-protein molecular weight includes the hexa-histidine 
tag attached on the C-terminal of the P450s during cloning procedure. 
  
Table I. 13: Comparison of theoretical and experimental masses of holo-protein.  
P450 of  
So ce56 
Holo-
protein 
theoretical 
MW (Da)* 
Holo -protein 
measured mass 
(Da) 
Cofactor 
theoretical 
MW (Da) 
Cofactor 
measured 
mass (Da) 
Spectrum 
(Appendix 
 VI. B) 
CYP109C1 46419.13 46409.77 ± 0.98 616.49 610.23 O7412AM 
CYP109C2 45540.64 45532.59 ± 0.43  616.49 609.16 O7410AM 
CYP109D1 45830.30 45823.14 ± 0.47  616.49 609.30 O7415AM 
CYP260A1 50363.24 50223.46 ± 0.58 616.49 607.43 O7418AM 
CYP264A1 43954.12 43815.30 ± 0.63 616.49 609.64 O7407AM 
CYP264B1 48031.13 47891.57 ± 0.32  616.49 609.62 O7405AM 
CYP266A1 47290.36 47282.04 ± 0.37 616.49 609.38 O7402AM 
 
Note: * The calculated theoretical holo-protein molecular weight includes the hexa-histidine 
tag attached on the C-terminal of the P450s during cloning procedure. 
. 
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4. 7. Determination of electron donors  
The genomic information of So ce56 has shown that none of the putative genes encoding the 
ferredoxins and ferredoxin reductases are in an adjacent position. As a result, in a plethora of 
several ferredoxins and ferredoxin reductases, it was difficult to predict particular electron 
donor partners for specific P450s for distinct physiological purpose. But it has been shown 
that bacterial P450s are known to use a variety of electron transfer mechanisms (Hannemann 
et al., 2007). Mostly in bacterial systems, electrons move from NAD(P)H to flavoproteins and 
the P450s accept electrons either from flavoproteins or ferredoxin (Fdx) proteins (which 
receive the electrons from ferredoxin reductase (Fdr) (Katagiri et al., 1968; Narhi et al., 
1986).  
 
To determine the redox partners, at first CO-difference spectra with the reduction of dithionite 
was recorded. Thus obtained peak maximum at 450 nm was compared with the NADPH 
reduced CO-complexed peak obtained by the reduction of dithionite in the presence of redox 
partners. Considering this, the combination of commercial spinach Fdx and FdR as 
heterologous electron transfer partners, a strategy that is often used in bacterial systems, has 
been followed with myxobacterial P450s. None of the tested P450s (CYP109C1, CYP109C2, 
CYP109D1, CYP110J1, CYP124E1, CYP260A1, CYP264A1, CYP264B1, CYP266A1 and 
CYP267B1) was able to get reduced with the spinach system. The other combination of 
heterologous electron transfer partners of bovine adrenal adrenodoxin (Adx) and adrenodoxin 
reductase (AdR) were also used in the ratio of P450s:Adx:AdR of 1:10:3. Among those tested 
P450s, except CYP266A1, all others were able to reduce by NADPH and gave a peak 
maximum at 450 nm during complexed with carbon monoxide in the presence of redox 
partners. During this, for CYP264A1 the dithionite reduced CO-difference peak was fully 
recovered with the reduction of NADPH within short interval of time. Likely, CYP109D1 
was also able to recover almost 75% of the dithionite reduced peak (Figure I. 19) when 
NADPH was used as reducing agent in presence of Adx and AdR. 
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Figure I. 19: Determination of electron transfer partners for CYP109D1 and 
CYP264A1. The dithionite reduced CO-difference (COD) spectrum (red line) was compared 
with the NADPH reduced CO-difference spectrum of instant (pink line), 1 min (black line), 2 
min (green line), 5 min (blue line) for A. CYP109D1 and B. CYP264A1. The NADPH 
reduced CO-difference spectra were recorded in a 1 ml mixture of P450:Adx:AdR of 1:10:3 
(200 pmol:2 nmol:600 pmol) in 10 mM potassium phosphate buffer, pH 7.4 containing 20% 
glycerol. 
 
4. 8. Screening of a compound library 
The potential physiological and biotechnological applications of P450 cannot be illustrated 
unless a potential substrate becomes known. In general, the identification of potential 
substrates for novel P450s is not easy. To explore the substrate range, four of the P450s 
(CYP109C1, CYP109C2, CYP260A1 and CYP266A1) were selected because of their higher 
expression yield and stability (Table I. 10). A compound library consisting of 17,000 
substances was screened for those P450s and the potential substrates and inhibitors were 
identified. Each of the primary screening results was validated as described in the ‘Method 
3.2.8’. According to the validated results of the positive hits, Type I and Type II binding 
ligands were identified. The numbers of the hits for CYP109C1, CYP109C2, CYP260A1 and 
CYP266A1 are tabulated in Table I. 14 and their structures with respective Chem-Div 
numbers are illustrated in Appendix VII. During the screening it was found that some of the 
Type I and Type II hits were common among the screened P450s and this is also illustrated in 
Appendix VII. 
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Table I. 14: Total numbers of Type I and Type II hits obtained from the screening of a 
compound-library for CYP109C1, CYP109C2, CYP260A1 and CYP266A1. The purified 
P450s of 900 ml of 3 µM each was required to screen a compound-library consisting of 
∼17,000 substances. During primary screening, individual P450 of 1.5 µM and each of the 
compounds of 0.5 µM was used, and screened in 384 wells micro-titer plate by an automated 
pipette robot cyclone ALH 3000 Workstation as described in Methods I. 3. 2. 8. The 
wavelength of 350-450 nm with Tecan-Safire plate-photometer and the absorbance of the 
substances were recorded. The primary hits were further validated by 200 µM, 150 µM, 100 
µM, 50 µM and 16 µM of individual compounds from the library with 1.5 µM final 
concentration of P450. The number represents the counts of the validated hits for the P450s. 
 
 
P450 of  
So ce56 
Numbers 
of  
Type I hits 
Numbers  
of 
Type II hits 
 
 
Total hits 
Remarks 
(For detail structure and 
Chem-Div nos) 
CYP109C1 16 9 25 Appendix VII. A 
CYP109C2 8 18 26 Appendix VII. B 
CYP260A1 17 20 37 Appendix VII. C 
CYP266A1 16 21 37 Appendix VII. D 
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5. Discussion 
Myxobacteria attract many researchers because of their pharmaceutical importance and 
complex physiology. They exhibit a multitude of possibilities for the production of bioactive 
substances. It was shown that about 100 novel basic compounds and 500 different variants 
have been isolated from these organisms (Reichenbach, 2001, 1999; Gerth et al., 2003). The 
genus Sorangium alone can produce nearly 50% of the metabolites isolated from 
myxobacteria (Gerth et al., 2003). Different strains of Sorangium cellulosum produce several 
novel antimicrobial macrolides, the thuggacins (Irschik et al., 2007), phoxalone (Guo et al., 
2008) and other components like a new sesquiterpene, sorangiodenosine (Ahn et al., 2008), a 
new free-radial scanvanger, soraphinol C (Li et al., 2008), and a novel class of antineoplastic 
agents - the epothilones and their analogs (Mulzer, 2008). The selected strain So ce56 
produces the natural secondary metabolites chivosazol, etnangien and myxochelin (Schneiker 
et al., 2007: Wenzel and Müllar, 2007; Menche et al., 2008). The genomic sequence of So 
ce56 also revealed several additional regions encoding for polyketide synthase (PKS) and/or 
non ribosomal polyketide synthase (NRPS) proteins, whose products have not been isolated 
till date (Schneiker et al., 2007). The complex life cycle of So ce56 is mediated by an 
extensive regulatory network, including enhancer binding proteins, two component regulatory 
systems, extra cytoplasmic function family protein sigma factors, and 
serine/threonine/tyrosine protein kinases (Perez et al., 2008). 
 
5. 1. Bioinformatic analysis 
The genome sequence project of the Sorangium cellulosum So ce 56 revealed 21 P450s with 
amino acids ranges from 390 to 493 in length (Table I. 10). This added 9 novel cytochrome 
P450 families (CYP259, CYP260, CYP261, CYP262, CYP263, CYP264, CYP265, CYP266 
and CYP267) into the P450 database. Furthermore, 7 new members of existing P450 families 
of CYP109 (CYP109C1, CYP109C2 and CYP109D1), CYP110 (CYP110H1 and 
CYP110J1), CYP117 (CYP117B1) and CYP124 (CYP124E1) were also disclosed. The 
presence of such higher numbers of P450s in the So ce56 genome underlines the potential 
significance during its lifecycle.  
 
The phylogenetic relationship of P450s of So ce56 shows 5 distinct P450 branches (Figure I. 
3). The cluster 1: CYP266A1, cluster 2: CYP267 (CYP267A1 and CYP267B1), cluster 3: 
CYP265A1, cluster 4: CYP109 (CYP109C1, CYP109C2 and CYP109D1), CYP124E1 and 
CYP264 (CYP264A1 and CYP264B1), and cluster 5: CYP110 (CYP110H1 and CYP110J1), 
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CYP117B1, CYP259A1, CYP260 (CYP260A1 and CYP260B1), CYP261 (CYP261A1 and 
CYP261B1), CYP262 (CYP262A1 and CYP262B1), and CYP263A1. Most interestingly, the 
cluster-1, CYP266A1, represents the most distant branch having 30% identity with human 
cytochrome P450 CYP5A1 (Thromboxane synthase), 30% identity with fungal P450 
CYP55A3 (Cylindrocarpon tonkinense D78512) and 36% with bacterial CYP107H1 of 
Bacillus subtilis BioI US1868. The functional role of this P450 could be interesting for further 
studies.  
 
All 21 P450s of So ce56 contain conserved K- helices (having glutamine and arginine), I-
helices (having threonine) and the heme binding motif. A variant of the heme binding motif 
was observed in CYP267A1 and CYP265A1, where leucine is present instead of 
phenylalanine (Table I. 7). The presence of leucine in the heme domain of CYP267A1 and 
CYP265A1 could be the topic for further investigations of heme signature variants if the 
substrates and redox partners are known. 
 
The bioinformatic analysis of So ce56 also revealed 8 ferredoxin genes and 2 reductases. In 
the So ce56 genome neither ferredoxin nor ferredoxin reductase genes were organized in a 
cluster with P450. It was shown that one P450 from S. coelicolor A(3)2 and five P450s from 
S. avermitilis were found to be in a cluster with a ferredoxin (Parajuli et al., 2004). Likewise, 
it has been shown that none of the ferredoxin reductase was directly clustered with P450 in S. 
avermitilis and S. coelicolor A(3)2, however CYP147B1 and CYP105Q1 from  S. avermitilis 
were associated with ferredoxin followed by ferredoxin reductase gene (Parajuli et al., 2004). 
In comparison with So ce56, the fully sequenced 9 Mb genome of Streptomyces avermitilis 
has 33 P450s with 9 Fdx and 6 Fdr genes (Tully et al., 1998). Likely, Streptomyces coelicolor 
A(3)2 has 18 P450s with 6 Fdx genes and 4 Fdr reductases in a 8.7 Mb chromosome (Lamb et 
al., 2002). Only one natural electron transfer chain was determined in S. coelicolor A(3)2, 
where the genes coding for ferredoxin reductase FDR1, ferredoxin Fdx4 and CYP105D5 were 
located in close distance in the genome and showed a functional role during fatty acid 
hydroxylation (Chun et al., 2007). The presence of 21 P450s, 8 Fdx and 2 Fdr in So ce56 
symbolizes the complex and ambiguous electron transfer pathways.  
 
5. 2. Genome mining of cytochrome P450 
As this is a very first study of P450s in So ce56, at the beginning of this work only gene 
sequences were available. Though various endogenous roles of P450s in several polyketide 
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synthetase (PKS) gene cluster during secondary metabolite formation were already verified in 
other strain of Sorangium cellulosum (Tang et al., 2000; Julien et al., 2000; Buntin et al., 
2008), the 13.1 Mbp genome of Sorangium cellulosum So ce56 was a new candidate. At the 
beginning, neither there was an idea of potential substrates for any of the P450s nor were the 
homologous or heterologous redox partners known. As a result, the study of the genomic 
organization of individual P450 at the beginning was the only way to hypothesize the 
potential redox partners or substrates. So, studies on the neighboring genes of the respective 
P450s were done to find possible genomic informations.  
 
In So ce56, all 21 P450s are distributed all over the genomic DNA (Figure I. 2). Concerning 
the distribution of genes (including P450s) in So ce56, Schneiker et al, 2007, studied the 
simultaneous analysis of the genome for GC content, dinucleotide frequency and codon usage 
and revealed a relatively uniform pattern of distribution of genes over the first two-thirds of 
the chromosome (i.e. up to 8.5 Mbp), but nine anomalous sections are present in the last third 
of the genome where the majority of the insertion sequences (16 of 18) is present (Schneiker 
et al., 2007). It was found that, among all the P450s 76% of them were within that 8.5 Mb 
genome and the rest (24%) were on the last third of the genome, where the insertion 
sequences are presents. It was also found that the three new P450 families, CYP264 
(CYP264A1 and CYP264B1), CYP265A1 and CYP267B1, along with three new members 
CYP109C2, CYP110J1 and CYP124E1, are present in the remaining last-third of the genome 
(Figure I. 12). Considering this, as 88.88% of the genes in this region was predicted to be 
transferred horizontally (Schneiker et al., 2007), the P450s found in this region could have 
evolutionary significance. Interestingly, most of the P450s lying in this region were either 
completely new-families or members. Thus no experimental data for these P450s are 
available though being members of old families. It is very remarkable that even being 
bacterial P450s, all the tested P450s (CYP264A1, CYP110J1, CYP267B1, CYP124E1, 
CYP264B1and CYP109C2 (Figure I. 2) present in this region were able to get electrons from 
bovine Adx and AdR.  
 
The genome mining of individual P450s of So ce56 disclosed several characteristic properties 
on the genomic level and also provided some information for putative substrates (at least for 
some novel P450s). Two of the P450s of So ce56, CYP263A1 and CYP265A1, have a distinct 
PKS/NPRS module but the gene products have not been isolated till date. The similar 
theoretical consideration of PKS/NRPS module in the genomic informations is also available 
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for several Strepetomyces and Mycobacterium sp. (Parajuli et al., 2004; Zhao and Waterman, 
2007). An understanding of the molecular basis for the biosynthesis of many complex 
polyketide antibiotics has only been gained over the past decade and has provided an 
explanation for the basis of the extensive structural diversity (Khosla et al., 2001). Moreover, 
within Streptomyces sp., it has been shown that P450s are involved in many polyketide 
biosynthetic pathways and catalyzed the stereo- and regio-specific oxidative taloring of 
antibiotics like novobiocin from S. spheroides  with CYP163A1 (Chen and Walsh, 2001), 
doxorubicin from S. peucitius with CYP129A2 (Dickens et al., 1997), amphotericin B from S. 
nodosus with CYP105H4 and CYP161A3 (Caffrey et al., 2001), complestatin from S. 
lavendulae with CYP165E1 and CYP165B5 (Chiu et al., 2001), avermectin from S. 
avermitilis with CYP171A1 (Ikeda et al., 1999), PKSIII of S. coelicolor with CYP158A2 
(Austin et al., 2004), and so on. In this regard, the potential roles of CYP263A1 and 
CYP265A1 from So ce56 could be further research topics. 
 
The genome mining of So ce56 also disclosed a putative terpene cyclase gene adjacent to 
CYP264B1 in the genome. This ORF resembles the genomic organization of CYP170A1 of S. 
coelicolor A(3)2 where the coupled action of this CYP170A1 with epi-isozizaene synthetase 
for the biosynthesis of albaflavenone has been described (Zhao et al., 2008). A similar cluster 
was also reported in S. avermitilis where the gene SAV2999 encoding CYP183A1 has been 
described to catalyse the conversion of pentalenene(3) to pentalen-13-al(7) by stepwise allylic 
oxidation via pentalen-13-ol(6) (Quaderer et al., 2006). This could also be a new aspect for 
further research.  
 
The genomic mining of the So ce56 P450s also disclosed the presence of several complex 
regulators and other hypothetical protein encoding genes in a cluster. Unfortunately, no 
experimental data are available for the P450s.  
 
5. 3. Expression, purification and characterization of cytochrome P450 
All 21 cytochrome P450s of So ce56 were successfully cloned and expressed in E. coli in a 
soluble form and the highest yield of expression (after purification) was up to 1400 nmol/L 
for CYP266A1 whereas six of the P450s (CYP264B1, CYP110H1, CYP263A1, CYP261A1, 
CYP262B1 and CYP261B) have yield of <5 nmol/L (Table I. 9). Concerning this, the careful 
analysis of the gene inferred the following three reasons for differential expression levels. 
Firstly, the gene products could be toxic or a metabolic burden for the host cell. An inducible 
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expression system could avoid this problem. However, most of the commonly used promoters 
in E. coli are not tightly regulated (Wilms et al., 2001). In this study, the expression vector 
pCWori+ was used which has Lac, Tac and UV5 promoters which are of bacterial origin 
where the basal level leakage was obvious during protein expression. As the pET system has 
T7 promoter of viral origin, such basal level leakage could be controlled. It was observed that 
one of the P450s, CYP109D1, of So ce56 when recloned in pET17b and co-expressed with 
the molecular chaperones pGro12_GroES/GroEL in host E. coli BL21(DE3) showed an 
expression level was 3-4 fold higher than the expression with pCWori+ in E. coli BL21. In 
addition, it was observed that the basal level leakage during expression could be somehow 
controlled by inducing the bacterial culture at high cell density.  
 
Secondly, the high GC content could be responsible for the poor expression in E. coli but the 
effect was not uniform for all the So ce56 P450s. The higher GC ratios present in the P450s of 
So ce56 reflect the differences in the codon usage during heterologous expression. An 
artificial gene modifying such codon usage and adapting to E. coli could be synthesized for 
those P450s with low expression level (Khorana et al., 1979). Though different approaches 
were implemented to synthesize the artificial genes, all of them were relatively expensive and 
time consuming. So during this work, this idea was not followed to improve the expression 
level of poorly expressed P450s. Alternatively, rare codon optimizing expression strains like 
E. coli Rosetta was used. These strains are engineered to contain extra copies of genes that 
can encode the tRNA that most frequently limit translation of heterologous protein expression 
in E. coli. In this study, the attempt of using such host for some of the low expressed P450s of 
So ce56 somehow increased the expression level but it was still not high enough. 
Interestingly, the study of heterologous expression of 18 different P450s from the GC rich 
micro-organism Streptomyces coelicolor A(3)2 has shown that the P450s expression levels 
were also not uniform and varied  from less than 50 to 3000 nmol/L culture (Lamb et al, 
2002). 
 
Lastly, the GC-rich regions are also known for maintaining a strong secondary structure 
which could influence for the sequencing or amplification and even the heterologous 
expression of the corresponding genes. The GC-rich P450s sequences of So ce56 may be the 
other limiting factor for the over-expression, as it might form more strong mRNA secondary 
structures. The translation initiation sequence is of crucial important for the expression of GC-
rich genomes and is thus a possible target for optimization of the expression (Tang et al., 
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1999). A practical method for the over-expression of GC-rich genes in E. coli by modification 
of the initial sequence was also published (Ishida et al., 1997). Regarding this, in the genome 
two of the P450s (CYP262A1 and CYP267A1) of So ce56 have GTG as a start codon which 
was converted to ATG during the cloning process where the expression yield of pure protein 
was fairly high (125 nmol/L) for CYP262A1 and even higher (1400 nmol/L) for CYP266A1.  
 
Moreover, in this study, the frequency of rare-codons in the P450s of So ce56 has also been 
analyzed. During the examination, a large number of rare-used codons in E. coli, particularly 
arginine (CGG and CGA), proline (CCC and CCT) and glycine (GGA and GGG) were 
observed (Table I. 15). The effect of rare-codons in all P450s was not uniform, irrespective of 
which the expression level in general was high.  
 
Table I. 15: The frequency of rare codons in Sorangium cellulosum So ce56 P450s. The 
rare-codon includes Arginine (Arg) , Proline (Pro) and Glycine (Gly).  
 
 Rare codons 
 
P450s of 
So ce56 
 
Gene* 
Arg 
(AGG, 
AGA, 
CGA) 
Pro 
(CCC) 
Gly 
(GGA, 
GGG) 
Expression  
level 
(nmol/L 
cell culture) 
CYP109C1 sce0122 5 10 9 1333 
CYP109C2 sce8913 7 6 5 1300 
CYP109D1 sce4663 4 12 7 205 
CYP110H1 sce3065 8 18 7 5 
CYP110J1 sce6424 10 12 14 60 
CYP117B1 sce5528 2 16 6 5 
CYP124E1 sce7868 5 16 9 15 
CYP259A1 sce4635 5 12 14 8 
CYP260A1 sce1588 8 9 8 850 
CYP260B1 sce4806 6 2 13 100 
CYP261A1 sce0200 5 9 9 5 
CYP261B1 sce5725 4 11 11 2 
CYP262A1 sce2191 6 10 8 25 
CYP262B1 sce1860 6 9 17 2 
CYP263A1 sce4885 3 16 9 900 
CYP264A1 sce6323 7 6 5 440 
CYP264B1 sce8551 9 8 9 4 
CYP265A1 sce8224 8 8 10 21 
CYP266A1 sce5624 5 8 8 1400 
CYP267A1 sce0675 1 11 3 23 
CYP267B1 sce7167 1 10 9 70 
* gene ID deposition in NCBI 
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Furthermore, several published results regarding the expression and purification of bacterial 
P450s have shown different expression conditions. The expression was shown to be 
optimized by different induction times, temperatures, shaking-speeds and aerations. As a 
result, there were no common expression parameters that can be equally followed for all the 
P450s of So ce56. However, it was found that the expression was always better during 
induction at higher OD of 0.9-1.5. This study also showed that the low shaking speed in a 
baffled flask with higher ratio of culture volume/flask generally yielded a better expression 
level. Regarding the optimum temperature for the expression, decreasing of the expression 
temperature from 37°C to 25-28°C was the best condition for a good expression of all the 
P450s of So ce56.  
 
All the P450s of So ce56 were purified by Ni-NTA affinity chromatography at 4°C. The 
protein was further purified by size exclusion chromatography during which the imidazole 
present after affinity chromatography was also removed. During this study, the effect of 
imidazole was not analyzed for any of the P450s. The purity of all the P450s was monitored 
by SDS-PAGE and the active form of the P450 was confirmed by COD measurements. 
Moreover, to illustrate the holo and apo-masses, seven of the P450s (CYP109C1, CYP109C2, 
CYP109D1, CYP260A1, CYP264A1, CYP264B1 and CYP266A1) were selected. The 
coincidence of the experimental holo-mass and the co-factor with that of theoretical values 
confirmed the active form (Table I. 12-13).  
 
The spectrophotometric characterization of all the P450s showed a typical nature of P450s 
with peak maxima at 450 or 448 nm (Table I. 10) of the CO-complexed reduced P450. In 
some of the P450s, the P420 shoulder was more pronounced and the addition of the putative 
substrates helped to recover the P450 peak with minor or no shoulder at 420 nm, which 
represents the instability of P450s in an absence of the substrate.  
 
In this study, the absence of redox partners for So ce56 P450s has been overcome by using the 
mammalian heterologous electron partners adrenodoxin reductase (AdR) (Sagara et al, 1993) 
and the soluble (2Fe-2S) cluster-containing ferredoxin, adrenodoxin (Adx4-108) (Uhlmann et 
al., 1994). They were able to transfer electrons to CYP109C1, CYP109C2, CYP109D1, 
CYP110J1, CYP124E1, CYP260A1, CYP264A1, CYP264B1, and CYP267B1. Likely, our 
group has already shown that the mammalian adrenodoxin and adrenodoxin reductase were 
able to couple with the bacterial CYP106A2 from Bacillus megaterium (Virus et al., 2006; 
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Hannemann et al., 2006; Lisurek et al., 2008; Virus et al., 2008) during the conversion of 
steroids.  
 
6. Outlook 
The myxobacterial strain Sorangium cellulosum So ce56 has the largest bacterial genome 
sequenced till date. Twenty-one P450s encoding ORFs, disclosing nine novel P450 families, 
were identified and a phylogenetic tree as well as a physical map of the So ce56 chromosome 
have been deduced. All P450s of So ce56 have been identified, cloned, expressed in E. coli 
and the corresponding soluble proteins were purified in an active form with a yield up to 1400 
nmol/L for CYP266A1. The characteristic ferrous-carbon monoxide [Fe(II)CO] complex 
having a typical peak maximum at 448 nm and/or 450 nm confirmed the active existence of 
So ce56 P450s. The apo- and holo- mass of selected P450s (CYP109C1, CYP109C2, 
CYP109D1, CYP260A1, CYP264A1, CYP264B1 and CYP266A1) were not only in 
agreement with theoretical masses but also confirm their active form. The absence of 
homologous redox partners was overcome by using mammalian Adx and AdR for nine of the 
P450s (CYP109C1, CYP109C2, CYP109D1, CYP110J1, CYP124E1, CYP260A1, 
CYP264A1, CYP264B1, and CYP267B1). Screening of a compound-library of potential 
substrates disclosed positive hits for CYP109C1, CYP109C2, CYP260A1 and CYP266A1 
and opened the way for in vitro substrate conversion and subsequent product identification 
studies.  
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CHAPTER II 
A. CYP109D1 from Sorangium cellulosum So ce56: A fatty acids hydroxylase 
 
A. 1. INTRODUCTION 
Myxobacteria have very complex fatty acids profiles and up to 40 different compounds 
belonging to all known classes of fatty acids were identified (Ware and Dworkin et al., 1973; 
Bode et al., 2005, Kaneda, 1991). It was shown that odd numbered, iso- or in some case, 
anteiso-branched fatty acids were predominant in myxobacteria and in some other gliding 
bacteria (Fautz et al., 1979). It was also presumed that the unexpected abundance of fatty 
acids play an important role in the complex life cycle of myxobacteria which culminates in 
the formation of fruiting bodies containing heat and desiccation resistant myxospores 
(Shimkets, 1999; Moraleda-Munoz and Shimkets, 2007; Kaiser, 2003). It was previously 
demonstrated that the straight chain fatty acids are dispensable in Myxococcus xanthus for 
vegetative growth and fruiting body formation (Bode et al., 2006). Moreover, fatty acids were 
identified to play a role in chemotaxis and it was also illustrated that 
phosphatidylethanolamine (PE) containing fatty acid, 16:1ω5(∆11), elicits a chemotactic 
response (Curtis et al., 2006).  
 
Members of cytochrome P450 families have been shown to play a pivotal role in fatty acid 
hydroxylation and conversion. Several publications have shown that mammalian, (Fer et al., 
2008; Hardwick, 2008; Holmes et al., 2004; Hashizume et al., 2002), plant (Imaishi et al., 
2007; Sangeewa et al., 2007; Morant et al., 2007; Coon, 2005), fungal (Kim et al., 2007; 
Katazume et al., 2008; Eschenfeld, et al., 2003) and bacterial (Li et al., 2000; Chun et al, 
2007; Green et al., 2001; Girhard et al., 2007; Cryle et al., 2006; Budde et a.l, 2006) 
cytochrome P450s were able to do fatty acid hydroxylation. Among them, P450BM-3 
(CYP102) has one of the highest turnover numbers for a monooxygenation reaction 
(Gustafsson et al., 2001) but the exact physiological role is still unclear. The hydroxy fatty 
acids have also gained industrial interests because of their special properties such as higher 
viscosity and reactivity compared with normal fatty acids (Bagby and Calson, 1989). These 
special chemical properties enable hydroxy fatty acids to have a wide range of industrial 
applications including the production of resins, waxes, nylons, plastics, lubricants, cosmetics 
and additives in coatings and paintings. In addition, hydroxy fatty acids were reported to 
contain antimicrobial activities against plant pathogenic fungi and some bacteria (Bajpai et 
al., 2004; Hou and Forman, 2000; Kato et al., 1984; Shin et al., 2004). Recently, much effort 
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has been focused on the microbial production of hydroxy fatty acids from various fatty acid 
substrates.  
 
A. 2. Objectives of the Chapter II. A 
1. To search for fatty acid hydroxylating P450s of So ce56.  
2. To show the functional role of the CYP109 family as fatty acid hydroxylases. 
a) To analyze the position of hydroxylation in the fatty acid products  
b) To compare fatty acid hydroxylation patterns of CYP109 family members 
(CYP109C1, CYP109C2 and CYP109D1) of So ce56. 
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A. 3. MATERIALS AND METHODS 
A.3.1. Materials 
The instruments, chemicals, enzymes, kits, reagents and other accessories used in this work 
were of high grade. They are illustrated in Appendix I. 
 
The included fatty acids in this study were even-carbon-saturated fatty acid [capric acid 
(decanoic acid) (C10H20O2), lauric acid (dodecanoic acid) (C12H24O2), myristic acid 
(tetradecanoic acid) (C14H28O2), and palmitic acid (hexadecanoic acid) (C16H32O2)], odd-
carbon-saturated fatty acid [tridecanoic acid (C13H22O2)], mono-unsaturated fatty acid [Oleic 
acid (cis-9-octadecanoic acid) (18:1 cis-9)] and branched fatty acids (13-methyl myristic acid 
and 15-methyl palmitic acid).  
 
A. 3. 2. Methods 
The bioinformatics studies, protein expression, purification and spectrophotometric 
characterizations are as illustrated in Chapter I.  
 
A. 3. 3. Spin state shift and substrate dissociation constant determination 
The spin-state shifts upon substrate binding were assayed at room temperature under aerobic 
condition using an UV-Vis scanning photometer (UV-2101PC, Shimadzu, Japan) equipped 
with two tandem cuvettes (Noble et al., 1999). One chamber of each cuvette contained 5 µM 
CYP109D1 in buffer E (Appendix III) and the second chamber contained buffer alone. The 
fatty acids dissolved in DMSO were added in small aliquots (< 5 µl) from an appropriate 
stock into the CYP109D1 containing chamber of the sample cuvette. Meantime, equal 
amounts of substrate were added into the buffer containing chamber of the reference cuvette. 
The spectral changes between 350 and 500 nm were recorded. When saturation of CYP109D1 
with a substrate was achieved, the dissociation constant (KD) was calculated by fitting a 
hyperbolic curve of the peak-to-trough difference to substrate concentration by using Sigma 
Plot program. 
 
A. 3. 4. In vitro assay of fatty acid and derivatization 
The in vitro reactions were performed in a final volume of 0.5 ml in buffer E (Appendix III) 
containing 200 µM fatty acids as a substrate and a NADPH-regenerating system, consisting of 
glucose-6-phosphate (5mM), glucose-6-phosphate dehydrogenase (1 unit) and magnesium 
chloride (1 mM). The combinations of reconstituted redox partners P450: Adx: AdR or P450: 
 89 
Fdx: FdR of 1: 10: 1 (1 μM: 10 μM: 1 μM) were used for assay purpose. During incubation at 
30°C on a thermo shaker, NADPH was added to 500 μM final concentration and the mixture 
was incubated for 20 min. The reaction was stopped with an equal volume of diethyl ether. 
The product was extracted with diethyl ether for two times and was vacuum dried. This 
product was dissolved in 35 µl of derivatizing solution (N,O-
bis(trimethylsilyl)trifluoroacetamide + 1% trimethylchlorsilan) in a GC-vile, incubated at 
70°C for 30 min prior to GC-MS analysis and was analyzed as below.  
 
A. 3. 5. Fatty acid hydroxylation and GC-MS analysis  
All the GC-MS experiments were performed in Institute of Technical Biochemistry, 
Universitaet Stuttgart in collaboration with Dr. Vlada B. Urlacher.  
 
GC-MS analysis was performed on Shimadzu GCMS-QP2010 (column: FS-Supreme-5, 
length: 30 m, internal diameter: 0.25 mm, film thickness: 0.25 μm) using helium as a carrier 
gas. The mass spectra were collected using electron ionization. The column oven was 
programmed as in Table II. 1. The programs that were used for fatty acid analysis are shown 
in Table II. 2. 
 
Table II. A. 1: The standard GC-MS parameters for fatty acids analysis. 
Standard GC parameters Standard MS parameters 
Injection mode split Ion source temperature 200°C 
Flow control mode Linear velocity Interface temperature 285°C 
Purge flow 3 ml/min Start m/z 50 
  End m/z 450 
 
Table II. A. 2 (1-4): The column oven program for fatty acid analysis. 
1. Column oven program for decanoic, 
dodecanoic and tridecanoic acid 
2. Column oven program for tetradecanoic 
and pentadecanoic acid 
Rate 
(°C/min) 
Final Temp 
(°C) 
Hold 
(min) 
Rate 
(°C/min) 
Final Temp 
(°C) 
Hold 
(min) 
--------- 165 1  --------- 190 1  
6 215 0 7 245 0  
30 275 1  30 275 1  
 90
and heptadecanoic acid 
Rate 
(°C/min) 
Final Temp 
(°C) 
Hold 
(min) 
Rate 
(°C/min) 
Final Temp 
(°C) 
Hold 
(min) 
--------- 190 1  --------- 190 1  
6 255 0  8 300 1  
30 285 1     
 
The mono-hydroxylated fatty acids were identified by their characteristic fragmentation 
pattern. The stereochemistry of the products was not identified. 
 
3. Column oven program for hexadecanoic 4. Column oven program for oleic acid 
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A. 4. RESULTS 
A. 4. 1. Search for a fatty acid hydroxylating P450 of So ce56 
The inherent role of the lipids during the complex life cycle of myxobacteria strains 
(Schneiker, et al., 2007; Ware and Dworkin, 1973), guided us to presume fatty acids as 
potential substrates for some of the cytochromes P450s. The amino acid sequences of fatty 
acid hydroxylating P450s [CYP102A1 of Bacillus megaterium, CYP102A2, CYP102A3 and 
CYP152A1 of Bacillus subtilis, P450foxy from Fusarium oxysporum, CYP152A2 of 
Clostridium acetobutylicum, P450BioI of Bacillus subtilis and CYP105D5 of Streptomyces 
coelicolor A(3)2] were retrieved from NCBI. The P450 amino acid sequences of So ce56 
were aligned (Appendix VII. A-B) and a unrooted phylogenetic tree was constructed. It was 
found that CYP109 (CYP109C1, CY109C2, CYP109D1), CYP124E1, CYP264 (CYP264A1 
and CYP264B1), CYP265A1, CYP267 (CYP267A1 and CYP267B1) of So ce56 were 
clustered with CYP109D5 of S. coelicolor A(3)2 and P450BioI of B. subtilis. Likely, CYP110 
(CYP110H1 and CYP110J1), CYP261 (CYP261A1 and CYP261B1), CYP262 (CYP262A1 
and CYP262B1) and CYP263A1 are clustered with CYP102A1 of B. megaterium, and 
CYP102A2 and CYP102A3 of Bacillus subtilis (Figure II. A. 1. a). 
 
In order to highlight the significance of fatty acid hydroxylating P450s in So ce56, CYP109 
family member (CYP109C1, CYP109C2 and CYP109D1) was selected for further studies. 
All these P450 members were found to have relatively high expression yield (Table I. 9, 
Chapter I). Moreover, the heterologous redox partners, Adx and AdR, were already identified 
as an efficient electron transfer partners (Chapter I) which is the bottle neck for the 
reconstitution of the monooxygenase activity. Furthermore, these P450s were found to have a 
very high homology with the enzymes P450BioI of Bacillus subtilis and CYP105D5 of 
Streptomyces coelicolor A(3)2 (Figure II. A. 1. B), the well characterized fatty acid 
hydroxylases for which the fatty acid hydroxylation patterns were already shown (Green et 
al., 2001 and Chun et al, 2007). The individual pairwise alignment of CYP109D1 showed 
30.6% identity (47.8% similarity) with P450BioI of Bacillus subtilis and 31.2% identity 
(44.2% similarity) with CYP105D5 of Streptomyces coelicolor A(3)2. As a result, several 
fatty acids were selected for the subsequent conversion study.  
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A. 
 
B. 
 
 
Figure II. A. 1. The radial view of best maximum-parsimony tree obtained by PHYLIP 
analysis. A. The amino acid sequences of fatty acid hydroxylating CYPs (CYP102A1, 
CYP102A2, CYP102A3, P450foxy, CYP152A1, CYP152A2, P450BioI and CYP105D5) 
were retrieved from EMBL database. The blue branches represent the cluster of So ce56 
P450s related with P450BioI (CYP107H1) from Bacillus subtilis and CYP105D1 of S. 
coelicolor A(3)2. The brown lines represent the cluster of So ce56 with CYP102 family from 
Bacillus sp and P450foxy from Fusarium oxysporum. CYP260 family members (black 
branch), CYP259A1 and CYP117B1 (yellowish green) of So ce56 are not clustered with other 
fatty acid hydroxylases. B. The relatedness of CYP109 (CYP109C1, CYP109C2 and CYPD1) 
family member of So ce56 with fatty acid hydroxylases CYP105D5 and P450BioI (cluster 
with green branches). P450s from Sorangium cellulosum So ce56, Streptomyces coelicolor 
A(3)2, Bacillus subtilis, Fusarium oxysporum, Bacillus megaterium and Clostridium 
acetobutylicum are shown in blue, violet, magenta, red, dark blue and black, respectively. 
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A. 4. 2. Spin state shift and substrate binding 
The differential spectroscopy study was firstly performed for CYP109D1 with long chain 
saturated fatty acids like lauric acid, myristic acid and palmitic acid. These fatty acids showed 
perturbation of the heme spectra of CYP109D1 with a shift of the resting Soret band from 420 
nm towards a new position at ∼390 nm, typical of the high spin form (Figure II. A. 2-4). The 
apparent dissociation constant (KD) and the maximum absorbance shift (Amax) obtained at the 
saturation of related fatty acids were calculated for CYP109D1. The calculated KD and ∆Amax 
were 1.84 (± 0.164) µM and 0.27 (±0.004) respectively for lauric acid, with a calculated 
regression (R) of 0.99 (Figure II. A. 2). In case of myristic acid, the KD was 2.02 (± 0.118) 
µM and ∆Amax was 0.41 (± 0.005) with R = 0.99 (Figure II. A. 3). Likely, KD and ∆Amax for 
palmitic acid were 1.43 (± 0.110) µM and 0.38 (± 0.006), respectively, with R = 0.99 (Figure 
II. A. 4). The very low KD values demonstrate the tight binding of these fatty acids with 
CYP109D1. 
 
A
 
B 
 
 
Figure II. A. 2:
 
A. Spectral shift induced by binding of lauric acid to CYP109D1. Varying 
concentrations of lauric acid, dissolved in DMSO, were titrated in small (µl) aliquots to the 
solution of CYP109D1 (5 µM) in 10mM potassium phosphate buffer, pH 7.4 containing 20% 
glycerol, with the starting spectrum subtracted from the subsequent traces, so that the final 
concentrations were 0.250 µM - 7.000 µM in paired-tandem cuvettes. B. The plot of 
absorbance change vs. concentration of the lauric acid. The points were plotted to 
hyperbolic fit and the values for KD = 1.84 (± 0.164) µM and ∆Amax = 0.27 (± 0.004) were 
obtained with regression (R) = 0.99 and standard error of estimate of 0.003. 
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Figure II. A. 3:
 
A. Spectral shift induced by binding of myristic acid to CYP109D1. 
Varying concentrations of myristic acid, dissolved in DMSO, were titrated in small (µl) 
aliquots to the solution of CYP109D1 (5 µM) in 10mM potassium phosphate buffer, pH 7.4 
containing 20% glycerol, with the starting spectrum subtracted from the subsequent traces, so 
that the final concentrations were 0.125 µM - 15.000 µM in paired-tandem cuvettes. B. The 
plot of absorbance change vs. concentration of the myristic acid. The points were plotted 
to hyperbolic fit and the values for KD = 2.02 (± 0.118) µM and ∆Amax = 0.41 (± 0.005) were 
obtained with regression (R) = 0.99 and standard error of estimate of 0.006.  
 
 
 
Figure II. A. 4:
 
A. Spectral shift induced by binding of palmitic acid to CYP109D1. 
Varying concentrations of palmitic acid, dissolved in DMSO, were titrated in small (µl) 
aliquots to the solution of CYP109D1 (5 µM) in 10mM potassium phosphate buffer, pH 7.4 
containing 20% glycerol, with the starting spectrum subtracted from the subsequent traces, so 
that the final concentrations were 0.125 µM - 13.000 µM in paired-tandem cuvettes. B. The 
plot of absorbance change vs. concentration of the palmitic acid. The points were plotted 
to hyperbolic fit and the values for KD = 1.43 (±0.110) µM and ∆Amax = 0.38 (±0.006) were 
obtained with regression (R) = 0.99 and standard error of estimate of 0.007.
 
 
A. 4. 3. Characterization of different members of CYP109 family of So ce56 
Two sequences of CYP109, P27632 and AF015825 from Bacillus subtilis were reported long 
before (Ahn and Wake, 1991 and Kunst, et al., 1997) but their substrates have not been 
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identified so far. As this work was the very first to illustrate the novel properties of a CYP109 
family member as a fatty acid hydroxylase, a detailed study was necessary. The percentage 
similarities among all CYP109 members were calculated and are illustrated in Table II. A. 3. 
All the subfamilies of CYP109 from Bacillus subtilis and So ce56 showed more than 50% 
similarity except for CYP109D1 of So ce56 and CYP109B (AF015825) of B. subtilis. 
 
Table II. A. 3: The percentage similarities among the different members of the CYP109 
families. The values were obtained from the pair wise sequence alignment and the values are 
expressed in percentage similarity of amino acid sequences. 
 
Bacillus subtilis Sorangium cellulosum 
 (So ce56) 
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CYP109A (P27632*) - 61.6 53.3 55.9 52.1 Bacillus 
subtilis CYP109B (AFO15825*) 61.6 - 55.5 58.3 46.6 
CYP109C1 53.3 51.5- - 79.3 51.2 
CYP109C2 55.9 58.3 79.3 - 52.3 
 
So ce56 
CYP109D1 52.2 46.6 51.2 52.3 - 
NOTE: * gene number in EMBL database 
 
A. 4. 4. Fatty acid hydroxylation and characterization 
The in vitro conversion of fatty acids catalyzed by CYP109D1 were performed in a 
reconstitution system with heterologous redox partners, Adx-AdR, and were measured by 
GC-MS after derivatization assuming that all the derivatized products were extracted with an 
equal efficiency. The substrate and products were identified by their characteristic 
fragmentation patterns. The possible derivatized masses for the major fragments were 
calculated by using ChemDraw Ultra 11.0 and were confirmed with an authentic library and 
the archived MS spectra of trimethylsilyl-(TMS) methyl-hydroxy fatty acids on 
http://www.lipidlibrary.co.uk. An overview of the characteristic fragments for the products of 
the investigated saturated fatty acid is illustrated in Table II. A. 4. 
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Table II. A. 4: The characteristic derivatized units (sizes) for the silylated hydroxylation 
products from the different fatty acids used in this work. The sub-terminal ω-
hydroxylations of saturated, unsaturated and branched fatty acids are shown. 
 Substrate ω-0 ω-1 ω-2 ω-3 ω-4 ω-5 ω-6 ω-7 
Capric acid (C10) - 117, 
317 
131 
303 
- - - - - 
Lauric acid (C12) - 117, 
345 
131,  
331 
145, 
317 
- - - - 
Tridecanoic acid (C13) - 117, 
359 
131, 
345 
145, 
331 
159, 
317 
173, 
303 
- -- 
Myristic acid (C14) - 117, 
373 
131, 
359 
145, 
345 
159, 
331 
173, 
317 
- - 
Sa
tu
ra
te
d 
fa
tt
y 
a
ci
d 
Palmitic acid (C16) - 117, 
401 
131, 
387 
145, 
373 
159, 
359 
173, 
345 
187, 
331 
 
U
n
sa
tu
ra
te
d 
 
fa
tt
y 
a
ci
d 
Oleic acid 
(18:1 cis9) 
- - - - - - 187, 
357 
201, 
343 
13-Methyl 
myristic acid 
- - 145, 
359 
159 
345 
173, 
331 
 - - 
Br
a
n
ch
ed
 
fa
tt
y 
a
ci
d 
15-Methyl 
palmitic acid 
- 
- 
- 
- 
145, 
387 
159, 
373 
173, 
359 
187, 
345 
201, 
331 
- 
 
A. 4. 4. 1. Hydroxylation of saturated fatty acid by CYP109D1 
Five saturated fatty acids of carbon-length C10 to C16 were tested in this work, including 
capric acid (C10), lauric acid (C12), tridecanoic acid (C13), myristic acid (C14) and palmitic 
acid (C16).  
 
As shown in Table II. A. 4 CYP109D1 was able to convert all the tested saturated fatty acids. 
They were hydroxylated at sub-terminal positions. The terminal hydroxylation was not 
obtained. Capric acid was hydroxylated at ω-1 (RT 8.11 min) and ω-2 (7.91 min) positions. 
Lauric acid gave 3 hydroxylated products at ω-1 (RT 9.86 min), ω-2 (RT 9.67 min) and ω-3 
(RT 9.30 min). Tridecanoic acid was hydroxylated at ω-1 (RT 15.16 min), ω-2 (RT 15.04 
min), ω-3 (RT 14.79 min), ω-4 (RT 14.65 min) and ω-5 (RT 14.55). Myristic acid was also 
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converted into 5 hydroxylated products of ω-1 (RT 9.36 min), ω-2 (RT 9.20 min), ω-3 (RT 
8.88 min), ω-4 (RT 8.68 min) and to ω-5 (RT 8.57). Similarly, palmitic acid was converted to 
7 hydroxylated products at ω-1 (RT 11.61 min), ω-2 (RT 11.41 min), ω-3 (RT 14.02 min), ω-
4 (RT 10.84 min), ω-5 (RT 10.67) and ω-6 (RT 10.57) (Figure II. A. 5). The characteristic 
fragmentation patterns of the silylated hydroxylation products of the investigated saturated 
fatty acids were assigned in each of the mass spectra in (Figure II. A. 6. 1-5). During product 
analysis, mainly two major fragments have been considered and the derivatization is shown in 
the inset of each mass spectra. 
 
 
Figure II. A. 5: GC chromatogram of subterminal ω-hydroxylation of saturated fatty 
acids by CYP109D1. A-E represents the hydroxylation of capric acid, lauric acid, tridecanoic 
acid, myristic acid and palmitic acid, respectively. The red and black lines represent the 
negative and the product, respectively. Substrate (S) and ω-hydroxylation are shown. The ‘*’ 
represents non specific product. 
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Figure II. A. 6. 1: Mass spectra of the hydroxylated products of capric acid by 
CYP109D1. The MS of A. ω-1 and B. ω-2 hydroxylated products of capric acid are shown. 
In the inset the derivatization pattern of each of the ω-products of capric acid are shown.   
 
A 
 
 
B 
 
 
C 
 
 
 
Figure II. A. 6. 2: Mass spectra of the hydroxylated products of lauric acid by 
CYP109D1. The MS of A. ω-1, B. ω-2 and C. ω-3 hydroxylated products of lauric acid are 
shown. In the inset the derivatization pattern of each of the ω-products of lauric acid are 
shown.   
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Figure II. A. 6. 3: Mass spectra of the hydroxylated products of tridecanoic acid by 
CYP109D1. The MS of A. ω-1, B. ω-2, C. ω-3, D. ω-4 and E. ω-5 hydroxylated products of 
tridecanoic acid are shown. In the inset the derivatization pattern of each of the ω- products of 
tridecanoic acid are shown.   
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Figure II. A. 6. 4: Mass spectra of the hydroxylated products of myristic acid by 
CYP109D1. The MS of A. ω-1, B. ω-2, C. ω-3, D. ω-4 and E. ω-5 hydroxylated products of 
myristic acid are shown. In the inset the derivatization pattern of each of the ω-products of 
myristic acid are shown.   
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Figure II. A. 6. 5: Mass spectra of the hydroxylated products of palmitic acid by 
CYP109D1. The MS of A. ω-1, B. ω-2, C. ω-3, D. ω-4, E. ω-5 and F. ω-6 hydroxylated 
products of palmitic acid are shown. In the inset the derivatization pattern of each of the ω-
products of palmitic acid are shown.   
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A. 4. 5. Comparison of hydroxylation patterns of saturated fatty acids obtained by other 
CYP109 members of So ce56 
The other two members of the CYP109 family, CYP109C1 and CYP109C2, were also used 
for saturated fatty acid hydroxylation. Both P450s (CYP109C1 and CYP109C2) were able to 
get electrons from the heterologous redox proteins, Adx and AdR (Chapter I). The spin shift 
experiment with corresponding saturated fatty acids for CYP109C1 and CYP109C2 was not 
done. Since CYP109C1 and CYP109C2 were clustered with CYP109D1 (Figure II. A. 1), 
fatty acids were selected as putative substrates and their conversion was studied directly. The 
GC-MS analysis was done and was compared with the hydroxylation pattern of CYP109D1. 
It was found that CYP109C1 was not able to convert any of the tested fatty acids. CYP109C2 
has converted all the tested saturated fatty acids into their corresponding hydroxylated 
products, except for capric acid (C10) (Table II. A. 5). It was found that CYP109C2 mediated 
hydroxylation reactions were less efficient but more selective than those of CYP109D1. 
CYP109C2 was able to convert lauric acid and tridecanoic acid at ω-1 to ω-3, myristic acid at 
ω-1 to ω-2 and palmitic acid only at ω-1 position. The details of hydroxylated products, and 
the corresponding retention times are demonstrated in Table II. A. 5. CYP109C2 catalyzed 
reaction showed that the sub terminal ω-1 hydroxylated products (area percent) were always 
dominating (Table II. A. 5). It was found that the hydroxylation pattern by CYP109C1 was 
more selective towards the sub-terminal end for the saturated fatty acids. It seemed that the 
hydroxylation pattern of CYP109C2 is not depending on the chain length. 
 
However, the hydroxylating reaction of CYP109D1 was much more efficient than that of 
CYP109C2 (Table II. A. 5). It was found that, CYP109D1 has converted ~57% of capric acid 
into ω-1 and ω-2 hydroxylated products. Likely, 72% of the lauric acid was converted to ω-1 
to ω-3, 88% tridecanoic acid to ω-1 to ω-4, 98% myristic acid to ω-1 to ω-4, and 71% of 
palmitic acid to ω-1 to ω-5. It was noticed that the hydroxylation pattern of CYP109D1 
depends on the chain length. In moderate short chain fatty acids like capric acid, lauric acid 
and tridecanoic acid, the sub-terminal ω-1 hydroxylation product is predominating and 
subsequently decreasing towards higher  ω-position with the product pattern of ω-1 > ω-2 > 
ω-3 > ω-4 hydroxylated product (Figure II. A. 5 and Table II.5). In case of long chain fatty 
acids like myristic acid and palmitic acid the sub-terminal hydroxylations were not consistent 
rather the higher ω-position of hydroxylations was more predominant. In case of myristic 
acid, 98% of the substrate was converted into ω-1 to ω-5 hydroxylated products where ω-3 
and ω-4 has 27 and 26% product predominance, respectively. Likely, for palmitic acid, 72% 
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of the substrate was converted into ω-1 to ω-7 hydroxylated products where 25% of the 
product was predominant in ω-5 and 27% in ω-6 position (Table II. A. 5). These results 
showed that CYP109D1 was much more efficient for saturated fatty acid hydroxylation than 
CYP109C2.  
 
A. 4. 6. Hydroxylation of other fatty acids by CYP109D1 
As CYP109C1 was not able to hydroxylate any of the tested saturated fatty acids and 
CYP109C2 has very low activity, only CYP109D1 was used to test the hydroxylation of 
unsaturated and branched fatty acids. 
 
A. 4. 6. 1. Hydroxylation of unsaturated fatty acid by CYP109D1 
The unsaturated fatty acid oleic acid was used in this work. CYP109D1 was able to convert 
the oleic acid (RT 13.67 min) into 2 hydroxylated product of ω-7 (RT 15.34 min) and ω-6 
(RT 15.64 min) (reconstitution with Adx and AdR) (Figure A. 7). During conversion, 56% of 
the oleic acid (200 µM) was converted into ω-7 and ω-6 products, where the ω-7 product was 
much predominated (50%). The characteristic fragmentation patterns of the oleic acid and its 
products are illustrated in Figure. A. 8. 
 
 
 
Figure II. A. 7: GC chromatogram of oleic acid hydroxylation by CYP109D1. The red 
and black line represents the negative control and conversion, respectively. ‘S’ represents the 
oleic acid and the ‘*’ represents the impurity. The ω-6 and ω-7 hydroxylated product peaks 
are shown. 
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Table II. A. 5: The product profiles of saturated fatty acids by the members of CYP109 
(CYP109C1, CYP109C2 and CYP109D1) of So ce56. The comparison of hydroxylation 
position, respective retention time (RT) and the area percentage of the substrate and the sub 
terminal ω-hydroxylated products for CYP109D1, CYP109C1 and CYP109C2 are illustrated. 
CYP109C1 has not shown any hydroxylation activity. 
 
 
ω-7 
 
 
ω-6 
 
 
ω-5 
 
 
ω-4 
 
 
ω-3 
 
 
ω-2 
 
 
ω-1 
 
 
 
P450s of  
So ce56 
 
Su
bs
tr
a
te
 
R
T/
A
re
a
 
%
 
 
Retention time (RT) in min / 
Area % 
To
ta
l 
C
o
n
v
er
sio
n
 
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             Capric acid      
CYP109C1 - - - -  - - - NC*  
CYP109C2 - - - - - - - - NC* 
CYP109D1 4.89/ 
43.03 
- - - - - 7.91/ 
2.80 
8.11/ 
54.17 
56.97 
   Lauric acid 
CYP109C1 - - - - - - - - NC* 
CYP109C2 6.12/ 
95.97 
- - - - 9.30/ 
0.24 
9.67/ 
1.46 
9.86/ 
2.33 
4.03 
CYP109D1 6.12/ 
27.74 
- - - - 9.30/ 
3.93 
9.67/ 
31.28 
9.86/ 
37.05 
72.26 
                                                                   Tridecanoic acid 
CYP109C1         NC*  
CYP109C2 12.42/ 
91.33 
- - - - 14.79/ 
0.93 
15.04/ 
2.31 
15.16/ 
5.43 
8.67 
CYP109D1 12.42/ 
11.66 
- - 14.55/ 
1.07 
14.65/ 
1.71 
14.79/ 
22.19 
15.04/ 
23.74 
15.16/ 
39.63 
 
88.34 
                                                                    Myristic acid 
CYP109C1 - - - - - - - - NC* 
CYP109C2 6.40/ 
84.92 
- - - - - 9.20/ 
3.11 
9.36/ 
11.97 
15.08 
CYP109D1 6.40/ 
1.80 
- - 8.57/ 
12.18 
8.68/ 
25.61 
8.88/ 
26.58 
9.20/ 
15.53 
9.36/ 
16.95 
98.2 
                                                                    Palmitic acid                                    
CYP109C1 - - - - - - - - NC* 
CYP109C2 8.14/ 
88.00 
- - - - - - 10.70/ 
12.00 
12.00 
CYP109D1 8.14/ 
28.56 
10.44/ 
11.97 
10.57/ 
27.60 
10.67/ 
24.77 
10.80/ 
4.93 
11.02/ 
1.44 
11.41/ 
0.55 
11.61/ 
0.21 
71.44 
 
Note: NC* - No conversion 
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Figure II. A. 8: Mass spectra of the hydroxylated products of oleic acid by CYP109D1. 
The MS of A. ω-6 and B. ω-7 hydroxylated products of oleic acid are shown. In the inset the 
derivatization pattern of each of the ω-products of oleic acid are shown. 
 
A. 4. 6. 2. Hydroxylation of branched fatty acid by CYP109D1 
In this work, the branched fatty acids, 13-methyl myristic acid and 15-methyl palmitic acid 
were used as substrates for CYP109D1 after reconstitution with Adx and AdR as redox 
partners. CYP109D1 was able to convert 13-methyl myristic acid at ω-2 (RT 12.95 min), ω-3 
(RT 12.47min) and ω-4 (RT 13.37min) (Table II. A. 6). In case of 15-methyl palmitic acid, 
the hydroxylation also occurred at sub-terminal positions at ω-2 (RT 15.10 min), ω-3 (RT 
14.63 min), ω-4 (RT 14.52) and ω-5 (RT 14.48) and ω-6 (14.45 min). The retention time and 
the area percentage of the substrate and the respective hydroxylation products are illustrated 
in Table II. A. 6. The characteristic fragmentation patterns are illustrated in Figure II. A. 9-10. 
The total conversion of both the fatty acids was below 15%. The terminal hydroxylation was 
not detected. 
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Table II. A. 6: Product profile of branched fatty acids with CYP109D1. Hydroxylation 
positions with respective retention time and area percentage of the substrate and product for 
CYP109D1 are illustrated. 
 ω-6 ω-5 ω-4 ω-3 ω-2 ω-1 Substrate 
Retention time (RT)  in min/ 
Area % 
13-methyl myristic acid 
To
ta
l 
C
o
n
v
er
sio
n
 
%
 
10.12/ 
98.00 
 - - 12.37/ 
0.59 
12.47/ 
0.49 
12.95/ 
0.87 
- 2.00 
15-methyl palmitic acid 
12.4/ 
84.90 
 14.45 
2.01 
14.48/ 
8.18 
14.52/ 
0.81 
14.63/ 
0.98 
15.10/ 
0.75 
- 15.1 
 
 
Figure II. A. 9: Mass spectra of the hydroxylated products of 13-methyl myristic acid by 
CYP109D1. The MS of A. ω-2, B. ω-3 and C. ω-4 hydroxylated products of 13-methyl 
myristic acid are shown. In the inset the derivatization patterns of each of the ω-products of 
13-methyl myristic acid are shown. 
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Figure II. A. 10: Mass spectra of the hydroxylated products of 15-methyl palmitic acid 
by CYP109D1. The MS of A. ω-2, B. ω-3, C. ω-4, D. ω-5 and E. ω-6 of hydroxylated 
products of 15-methyl palmitic acid are shown. In the inset the derivatization pattern of each 
of the ω-products of 15-methyl palmitic acid are shown.   
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A. 5. Discussion 
Fatty acids occur widely in nature as metabolic intermediates or secondary metabolites. In 
bacteria, the straight chain fatty acids lauric acid, myristic acid, palmitic acid, stearic acid, 
hexadecanoic acid, octadecanoic acid, cyclopropanoic acid, 10-methyl hexadecanoic acid and 
2- or 3-hydroxy fatty acids are commonly found (Lechevalier, 1977; Siristova et al., 2008). 
The occurrence and functional role of hydroxylated long chain fatty acids in animals, plants 
and fungi are well established (Dyk et al., 1994; Lösel, 1988). Many of these compounds 
have potential physiological activities and play an important role in the cell signaling process. 
A large number of fungi that produce hydroxylated long chain fatty acids are plant pathogens. 
However, much less is known about the function of hydroxy fatty acids in bacteria. It was 
shown that Nocardia cholesterolicum and Flavobacterium DS5 convert oleic acid to 10-
hydroxy stearic acid and linoleic acid to 10-hydroxy-12 (Z)-octadecanoic acid which act as 
bioactive compounds (Hou, 2008). In Mycobacterium tuberculosis and Mycobacterium leprae 
3-hydroxylated long chain fatty acids play a crucial role in the envelope architecture 
(Rafidinarivo et al., 2008). Though the hydroxyled fatty acids govern some vital functions in 
bacteria, the real mechanisms of the production were not clear. However, it has been shown 
that the terminal and sub-terminal hydroxylation of long chain fatty acids are generally 
ascribed to the action of cytochromes P450 (Boddupalli et al., 1990; Li et al., 2000) and thus 
obtained fatty acid derivatives speculated to have some physiological role.  
 
It has been shown that the fatty acids and their derivatives are of prime concern in the life 
cycle of myxobacteria (Shimkets, 1999; Curtis et al., 2006; Rosenbluh and Dworkin, 1996; 
Gerth et al, 2003; Guo and Tao, 2008; Ahn et al, 2008). Considering the physiological 
significance of lipids in myxobacteria, fatty acids were assumed as putative substrates for 
some of the P450s of So ce56. Though several homologues of fatty acid hydroxylases were 
identified, only the enzymes of the CYP109 family (CYP109C1, CYP109C2 and CYP109D1) 
were selected for further studies in this dissertation because of their higher expression level 
(Chapter I) and identified redox partners (Chapter I). The putative substrates, fatty acids 
(lauric acid, myristic acid and palmitic acid), were firstly used to characterize the binding 
spectra with CYP109D1, the most distant P450 among three members of CYP109 family 
(CYP109C1, CYP109C2 and CYP109D1) (Figure II. A. I) and showed a tight binding. 
Beside this, CYP109D1 also hydroxylated capric acid into ω-1 and ω-2, lauric acid to ω-1 to 
ω-3, tridecanoic acid to ω-1 to ω-5, myristic acid to ω-1 to ω-5, and palmitic acid to ω-1 to ω-
6. Further on, the other two CYP109 members (CYP109C1 and CYP109C2) of So ce56 were 
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used to study the in vitro conversion of saturated fatty acids. Under identical experimental 
condition, CYP109C1 was not able to convert any of the tested saturated fatty acids. 
However, the sub-terminal hydroxylated products of saturated fatty acids were obtained in 
case of CYP109C2 although the area percentage of the products was much lower than that 
with CYP109D1. It could be that either the predicted substrates (fatty acids) are not good 
substrates for CYP109C2 or that the redox partners might not be efficient enough with this 
P450. Our data show that the three P450s (CYP109C1, CYP109C2 and CYP109D1), despite 
being same family members and homologues to each other, were not able to perform the same 
reactivity under identical reaction conditions. An application of theoretical studies such as 
docking experiments should be the next stage in gaining a better understanding of the effect 
of fatty acids on CYP109C1, CYP109C2 and CYP109D1. An investigation on the 
hydroxylation of saturated fatty acid was also done for CYP105D5 from S. coelicolor A(3)2  
where ω-1, ω-2, ω-3 and ω-4 hydroxylation of lauric acid and ω-1 hydroxylation of oleic acid 
(Chun et al., 2007) were described. Likewise, P450BioI (CYP107H1) from Bacillus subtilis 
was also shown to catalyze the ω-hydroxylation of myristic acid (Green et al., 2001). In both 
the cases the distinct physiological role is not clear. Similarly, even for the well studied fatty 
acid hydroxylase P450 BM-3 (CYP102A1) the physiological role is currently unclear. 
However, Wolf’s group speculated that the role of P450BM-3 is to protect Bacillus 
megaterium by removing toxic fatty acids from the environment (Gustafsson et al., 2001). 
Likewise, the hydroxylation of fatty acids by CYP102A1 was also shown (Capdevila et al., 
1996) but the physiological role again was not clear. In this study, though the clear 
physiological role of the products of hydroxylated saturated fatty acids during the life cycle of 
So ce56 is not clear, it is speculated that the hydroxylated products obtained by P450s could 
successively be converted into related alcohols and carboxylic acids which could have 
important role during normal homeostasis or during other biosynthetic process.  
 
In our study, the hydroxylation of fatty acid by CYP109D1 was further extended by using 
mono-unsaturated fatty acid and branched-fatty acid. CYP109D1 was able to convert oleic 
acid (the monounsaturated omega-9-fatty acid) into the ω-6 hydroxylated product (12-
hydroxy-9-octadecenoic acid) also called as ricinoleic acid which has various physiological 
and biotechnological significances. It is reported that 12-hydroxyoctadecanoic, ricinoleic and 
other fatty acids can enhance the production of greenish-yellow pigment (identified as 
phenazine-1-carboxylic acid) in Pseudomonas species (Keudell et al., 2000). As Sorangium 
cellulosum So ce56 are also yellowish-orange colored, the importance of such hydroxylated 
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product by P450 could be a matter of further studies. It was shown that the ricinoleic acid can 
also undergo many familiar organic reactions to form useful derivatives like epoxidated, 
hydrogenated and hydroxylated forms (Park et al., 2004). So it is assumed that CYP109D1 
possibly could have an important role to produce some physiologically important derivatives 
from unsaturated fatty acids during the lifecycle of So ce56. Moreover, ricinoleic acid could 
have some biotechnological applications. The presence of hydroxyl- and carboxyl-groups as 
well as ∆-9 unsaturation make ricinoleic acid beneficial as an important precursor for the 
synthesis of useful bio-materials like biopolymers (Ebata et al., 2007). It was also reported 
that ricinoleic acid can be enzymatically polymerized to yield a higher molecular weight 
polyricinoleate, which showed an excellent low temperature flexibility and elasticity to a 
thermosetting elastomer (Ebata et al., 2007). 
 
Branched chain fatty acids also have special importance in microbes. Monomethyl branched-
chain fatty acids (mmBCFAs) in iso- or in an anteiso- configuration are found in various 
bacteria including cold tolerant and thermophilic species (Merkel and Perry, 1977; Annous et 
al., 1997; Batrakov et al., 2000; Jahnke et al., 2001, Groth et al., 2002, Nichols et al., 2002, 
Ferreira, et al., 1997). In most of the cases, mmBCFs play a contributing role to the 
membrane function, regulating fluidity (Rilfors et al., 1978; Suutari and Laakso, 1994; Cropp 
et al., 2000; Jones et al., 2002) and protein permeability (van de Vossenberg, 1999). The 
branched fatty acids are also responsible for the pathogenic role in some microbes, e.g. 
mycocerosic acid present in the cell wall of the pathogenic mycobacterium is responsible for 
the growth and pathogenesis (Gago, et al., 2006). The role of branched-chain fatty acids 
during the tolerance of pH stress in Listeria monocytogenes was also studied and it was 
shown that a higher proportion of branched fatty acid is produced during alkaline condition 
for the adaptability (Giotis et al., 2007). Along with this, it has been shown that even for the 
growth and development of the eukaryotic cell Caenorhabditis elegans, mono-methyl 
branched fatty acids became essential (Kniazeva et al., 2004). Concerning this, in several 
myxobacterial studies the pronounced role of branched chain fatty acid has been documented 
during gliding motility, chemotaxis and fruiting body formation. The fatty acids present in the 
total hydrolysates of several gliding bacteria (Myxococcus fulvus, Stigmatella aurantiaca, 
Cytophaga johnsonae, Cytophaga sp. strain Samoa and Flexibacter elegans) showed that 13-
methyl-tetradecanoic acid, 15-methyl-hexadecanoic acid, hexadecanoic acid, and 
hexadecenoic acid, 2- and 3-hydroxy fatty acids comprised up to 50% of the total fatty acids. 
It was shown that 2-hydroxy-15-methyl hexadecanoic acid was the characteristic fatty acid for 
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the myxobacteria in contrast; 2-hydroxy-13-methyl-tetradecanoic acid, 3-hydroxy-13-methyl-
tetradecanoic acid, and 3-hydroxy-15-methyl-hexadecanoic acid were dominant in the 
Cytophaga and Flexibacter group (Fautz, et al., 1979). Similarly, M. xanthus fatty acids 
(including the branched-chain fatty acids) have been observed to be important for a variety of 
the effects on developing cell-stages and showed that the branched-chain fatty acids were 
released during the cell to cell signaling (Downard and Toal, 1995). It has also been shown 
that phosphatidylethanolamine (PE) containing 16:1 omega-5C is likely to play a role in 
developmental chemo-attraction in Myxococcus xanthus (Kearns et al., 2001). Likewise, it 
was also shown that the iso-branched ether lipids are specific markers that are observed 
during the developmental sporulation in the M. xanthus (Ring et al., 2006). In order to 
highlight this, two of the branched fatty acid, 13-methylmyristic acid and 15-methyl palmitic 
acid, were also tested. CYP109D1 was able to hydroxylate both fatty acids at sub-terminal 
position. Terminal hydroxylation was not observed. It is assumed that the hydroxylated 
products of the branched chain fatty acid and other fatty acids might have an important role 
during gliding motility, cell signaling and fruiting body formation as well as energy storage 
and dissemination.  
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CHAPTER II 
B. CYP109D1 from Sorangium cellulosum So ce56: A terpenoid epoxidase/hydroxylase 
 
B. 1. INTRODUCTION  
B. 1. 1. Terpenoid compounds 
Terpenes and terpenoids are the most diverse family of natural products synthesized notably 
from plants serving a range of important physiological and societal functions (Roberts, 2007). 
Over 40,000 different terpenoids have been isolated mainly from plant but also from animal 
and microbial species (Rohdich, et al., 2005; Withers and Keasling, 2007). The basic 
molecular formulae of terpenes are the multiples of (C5H8)n where ‘n’ is the number of linked 
isoprene units. Terpenes could be hemiterpenes (with one isoprene unit e.g. prenol, isovaleric 
acid), monoterpenes (with two isoprene units, C10H16, e.g. geraniol, nerol, limonene), 
sesquiterpenes (with three isoprene units, C15H24, e.g. farnesences, farnesol, nootkatone etc), 
diterpenes (with four isoprene units, C20H32, e.g. cafestol, cembrene, taxadiene), sesterterpene 
(with 25 carbons and five isoprene units e.g. geranylfarnesol), triterpenes (with six isoprene 
units, C30H48, e.g. several precursors of steroids), tetraterpenes (with eight isoprene units, 
C40H64, e.g. lycopene, carotenes etc) and polyterpenes (with long chains of many isoprene 
units e.g. rubber).  
 
Monoterpenes, in particular, represent a cheap and abundantly available pool of chiral 
substances that can be transformed into valuable bioactive compounds which are used in 
flavor, fragrance, and pharmaceutical industries or as building blocks in organic chemistry (de 
Carvalho and da Fonseca, 2006). Though the oxygenated products of terpenes are highly 
valuable compounds, their selective oxidation under mild conditions is still a great challenge. 
The regio- and stereo- selective functionalization of terpenes, especially terpene 
hydrocarbons, is known to be a difficult task for organic chemistry, and the few approaches 
described in the literature show several disadvantages with respect to reaction complexity and 
specificity (Newhall, 1958; Bhawal et al., 2001; Stainslaw et al., 2002; Duetz et al., 2003). In 
such cases, the application of P450s monooxygenase could be useful. It is already shown that 
cytochrome P450 monooxygenases are capable of doing selective oxidation of different 
terpenes and terpenoids, often with a high activity (Peterson et al., 1992; Hawkes et al., 
2002).  
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B. 1. 1. 1. Geraniol and nerol  
The acyclic monoterpenes studied in this work were geraniol and nerol which are 
monoterpenoids and alcohols (Figure II. B. 1). Geraniol is abundantly present in the essential 
oils of rose, palmarosa and citronella, and widely used in fragrance chemistry. Geraniol is 
also a pheromone of certain species of bees, being secreted by the scent glands of worker bees 
to signal the location of nectar-bearing flowers and the entrances to their hives. Geraniol also 
finds an application as insect repellants or deterrants 
(http://chemicalland21.com/specialtychem/perchem/NEROL.htm). Moreover, it has been 
shown that the geraniol and its derivatives  are present in 76% of the investigated deodorants 
on the European market, in 33% of the cosmetic based natural ingredients (Rastogi et al., 
1998) and in 41% domestic and household products (Rastogi et al., 2001). Nerol is the cis-
isomer of geraniol. They are also one of the compounds in the fragrance mix (FM) that is used 
for clinical screening of contact allergy among consecutive dermatitis patients which is 
responsible for only 5% of positive patch test reactions to the individual components of FM 
(Schnuch et al., 2004) and is considered to be a weak allergen.  
A 
OH 
 
Geraniol (C10H18O)  
B 
HO
 
Nerol (C10H18O) 
Figure II. B. 1: Structure of linear monoterpenes. A. geraniol B. nerol 
 
B. 1. 1. 2. Limonone 
Limonene (4-isopropenyl-1-methylcyclohexene), a monocyclic monoterpene, is the most 
widespread terpene in the world and is formed by more than 300 plant species (Burdock, 
1995). (4R)-(+)-Limonene is the most widespread form. (4R)-Limonene is the major 
constituent of citrus peel essential oils, in which it is usually found at concentrations between 
90 and 96% (Nonino, 1997). However, several plants form a mixture of both enantiomers, 
while others produce only (4S)-(-)-limonene (Burdock, 1995). Different studies have been 
undertaken to evaluate possibilities of biotransformation of limonene with an aim to produce 
more valuable natural flavor compounds (Cadwallader, et al., 1989; Chang and Oriel, 1994; 
Dhere and Dhavlikar, 1970, Noma et al., 1992, van Dyk, 1998, Wust and Croteau, 2002). 
Five different microbial transformation pathways for limonene have been proposed (van der 
Werf et al., 2000) and are illustrated in Figure II. B. 2. 
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Figure II. B. 2: Microbial biotransformation pathways for limonene. 
 
B. 1. 1. 3. Ionone 
Ionones are sesquiterpenoids, naturally occurring unsaturated hydrocarbons whose carbon 
skeletons are composed exclusively of isoprene C5 units [CH2=C(CH3)-CH=CH2], consisting 
of five carbon atoms attached to eight hydrogen atoms (C5H8). Ionone can be synthesized 
from citral and acetone with calcium oxide as a basic heterogeneous catalysis and serves as an 
example of an aldol condensation followed by rearrangement reactions (Noda et al., 1998; 
Russell and Kenyo, 1955).  
 
Ionones (α- , β-, and  ϒ) and their hydroxyl forms are essential intermediates for the synthesis 
of a number of carotenoids (Eschenmoser, et al., 1981; Oritani and Yamashita, 1984) and can 
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be used in the industrial synthesis of zeaxanthin and cantaxanthin. Ionone derivatives with a 
trimethylcyclohexane building block constitute substantial aroma components of floral scents 
(Eugster and Maeki-Fischer, 1991; Winterhalter and Rouseff, 2002), and thus attracted an 
attention of flavor and fragrance industry. The α-ionone shows a more floral odour than beta. 
It is also used in vitamin A (retinol) production for cosmetics and toiletries. α-ionone and its 
derivatives have been described as effective male attractants for B. latifrons (Flath, et al., 
1994; Ishida, et al., 2008). They form important components of insect lures (Donaldson, et 
al., 1990; McQuate and Peck, 2001) which can favor insect pollination.  
 
On the other hand, the ionone derivatives, e.g. 3-hydroxy-β-ionone, could provide valuable 
intermediates for the chemoenzymatic synthesis of carotenoids, e.g. for astaxanthin and 
zeaxanthin (Loeber, et al., 1971). However, β-ionone has been analyzed for colon cancer 
chemoprevention and treatment, and a β-ionone induced cell growth inhibition and apoptosis 
in human colon cancer HCT116 cell line was shown (Janakiram, et al., 2008). It has also been 
reported that the β-ionone and several 3-hydroxy esters of β-ionone have antifungal activity 
(Wyatt and Kue, 1992). Hydroxy-β-ionones are also versatile compounds for the synthesis of 
phytohormones like abscisic acid (Oritani and Yamashita, 1994). The possible products from 
the β-ionone are illustrated in Figure II. 7. 
 
Figure II. B. 3: Possible conversion of β-ionone. Similar compounds are represented by the 
same color. 
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B. 1. 1. 3. 1 Role of cytochrome P450 in preparation of ionone derivatives 
A few methods of preparing hydroxy derivatives of ionones like the chemical optical 
resolution of α-ionone (Haag, et al., 1980) or on selective enzymatic hydrolysis of the 4-
hydroxy-β-ionone have been published (Oritani and Yamashita, 1994; Kakeya, et al., 1991). 
Microbial transformation of the α- and β-ionone has been reported for several fungal strains, 
especially Aspergillus sp (Lorroche et al., 1995; Mikam et al., 1981; Yamazaki et al., 1988). 
Similarly, the conversion of β-ionone into 4-hydroxy-β-ionone and the conversion of α-
ionone into 4-hydroxy-α-ionone by the several Streptomyces sp was studied (Lutz-Wahl, et 
al., 1998). The biotransformation of the α-ionone and β-ionone catalyzed by P450s derived 
from actinomycetes (Celik, et al., 2005) and the engineered cytochrome P450BM-3 
(Urlacher, et al., 2006). 
 
B. 2. Objective of Chapter II. B. 
1. To find terpenes and terpenoids as substrates for CYP109D1 
2. To show CYP109D1 as a biocatalyst for epoxidation/hydroxylation of linear, cyclic 
and sesquiterpenoids. 
a. To analyze epoxidation of linear and cyclic mono terpenoids.  
b. To analyze the hydroxylation of sesquiterpenoids. 
c. To illustrate the regioselectivity of hydroxylation by docking. 
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B. 3. MATERIAL AND METHODS 
B. 3 1. Materials 
The bacterial stains, other proteins, oligonucleotides and the vectors were as illustrated in 
Chapter I. 
 
B. 3. 2. Synthesized compound 
The synthesized products of geraniol  E-3,7-dimethyl-6,7-epoxy-2-octen-1-ol and E-3,7-
dimethyl-2,3-epoxy-6-octen-1-ol, and the products of nerol Z-3,7-dimethyl-2,3-epoxy-6-
octen-1-ol and Z-3,7-dimethyl-6,7-epoxy-2-octen-1-ol were used as authentic standard. Their 
synthesis procedures were published elsewhere (Watanabe et al., 2007). These synthesized 
products were available in Institute of Technical Biochemistry, Universitaet Stuttgart. 
 
B. 3. 3. Methods 
The bioinformatics studies, protein expression, purification and spectrophotometric analysis 
were as illustrated in Chapter I, except that the yield of protein expression was increased by 
coexpression of chaperons. CYP109D1 was recloned from pCWori (pCWori_CYP109D1) 
into expression vector pET17b and coexpressed with molecular chaperones GroES/GroEL as 
described previously (Nishihara et al., 1998; Zöllner et al., 2008). The expression host, E. coli 
BL21(DE3) was transformed with two expression plasmids, pET17b_CYP109D1, and  
pGro12_GroES/GroEL and cultured overnight in TB medium containing 100µg/ml ampicillin 
and 50µg/ml kanamycin. The overnight culture was hundred fold diluted in 200 ml of the TB 
medium in 2 liter baffled flask containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and 
grown at 37°C and 95 rpm unless the optical density at 600 nm reached 1.2. Upon culturing 
the heme synthesis was supported by the addition of 0.8 mM of δ-ALA and the expression 
was induced with 1 mM IPTG. For the chaperone expression 4 mg/ml final concentration of 
arabinose was added. At the same time 50 µg/ml of the ampicillin was also added to 
overcome ampicillin degradation at high temperatures or it deactivation by beta-lactamases. 
The cultures were grown at 28°C for additional 24-36 hours at 95 rpm. The cultures were 
harvested by centrifugation at 4500 rpm and the pellet was stored at -20°C until purification 
of the protein. CYP109D1 was purified and the active form of P450 was confirmed by CO-
difference spectrum (COD) measurements as described in Chapter I. 
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B. 3. 3. 1. In vitro assay  
The substrates used in this work were acyclic (geraniol and nerol) and cyclic (limonene) 
monoterpenes as well as sesquiterpenoides (α-ionone and β-ionone). Reactions were 
performed in a final volume of 0.5 ml of buffer E (Appendix II) with 200 µM substrate and a 
NADPH-regenerating system, consisting of glucose-6-phosphate (5mM), glucose-6-
phosphate dehydrogenase (1 unit) and magnesium chloride (1 mM). The reconstitution with 
the redox partners Adx and AdR was performed with the ratios of CYP109D1: Adx: AdR of 
1: 10: 1 (1 µM: 10 µM: 1 µM) was used. During incubation at 30°C on a thermo shaker, 
NADPH was added to 500 µM final concentration and the mixture was incubated for 30 min. 
The reaction was stopped and extracted twice with an equal volume of ethyl acetate. The 
organic phase was pooled and the volume was reduced to 200 µl with the flow of nitrogen 
gas. The samples were run on either thin layer Silica Gel 60 F254 plates and/or directly 
analyzed using gas chromatography coupled with mass spectrometry as mentioned below. 
 
B. 3. 3. 2. Gas chromatography coupled with mass spectrometry (GC-MS) analysis 
All the GC-MS measurements were carried out at Institute of Technical Biochemistry, 
Universitaet Stuttgart. GC-MS was performed on a Shimadzu GC/MS QP2010 (Kyoto, Japan) 
equipped with an FS  Supreme-5 column (0.25 mm x 30 m, 0.25 µm, CS-Chromatography 
Service, Langerwehe, Germany). The following program was used for the analysis of the 
substrates and products. 
 
Geraniol and nerol: The column temperature was controlled at 120°C for 3 min. The 
temperature was then raised to 165°C at the rate of 5°C min-1, and then to 280°C at 30°C min-
1
. It was kept at 280°C for 1 min. The temperatures of injector and the interface were fixed at 
285°C respectively.  
 
Limonene:  The column temperature was controlled at 80°C for 2 min. The temperature was 
then raised to 180°C at the rate of 10°C min-1, and then to 250°C at 30°C min-1. It was kept at 
250°C for 1 min. The temperatures of injector and the interface were fixed at 250°C.   
 
α- and β-ionone: The column temperature was controlled at 150°C for 1 min. The 
temperature was then raised to 250°C at 20°C min-1. It was kept at 250°C for 5 min. The 
temperatures of injector and the interface were fixed at 250°C respectively.  
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B. 3. 3. 3. Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) was used to monitor the conversion of α- and β-ionone and 
to inspect the substrate and/or product fractions obtained during the silica column 
chromatography. Samples/products were spotted onto TLC aluminum sheets (5 x 10 cm2, 
silica gel layer thickness, 0.2 mm; Silica Gel 60 F254; Merck), and the plates were developed 
in solvent tank containing n-hexane:ethyl acetate (3:2). Products were visualized firstly at UV 
light at 254 nm and then confirmed by spraying with a vanillin solution (2.5% (w/v) vanillin 
in ethanol:sulfuric acid (H2SO4) (95:5) and subsequent heating at 110°C for 2 min. 
 
B. 3. 3. 4. Isolation of 3-hydroxy-α-ionone from the reaction mixture 
For the identification of the products of α-ionone oxidation, the in vitro reaction described 
above was scaled up 120 times. The organic phase was dried using vacuum; the obtained 
product was completely dissolved in the mixture n-hexane:ethyl acetate (3:2) and purified on 
the 150 ml silica gel column. The complete separation of remained α-ionone and the product 
was monitored by TLC. The purified product fractions were pulled and dried in the rotary 
vacuum device (SpeedVac Concentrator 5301, Eppendorf) and 10 mg was used for NMR 
analysis (Avance 500 (Bruker Biospin GmbH, Rheinstetten, Germany). The structure was 
confirmed by 1H- and 13C NMR and IR analysis. 
 
B. 3. 3. 5. Computational methods 
The computational work was done in collaboration with PD Dr. Michael C. Hutter, Center for 
Bioinformatics, Saarland University. 
 
P450eryF (CYP107A1) from Saccharopolyspora erythreae (accession code Q00441) shows a 
sequence identity of 31.6% to CYP109D1 of Sorangium cellulosum So ce56. The 
corresponding crystallographic structure (pdb entry 1Z8P) was chosen as structural template. 
The alignment generated with CLUSTAL W (version 2) (Larkin et al, 2007) was used as 
input for SWISS-MODEL (Arnold et al, 2007; Schwede et al, 2003; Guex et al, 1997). The 
coordinates of the heme-porphyrin atoms from the template structure were added 
subsequently to the obtained homology model. The vicinity around the porphyrin was 
structurally relaxed by force field optimization using the AMBER3 set of parameters as 
implemented in HYPERCHEM (version 6.02, 1999). The carboxylate groups of the heme-
form ionic hydrogen-bonds with the side chains of Arg293, Arg104, His100, and His349. 
Compounds for docking were generated manually and energetically optimized using the 
  120 
MM+ force field as implemented in HYPERCHEM AUTODOCK (version 4.00) was applied 
for docking of α- and β-ionone into the homology model of CYP109D1 (Huey et al, 2007; 
Morris et al, 1998). The Windows version 1.5.2 of Autodock Tools was used to compute 
Gasteiger-Marsili charges for the enzyme and the ligands (Sanner et al, 1999). A partial 
charge of +0.400 e was assigned manually to the heme-iron, which corresponds to Fe(II), that 
was compensated by adjusting the partial charges of the legating nitrogen atoms to –0.348 e. 
Flexible bonds of the ligands were assigned automatically and verified by manual inspection. 
A cubic grid box (50 x 50 x 50 points with a grid spacing of 0.375 Å) was centered above the 
heme-iron at the putative position of the ferryl oxygen. For each of the ligands 100 docking 
runs were carried out applying the Lamarckian genetic algorithm using default parameter 
settings, except for the mutation rate that was increased to 0.05. 
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B. 4. RESULTS 
B. 4. 1. Expression and purification of recombinant CYP109D1 
Previously, CYP109D1 was expressed in E. coli BL21 using a bacterial expression vector 
pCWori and the expression level was only 205 nmol.L-1 culture media (Chapter I) . The co-
expression of pET17b_CYP109D1 with the molecular chaperons GroES/GroEL resulted the 
four fold increased in the expression level with up to 900 nmol/L soluble P450 enzyme. CO-
difference spectra (COD) (Omura and Sato, 1962) demonstrate peak maximum at 450 nm 
which confirmed the active form of the enzyme.  
 
B. 4. 2. Conversion of geraniol by CYP109D1 
The homologous redox partners for CYP109D1 from So ce56 are not known so far. 
Therefore, the heterologous redox partners adrenodoxin (Adx) and adrenodoxin reductase 
(AdR) were used for in vitro conversion. GC-MS analyses demonstrated that CYP109D1 was 
able to convert geraniol into epoxidated products. The substrate geraniol has a retention time 
(RT) of 6.37 min and the product peaks I, II and III were obtained at RT of 8.15, 8.72 and 
8.93 min, respectively (Figure II. B. 4).  
 
 
Figure II. B. 4: The GC diagram of geraniol conversion. The solid and dashed lines 
represent conversion and negative control (geraniol only), respectively. ‘S’ is the substrate 
and the inset highlights the products. Peak I, peak II and peak III are identified as 2,3-epoxy, 
6,7-epoxy and 2,3-,6,7-diepoxygeraniol, respectively. The ‘*’ represents a non-specific peak. 
 
The mass spectra of the peak I and peak II corresponded to the authentic 2,3-epoxy- and 6,7-
epoxygeraniol, respectively. Peak III was correlated with the diepoxidated geraniol at 2,3- and 
6,7-C-C double bonds, respectively (Figure II. B. 4). All the mass spectra were identical with 
the mass spectra of the authentic epoxides of geraniol (Figure II. B. 5). 
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Figure B. 5: Mass spectra of geraniol obtained from the NIST arbitrary library. The MS 
of this arbitrary was determined from authentic reference compounds. A. The MS of peak I is 
shown to be 2,3-epoxygeraniol. B. The MS of peak II is shown to be 6,7-epoxygeraniol C. 
The MS of peak III is shown to be 2,3-, 6,7-epoxygeraniol. 
 
B. 4. 3. Conversion of nerol by CYP109D1 
CYP109D1 was also able to convert nerol into two distinct products, peak I and peak II, 
showing retention times of 7.90 and 8.10 min, respectively (Figure II. B. 6).  
 
 
Figure II. B. 6: GC diagrams of nerol conversions. The solid and dashed lines represent 
conversion and negative control (nerol only), respectively. ‘S’ is the substrate. Peak I and 
peak II are identified as 2,3-epoxy and 6,7-epoxynerol, respectively. The ‘*’ represents non-
specific peaks. 
 
The mass spectra of the peak I and peak II corresponded to the 2,3-epoxy- and 6,7-
epoxynerol, respectively (Figure II. B. 6). The product mass spectra were also compared to 
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the mass spectra of the authentic epoxidated products of nerol and revealed identical peaks 
(Figure II. B. 7). 
A. 
 
B. 
 
 
Figure II. B. 7: Mass spectra of nerol obtained from the NIST arbitrary library. The MS 
are the same as that for the authentic products of the nerol. A. The MS of peak I is shown to 
be 2,3-epoxynerol. B. The MS of peak II is shown to be 6,7-epoxynerol  
 
B. 4. 4. Conversion of limonene by CYP109D1 
GC-MS analyses demonstrated that CYP109D1 was able to convert (R)-(+)-limonene into 
several products. The total conversion of the substrate was nearly 10%. Six product peaks I, 
II, III, IV, V and VI, at retention times of 6.78, 7.40, 7.46, 8.39, 8.45 and 8.71 min, 
respectively, were obtained (Figure II. B. 8). 
 
 
Figure II. B. 8: GC diagrams of (R)-(+)-limonene conversions. In the figure, the solid line 
represents the conversion and the dashed line is for negative control ((R)-(+)-limonene only). 
Peak I is identified as a terpineol, peak II and peak III as cis- and/or trans- limonene-1,2-
epoxide, and peak IV, peak V and peak VI as cis- and/or trans-carveol. The ‘*’represents 
non-specific peaks. 
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The products of (R)-(+)-limonene could be in cis- or trans-form. In the absence of authentic 
standards, the absolute configuration of the products could, however, not been identified. So, 
the product mass spectra were compared with data in the NIST arbitrary library. According to 
the found coincidence, the mass spectra of the peak I was matched with terpineol (Figure II. 
B. 9), peak II and peak III with cis- and/or trans- limonene-1,2-epoxide (Figure II. B. 9), peak 
IV, peak V and peak VI with cis- and trans-carveol (Figure II. B. 9). Though the 
configuration was not able to be allocated, it was clear that CYP109D1 was able to 
hydroxylate and epoxidate (R)-(+)-limonene at several positions. 
 
 
 
Figure II. B. 9: Mass spectra of (R)-(+)-limonene obtained from the NIST arbitrary 
library. A. The MS of the peak I is identified as a terpineol, B. peak II and peak III are 
identified as cis- and/or trans- limonene-1,2-epoxide. C. The peak IV, peak V and peak VI are 
identified as cis- and/or trans-carveol. 
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B. 4. 5. Conversion of ionone by CYP109D1 
B. 4. 5. 1. Conversion of α-ionone 
Besides hydroxylating acyclic and monocyclic monoterpenes, CYP09D1 was able to convert 
α-ionone into a single product. The product, peak I, was obtained at a retention time of 5.03 
min (Figure II. B. 10) and the mass spectrum of the product is illustrated in Figure II. B. 11. A 
similarity search for the mass spectrum within the NIST arbitrary library did not give the 
precise expected hints on the product. Therefore, we purified and characterized this product. 
 
 
Figure II. B. 10: GC diagrams of α-ionone conversions. The solid line represents the 
conversion and the dashed line is for negative control (α-ionone only). The product peak is 
identified as 3-hydroxy-α-ionone and is illustrated in the inset. 
 
 
Figure II. B. 11: Mass spectra of 3-hydroxy-α-ionone obtained from the NIST arbitrary 
library.  
 
B. 4. 5. 2. Identification of the product of α-ionone oxidation 
A large scale conversion and purification on silica gel column was done to obtain enough 
amounts of the single product of α-ionone. After the silica gel preparation, 16 mg of the 
purified product were obtained. The identification of additional functional groups in the 
product molecule was done through IR spectroscopy, and was confirmed by 1H and 13C NMR. 
The product was found to be 3-hydroxy-α-ionone (Table II.B.4). The detailed results of the α-
ionone products were as follows. 
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TLC: Rf = 0.67 (for substrate), 0.30 (for product), hexane- ethyl acetate (3:2) 
GC-MS (EI). (tR = 5.030 min.), (208, M+, 27%), (109, 100%), (81, 31.88%), (125, 28.65%), 
(91, 16.93%), (107, 16.05%), (137, 12.95%), (152, 11.78%) 
IR. The IR-spectroscopy study of the product gave a characteristic IR absorption of O-H. The 
O-H stretch hydrogen bond of alcohol was appeared in the region of 3600-3200 cm-1  with 
vmax/cm-1 (FT). 3449 
1H NMR: δH (CDCl3; 200 MHz), 6.47 (1 H, dd, J = 15.7 and 10 Hz); 6.03 (1 H; d, J = 15.8 
Hz); 5.56 (1 H, br); 4.20 (1 H, br); 2.43 (1 H; d, J = 10 Hz); 2.19 (3 H, s); 1.77 (1 H, dd, J = 
13.6 and 6.0 Hz); 1.51 (3 H, s); 1.33 (1 H; dd, J = 13.6 and 6.6 Hz); 0.96 (3 H, s); 0.82 (3 H, 
s). 13C NMR δ: 33.35 (C-1), 43.83 (C-2), 65.48 (C-3), 125.83 (C-4), 135.20 (C-5), 54.30 (C-
6), 147.06 (C-7), 133.62 (C-8), 198.30 (C-9), 27.20 (C-10), 29.70 (C-11), 24.21 (C-12), 22.66 
(C-13).  
 
B. 4. 6. Conversion of β-ionone 
CYP109D1 was also able to convert β-ionone into a single product. The product, peak I, was 
obtained at a retention time of 5.77 min (Figure II. B. 12) and the mass spectrum of the 
product is illustrated in Figure II. B. 13.The similarity search of the mass spectra within the 
NIST mass spectra library showed that the MS-data was 83% similar to that of 4-hydroxy-β-
ionone. Analysis of the authentic 4-hydroxy-β-ionone (Urlacher et al., 2006) by GC-MS 
confirmed that the product was 4-hydroxy-β-ionone. The detailed results for the β-ionone 
product were as follows. 
TLC. Rf = 0.93 (for substrate), 0.34 (for product), hexane-ethyl acetate (3:2) 
GC-MS (EI). (tR = 5.199 min.), (208, M+, 15%), (109, 100%), (123, 29.41%), (91, 22.90%), 
(208, 19.63%), (95, 19.00%), (137, 17.85%), (79, 15.78%), (107, 15.68%). 
 
 
Figure II. B. 12: GC diagrams of β-ionone conversions. The solid line and the dashed line 
represent the conversion and negative control (β-ionone only), respectively. The product peak 
is identified as 4-hydroxy-β-ionone and is illustrated in the inset. 
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Figure II. B. 13: Mass spectra of β-ionone obtained from the NIST arbitrary library.  
 
B. 4. 7. Homology modeling and docking of CYP109D1 with α- and β-ionone. 
Unfortunately, the crystal structure of CYP109D1 is not known yet. To get more insight into 
the structural basis for the regiospecificity of hydroxylation of α- and β-ionone, computer 
modeling of CYP109D1 and its complexes with α- and β-ionone has been performed in 
cooperation with PD Dr. Michael C. Hutter, Center for Bioinformatics, Saarland University. 
 
CYP109D1 from So ce56 has the highest identity (31.6%) with P450eryF (CYP107A1) from 
Saccharopolyspora erythreae among the known crystal structures of bacterial cytochrome 
P450s that have been documented in protein data bank (PDB). The alignment is shown in 
Figure 14.  
 
The corresponding crystallographic structure (pdb entry 1Z8P) was chosen as structural 
template. The carboxylate groups of the heme- moiety form ionic hydrogen-bonds with the 
side chains of Arg293, Arg104, His100, and His349. Both the R and S-isomer of α-ionone 
were found in binding poses that have the 3-position in suitable arrangement for 
hydroxylation (Figure 15). The distances towards the iron atom are 3.90 Å for the R-isomer 
and 2.96 Å for the S-isomer, respectively. Both the isomers show a hydrogen-bond (2.1 Å) 
between the carbonyl oxygen and the NE2-nitrogen atom of His 94. All other obtained 
binding poses exhibit the alternative sites for hydroxylation much more distant. This indicates 
structural implications as reason for the regioselective hydroxylation of α-ionone. Likewise, 
the closest distance found between the iron atom and the 4-position in β-ionone is 4.34 Å, 
whereas all other hydroxylation sites within the ring are again further away. The larger 
separation found for β-ionone agrees very well with the lower turn-over compared to β-
ionone. 
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Figure 14: The obtained alignment and secondary structure of CYP109D1 (target) and 
the template (pdb entry 1z8p). In the figure, the α-helices are denoted by ‘h’ and the β- 
sheets are indicated by ‘s’. 
 
 
 
Figure 15: Obtained docking positions in the homology model of CYP109D1. α-ionone R-
isomer is shown in pink, S-isomer in cyan, β-ionone in orange. The respective carbonyl 
oxygen atoms are shown in red. The positions where hydroxylation occurs are marked as 
balls.  
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B. 5. Discussion 
Most of the terpenes and terpenoids are commercially valuable with activities usually 
depending on characteristic functional groups and the absolute stereochemical configurations. 
Several attempts have been undertaken to discover new biologically active terpenoids, having 
higher market value. However, the selective oxy-functionalization of the these compounds 
and oxidation of the resulting alcohols to the corresponding carbonyls, which are the key 
reactions in the fine chemical industry, are still challenging to organic chemistry due to low 
specificities and the need for hazardous and expensive catalysts and reactants (Newhall, 1958; 
Lochynski et al., 2002; Sheldon, 2000; Duetz et al., 2003; Buehler and Schmid, 2004).   
 
This requirement can only be met either by conventional isolation methods or by the 
enzymatic or microbial production of terpene and terpenoid derivatives from natural raw 
material, which has been the target of intensive research activities during the past decades 
(Schrader and Berger, 2001). Nowadays, biocatalysis offers promising synthetic alternatives 
due to the huge natural diversity of oxygenating and oxidizing enzymes acting as highly 
regio- and stereo-selective catalysts. The great majority of these biotransformations, including 
some terpene oxidations, were conducted with whole cells expressing cytochrome P450s 
which, however, resulted in rather low productivities and the formation of some other by-
products (Schrader and Berger, 2001; de Carvalho and da Fonseca, 2006). Although such 
items usually show low activities, instability, and depend on the costly cofactors NAD(P)H 
and/or redox partners that are usually associated with P450 enzymes, they still provide a great 
technical potential because of their high regio- and stereo-selectivity (Duetz et al., 2001, 
2003; Urlacher and Schmid, 2002). In addition, recent methods like directed evolution can be 
used to improve the stability and efficiency of these proteins. 
 
From a viewpoint of chemical synthesis, monoterpenes are particularly interesting as 
flavorings and fragrances or as pharmaceuticals (de Carvalho and da Fonseca, 2006). They 
can contain alkene functional groups with different degrees of substitution. They can also 
have other functionalities that may further alter the chemistry of the carbon-carbon double 
bond. These products are only possible through radical-reactions but are not easy and most of 
the time not selective to introduce desired epoxidation or chiral alcohol functions in those 
compounds. As those disadvantages can be overcome by the application of P450, we have 
cloned and expressed a cytochrome P450, CYP109D1. Using a reconstituted system with Adx 
and AdR as redox partners, we were able to demonstrate the conversion of monoterpenes as 
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well as sesquiterpenes. Geraniol and nerol, the oldest known organic compounds, were 
chosen for this work as acyclic monoterpenes. CYP109D1 was able to convert both the 
compounds into 2,3- and 6,7-epoxy- as well as into the 2,3-6,7-diepoxy form (only for 
geraniol). It was reported that cytochrome P450 BM-3 mutant (R47L/Y51F/F87V) was able 
to convert geraniol into two and nerol into three epoxidized products (Wong et al., 2000; 
Watanabe et al., 2007). It is notable that even the wild type CYP109D1 was able to give 
selective epoxidated products and the study of selective mutants of CYP109D1 might be 
useful to produce more regio- or stereo-selective products. These epoxy derivatives have 
several applications. Some terpene epoxides like 6,7-epoxygeraniol are the major constituent 
of juvenile hormones in several beetles (Bowers, 1969; Archelas, et al., 1993 ), and 2,3-
epoxygeraniol as well as the corresponding acetate are part of the pheromone bouquet of male 
neotrophical orchid bee (Eltz et al., 2006). Likewise, 2,3-epoxynerol is used by acarid mites 
as sex pheromone (Mori et al., 1995). The acyclic terpene-derived epoxides have also been 
used as valuable building blocks for the synthesis of the aggregation pheromone of the 
Colorado potato beetle (Tashiro and Mori, 2005), alpha-damascone (Bovolenta et al.,2004; 
Fráter, et al., 1998; Sefton et al., 1989), 2,2-dialkylchromanols (Inoue et al., 1998)  or 
antibiotic terpene (+)-tuberine (Taber, et al., 1994) and decalins (Corey and Sodeoka, 1991). 
 
As a cyclic monoterpene, (R)-(+)-limonene was chosen for our investigations. The conversion 
of (R)-(+)-limonene to several products like terpineol, (cis- and/or trans-) limonene-1,2-
epoxide, and cis- and/or trans- carveol, showed that CYP109D1 is not stereo- and 
regioselective in the case of this substrate. Thus, the production of mutants of CYP109D1 
with higher regio- and stereoselectivity of hydroxylation/epoxidation of limonene to obtain 
more valuable derivatives could be the focus of further studies. There have been many reports 
concerning the biotransformation of limonene with the aim towards the production of more 
valuable natural flavor compounds (Cadwallader et al., 1989; Haudenschild et al., 2000; 
Rama and Bhattacharyya, 1977 and van Dyk, et al., 1998). One enzyme system that 
transforms limonene to perillyl alcohol was found in Bacillus stearothermophilus BR388. 
However, this enzyme system was not sufficiently regiospecific and significant quantities of 
carveol, carvone, and terpineol were produced (Oriel et al., 1997). Furthermore, it was shown 
that the cytochrome P450 in Mycobacterium sp. strain HXN-1500 was able to specifically 
hydroxylate (L)-limonene at position 7 to produce enantiopure (-)-perillyl alcohol with a 
specific activity of 3 U/g (dry weight) of cell (van Beilen et al., 2005). Likewise, (R)-
limonene has been shown to be oxidized by CYP102A7 to racemic mixtures of (R)-limonene-
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1,2-epoxide, limonene-8,9-epoxide and carveol (Dietrich et al., 2008). It has also been shown 
to be regio- and stereoselectively converted by Xanthobacter sp. C20 to form (4R,8R)-
limonene-8,9-epoxide (van der Werf, et al., 2000). Interestingly, cytochrome P450 enzymes 
in liver microsomes of some animals have been shown to oxidize limonene to several 
oxidation products such as 1,2- and 8,9-epoxides, carveol (a product by 6-hydroxylation), 
perillyl alcohol (a product by 7-hydroxylation) (Watabe et al., 1980, 1981; Jager et al., 1999; 
van Beilen, 2005, Shimada et al., 2002). It has also been reported that limonene enantiomers 
were oxidized to carveols and perillyl alcohols by CYP2C11 in liver microsomes of untreated 
rats and by CYP2B1 in those of phenobarbital-treated rats (Miyazawa et al., 2002). Similarly, 
other studies showed that (+) - and (-)-limonene enantiomers were oxidized to respective 
carveol (6-hydroxylation) and perillyl alcohol (7-hydroxylation) metabolites by CYP2C9 and 
CYP2C19 in human liver microsomes (Miyazawa, et al., 2002).  
 
The study of terpenoid hydroxylation by CYP109D1 was further extended by the use of 
sesquiterpenoids as substrates. Most interestingly, CYP109D1 was able to catalyze the 
selective hydroxylation of the sesquiterpenes α- and β-ionone which are valuable fragrance 
constituents. Due to their organoleptic properties and the distinctive fine violet and rose 
scents, manufacturers of perfumes, soaps, cosmetics and fine chemicals have special interest 
on them (Ohloff, 1994; Pybus and Sell, 1999). Moreover, ionones are also appreciated as 
important synthetic building blocks (Fra´ter et al., 1998; Buchecker et al., 1973; Baraldi et al., 
1986; Ubelhart et al., 1986; Colombo et al., 1992). Among this, 4-hydroxy-β-ionone is an 
important intermediate for the synthesis of the carotenoids (Enzell et al., 1977; Eschenmoser 
et al., 1981, Brenna et al., 2002) and also of deoxyabscisic acid, a synthetic analogue of the 
phytohormone abscisic acid (Oritani and Yamashita, 1984; Tamura and Nagao, 1970). 
 
This study has demonstrated that CYP109D1 was able to convert α-ionone into 3-hydroxy-α-
ionone that was confirmed by 1H and 13C NMR. The bioconversion of α-ionone and β-ionone 
to their corresponding mono-hydroxylated derivatives along with other compounds have been 
examined using a recombinant Escherichia coli whole cell system expressing cytochrome 
P450 SU1 and SU2, or P450 SOY (Celik A, et al., 2005). Likewise, P450BM-3 of Bacillus 
megaterium also showed the conversion of α-ionone into several mixtures of different 
hydroxylated and/or epoxidated product (Carmichael and Wong, 2001). Similarly, the triple 
P450 BM-3 mutant (F78Q L188Q A74G) produced a mixture of different hydroxylated 
products from  α-ionone (Appel et al., 2001). Along with this, the P450BM-3 mutant F87V 
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also produced four products from  α-ionone (Urlacher et al, 2006). In this regard, we showed 
that CYP109D1, despite being wild type, was able to give a single hydroxylated product (3-
hydroxy-α-ionone) from  α-ionone. To the best of our knowledge, the single hydroxylated 
product of α-ionone alone has not been obtained so far using a P450-catalyzed reaction, even 
for the rationally designed mutant of P450BM-3, which produced a mixture of other products 
along with 3-hydroxylated-α-ionone. We further demonstrated that CYP109D1 converted β-
ionone into 4-hydroxy-β-ionone exclusively, which was confirmed by comparison to an 
authentic standard (Watanabe et al, 2007). The hydroxylation of β-ionone into 4-hydroxy-β-
ionone was also published for wild type P450 BM-3 and its improved mutants (e.g. A74E 
F87V P386S) (Urlacher et al, 2006).  
 
To further elucidate the structural basis for the regioselective hydroxylation catalyzed by 
CYP109D1, we performed docking studies using a homology model of CYP109D1. 
According to the computed interaction energies, both the α- and β-ionone should bind with 
micro-molar affinity. The obtained docking positions show that both ionones in corresponding 
orientations enable the experimentally observed regioselective hydroxylation (Figure 5). 
Other binding positions that would allow alternative hydroxylation in the 4-position of α-
ionone (both R and S-isomer) were not found. Likewise, no plausible docking positions 
allowing the hydroxylation in the 3-position of β-ionone were obtained. Moreover, as 
mentioned above, we found a higher amount of corresponding products for α-ionone 
compared to β-ionone under identical reaction conditions. This agrees very well with the 
docking results. The distance between the iron atom, the putative ferryl oxygen, and the site 
of hydroxylation is considerably larger for β-ionone. 
 
Finally, our results demonstrated that CYP109D1 acts as selective epoxidase or hydroxylase 
during terpene and terpenoid conversions which generates more valuable compounds for 
fragrance- and flavor-industry. 
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CHAPTER III 
CYP260A1 from Sorangium cellulosum So ce56 
 
1. INTRODUCTION 
Genomic sequence of organisms has been determined at an accelerating rate and the genes 
encoding cytochrome P450 enzymes are also increasing. This large pool of the putative P450 
genes has been considered as a potential resource for new versatile biocatalysts (Bernhardt, 
2006). The genomic sequencing project of Sorangium cellulosum So ce56 also revealed 
several new P450 family members. Among them, CYP260A1 represents a novel bacterial 
P450 which could have potential function as a biocatalyst for the oxidative metabolism of 
endogenous and/or exogenous compounds. However, the identification of natural substrates 
for such novel P450 enzyme is not easy. Based on the sequence homologies with functionally 
characterized P450s enzymes, in some extent, it is possible to predict general functions of the 
P450 enzyme. Nevertheless, the sequence information of P450 alone is not sufficient enough 
to determine their catalytic functions or actual substrates.  
 
Cytochrome P450 enzymes catalyze several reactions as described before in ‘General 
Introduction’. Owing to the broad range of reactivities of the P450 enzymes, several in vitro 
screening techniques have been developed to access the potential substrates and inhibitors, 
including radiometric, fluorogenic, and rapid liquid chromatography/mass spectrometry 
(LC/MS)-based assays (Crespi et al., 1997; Cohen et al., 2003; Di et al., 2007; Trubetskoy et 
al., 2005; Furuya et al., 2008; Sukumaran et al., 2009; Rebe et al., 2009). Among them, the 
most feasible and simple method is spin-shift where the heme prosthetic group of the 
cytochrome P450 serves as a useful chromophore during substrate and inhibitor binding 
studies. The oxidation of P450 bound substrate occurs at the heme, as a result certain aspects 
of substrate binding can be monitored readily with a spectrophotometer. Three specific types 
of substrate binding spectra (Type I, Type II and reverse Type I) have been identified 
(Schenkman et al., 1981) as described before in ‘General Introduction’. Generally, nitrogen-
containing heme ligands, which bind more avidly than oxygen-containing ligands, are more 
often inhibitors than substrates (Gigon et al., 1968). Many substrates (Type I ligands) displace 
the heme water ligand, shifting the iron spin equilibrium toward the high-spin form, whereas 
nitrogen heterocycles and anilines (Type II ligands) can replace the water ligand to stabilize 
the low-spin form. However, some Type II ligands can also act as substrates (Kunze et al., 
2006; Pearson et al., 2006).  
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2. Objectives of Chapter III 
1. To screen a compound library consisting of ∼17,000 substances for CYP260A1. 
2. To select structural analogues of the screening hits.  
3. To determine and analyze substrates and their products. 
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3. MATERIALS AND METHODS 
3. 1. Materials 
The chemicals, reagents and other accessories used in this work were of high grade. They are 
illustrated in Appendix I. 
 
3. 2. Methods 
3. 2. 1. Screening of a compound library 
The detailed procedure for the screening of a compound library was described in Chapter I. 
 
3. 2. 2. Analytical methods 
3. 2. 2. 1. In vitro steroid assay  
The steroids, progesterone and DOC were used as substrates and were analyzed as described 
below. 
 
Reactions were performed in a final volume of 0.5 ml of buffer E (Appendix III) containing 
200 µM steroid as a substrate and a NADPH-regenerating system, consisting of glucose-6-
phosphate (5 mM), glucose-6-phosphate dehydrogenase (1 unit) and magnesium chloride (1 
mM). The combinations of reconstituted redox partners CYP260A1: Adx: AdR of 1: 10: 1 (1 
µM: 10 µM: 1 µM) were used for assay purpose. During incubation at 30°C on a thermo 
shaker, NADPH was added to 500 µM final concentration and the mixture was incubated for 
15 min to 2 hr. The reactions were stopped with an equal volume of chloroform. The products 
were extracted with chloroform for two times. Thus obtained organic phases were vacuum 
dried, dissolved in 200 µl of solvent acetonitrile:water (40:60) and were analyzed by HPLC as 
described below. 
 
3. 2. 2. 2. In vitro nootkatone assay 
The other substrate used in this work was nootkatone. The assay was done as described above 
with 200 µM of nootkatone as a substrate. The samples were measured by HPLC or GC-MS 
as mentioned below.  
 
3. 2. 2. 3. High performance liquid chromatography (HPLC) of steroids and nootkatone 
HPLC is widely used to separate, identify and quantify the compounds. The sample to be 
separated is transported under pressure in the mobile phase through a column which holds the 
stationary phase. Separation is based on the differences of the solubility of substances in the 
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mobile and stationary phase. In this work, reversed phase HPLC (RP-HPLC) was used where 
the mobile phase was more polar than the stationary phase. Due to this, the more hydrophobic 
substance will retained longer in the column.  
 
After evaporation of the organic (chloroform) phase, the steroids (progesterone and DOC) and 
nootkatone were resuspended in acetonitrile and separated on a Jasco reversed phase HPLC 
system (Tokyo, Japan) composed of an auto sampler AS-2050 plus, pump PU-2080, gradient 
mixer LG-2080-02 and an UV-detector UV-2075. A reversed phase column (Nucleodur 
R100-5 C18ec, particle size 3 µm, length 125 mm, internal diameter 4 mm, Macherey-Nagel) 
or reversed phase column (150 Novapac C18, 3.9 id, 4 µm) was used to separate the steroids 
(progesterone and DOC) and nootkatone. Progesterone and nootkatone were monitored at 240 
nm with retention time (RT) of 35 min whereas for the DOC same wavelength with RT of 10 
min was used. In all cases, the column temperature was kept constant at 25°C with a peltier 
oven. The mobile phase was a mixture of acetonitirile:water (40:60) for both the substrates. 5 
µl of the samples were injected for analysis. The peaks were identified by using the 
ChromPass software (V.1.7.403.1, Jasco). Pure steroids (>99%) were used as standards to 
identify the retention time (RT) of the peaks on HPLC. The separation of the progesterone 
was done by a gradient elution as mentioned in Table III.1.  
 
Table III. 1: HPLC gradient used for the analysis of progesterone conversion. The 
gradient of phase A (40:60 acetonitrile/water) and phase B (100% acetonitrile) are shown.  
Time (min) 0 10 15 18 22 
Flow 
(ml/min) 
1.0 1.0 1.0 1.0 1.0 
A (%) 100 100 50 50 100 
B (%) 0 0 50 50 0 
 
3. 2. 2. 4. GC-MS analysis of nootkatone  
The GC-MS measurement was performed in Institute of Technical Biochemistry, Universitaet 
Stuttgart. The analysis was performed on Shimadzu GCMS-QP2010 (column: FS-Supreme-5, 
length: 30 m, internal diameter: 0.25 mm, film thickness: 0.25 µm) using helium as a carrier 
gas. The mass spectra were collected using electron ionization. The column oven was 
programmed as in Table III. 2 for the measurement of nootkatone and its products. 
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Table III. 2. GC-MS analysis and identification of in vitro products of nootkatone 
Column Oven Temp  
Injection Temp 
150°C 
250°C 
  
Rate (°C/min) Final Temperature (°C) Hold (min) 
--------- 150 4 
Program 
10 250 3 
 50 300 1 
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4. Results 
4. 1. Screening and validation of substrates/ligands 
The myxobacterial cytochrome P450 CYP260A1 is one of the novel members of bacterial 
cytochrome P450s. The genomic information of this P450 (Chapter 1) was not able to give a 
precise hint for putative substrates. To solve this, a compound library consisting of ∼17,000 
substances was screened at the Forschungsinstitut für Molekulare Pharmakologie in Berlin, in 
cooperation with Prof. Oschkinat/Dr. von Kries.  
 
During screening, binding spectra of potential ligands with CYP260A1 were observed and the 
potential substrates (having Type I binding) and the potential inhibitors (having Type II 
binding) were identified. For this, primary screening was done with 1.5 µM of CYP260A1 
and 0.5 µM of ligand. Then, each of the primary screening hits was validated again with 1.5 
µM each of CYP260A1 and the corresponding ligand. After this, concentration dependent 
validation was done with fixed concentration of CYP260A1 (1.5 µM) and respective ligands 
of 6.25 µM, 12.5 µM, 25 µM, 50 µM and 100 µM. Altogether 33 positive hits (including both 
Type I and Type II ligands) were obtained. Among them, 15 ligands showed Type I binding 
and the rests 19 ligands showed Type II binding spectra. The detailed structures of the ligands 
with Chem-Div number are shown in Appendix VII (C). Validated representative Type I 
binding spectra for five of the ligands (Chem-Div nos: 25796, 25800, 25826, 26173 and 
26267) are shown in Appendix VII (E).  
 
4. 2. Selection of structural analogues of the Type I binding ligands  
Though the screening of the compound-library identified Type I (potential substrates) and 
Type II (potential inhibitors) hits, the real physiological significance of those ligands is not 
known. As this work was more focused on the substrate identification, the best Type I 
validated hits (Chem-Div nos: 25796, 25800, 25826, 26173 and 26267) displaying absorption 
maxima at 390 were chosen and searched for analogous compounds. This is necessary, since 
the Chem. Div. library contains rather complicated compounds with limited accessibility. On 
the basis of the chemical structure of those ligands, the structural analogous compounds 
having distinct physiological functions were searched manually. The ligands 25796 and 
25800 have the ring structure similar to that of ent-Kaurene, gibberellic acid and abietic acid 
(Table III. 3). Likely, the ligands 25826, 26173 and 26267 have an analogue ring-structure of 
steroids like progesterone, DOC and pregnenolone.  
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Table III. 3: Structure analogues of selected Type I binding hits of screening.  
Type I binding ligand 
(Structure and Chem-Div 
nos) 
Structure analogues of  
Type I ligand 
Remark 
 
25796_N062-0002 
 
ent-Kauren 
ent-Kaurene is the 
intermediate product for 
gibberellin biosynthesis 
pathway 
 
25800_N062-006 
 
ent-Gibberellin 
Gibberellin is plant growth 
hormone 
 
 
Abietic acid 
Abietic acid (resin acid) is 
used in lacquers, varnishes 
and soaps and for the analysis 
of resins and the preparation 
of metal resinates. 
 
25826_N045-0002  
Progesterone 
Progesterone, DOC, 
pregnenolone are the 
important steroid in human 
and mammalian 
 
O
O
OH
OH
O
 
26173_1563-0004 
 
11- deoxycorticosterone 
(DOC) 
 
O
O
O
 
26267_N050-0003 
 
Pregnenolone 
 
 155 
4. 3. Binding of steroids to CYP260A1 
In this work, to study the substrate binding and its conversion, progesterone and DOC (the 
analogue structure of 25826 and/or 26173 and /or 26267) were selected. The selected steroids 
were tested by difference spectroscopy. Both steroids were able to induce a high spin shift 
(Type I binding) representing the displacement of the water molecule bound to the sixth 
position of the heme iron (Figure III. 1-2).  
 
They were further used to determine the apparent dissociation constant (KD) and the 
maximum absorbance shift (Amax) by titration with increasing substrate concentrations. The 
KD and Amax for progesterone were 7.28 (± 2.67) µM and 2.29 (± 0.22), respectively, with a 
correlation coefficient of 0.99 (Figure III. 1). For DOC, the calculated KD was 8.49 (± 2.24) 
µM and Amax was 1.90 (± 0.14) (with a correlation coefficient of 0.99) (Figure III. 2).  
A. 
 
B. 
 
 
 
Figure III. 1: Type I binding spectra of CYP260A1 with progesterone. Varying 
concentrations of progesterone (dissolved in DMSO) were added to a solution of CYP260A1 
(10 µM) in 10 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol (v/v). A. 
Difference spectra of CYP260A1 with progesterone. The difference spectra with the 
starting spectrum subtracted from the subsequent traces. The concentrations of added 
progesterone were 2.5 (black line), 5.0 (red line), 7.5 (bright green line), 10.0 (blue line), 12.5 
(pink line), 15.0 (dark green line), 17.5 (brown line), 20.0 (light green line) , 30.0 (blue line), 
and 50.0 (grey line) µM. B. Plot of absorbance change vs. concentration of progesterone 
(from part A). The individual titration was performed for three times. The mean values and 
their standard deviations of the difference between absorption maxima and minima were 
calculated. The points were fitted to a quadratic equation (in Sigma Plot) and the calculated 
KD and Amax with a correlation coefficient of 0.99 were 7.28 (± 2.67) µM and 2.29 (± 0.22), 
respectively. Each point represents the mean of three successive measurements. 
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A 
 
B  
 
 
Figure III. 2: Type I binding spectra of CYP260A1 with DOC. Varying concentrations of 
DOC (dissolved in DMSO) were added to a solution of CYP260A1 (10 µM) in 10 mM 
potassium phosphate buffer (pH 7.4) containing 20% glycerol (v/v) A. Difference spectra of 
CYP260A1 with DOC. Difference spectra, with the starting spectrum subtracted from the 
subsequent traces. The concentrations of added DOC were 2.5 (black line), 5.0 (red line), 7.5 
(blue line), 10.0 (brown line), 12.5 (dark green line), 15.0 (grey line), 17.5 (dark blue line), 
20.0 (light green line), 25.0 (green line) and 50.0 (yellow line) µM. B. Plot of absorbance 
change vs. concentration of DOC (from part A). The individual titration was performed for 
three times. The mean values and their standard deviations of the difference between 
absorption maxima and minima were calculated The points were fitted to a quadratic equation 
(in Sigma Plot) and the calculated KD and Amax  with a correlation coefficient of 0.99 were 
8.49 (± 2.24) µM and 1.90 (± 0.14), respectively. 
 
4. 4. Conversion of steroids by CYP260A1 
The in vitro conversion of progesterone and DOC, the analogues of the Type I ligand hits of 
the screening, with CYP260A1 was analyzed by using HPLC. In this study, this technique 
was not used for the quantification purpose but, rather used to test the ability of the novel 
P450 CYP260A1 to hydroxylate (convert) the steroids (progesterone and DOC). The product 
peaks of progesterone and DOC were assigned with respect to the retention time (RT) of 
several standards of hydroxylated products of the progesterone which were run at the same 
time. The standard hydroxylated products of progesterone that are used in this work were 
11α-, 6β-, 15β-, 11α,6β-, 9α and 15β,11α- hydroxylated progesterone. The applied HPLC 
condition was able to separate them (Figure III. 3). During this work, the RT for the standard 
hydroxylated progesterone of 15β,11α-, 11α,6β-, 11α-, and 9α- were 1.47, 1.64, 4.14 and 4.79 
min, respectively. The applied method was also suitable enough to separate the respective 
substrates as well as the expected products (Figure III. 4-5).  
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Figure III. 3: The hydroxylated and dihydroxylated standards progesterone peaks. The 
chromatograms were recorded at 240 nm after HPLC separation with a gradient solvent 
system consisting of phase A (acetonitrile/water 40:60) and phase B (100% acetonitrile) at a 
flow rate of 1 ml/min on a C18 reverse phase column. The applied method was able to 
separate all the hydroxylated and dihydroxylated standards of progesterone products of 9α- 
(red line), 11α- (green line), 11α, 6β- (blue line), 15β,11α- (pink line), 15β- (grey line) and 
6β- (black line). 
 
4. 4. 1. Conversion of progesterone by CYP260A1 
In presence of the heterologous redox partners, Adx and AdR, CYP260A1 was able to convert 
progesterone into several products. During HPLC analysis, progesterone and its products 
were eluted from the column within less than 20 min (Figure III. 4). The substrate peak was 
obtained at 16.08 min. During 1 hr incubation of the in vitro assay, one major product (peak II 
at 2.66 min), four minor products (peaks I, III, IV and V at 2.29, 4.67, 5.65 and 8.23 min, 
respectively) and five very minor products (peak a, b, c, d and e at 1.17, 1.58, 1.85, 3.32 and 
4.09, respectively) were obtained (Figure III. 4).  
 
 
Figure III. 4: HPLC chromatogram of progesterone conversion by CYP260A1. The 
conversion (red line) and control, progesterone only, (black line) are shown. Several controls 
like the absence of CYP260A1 (blue line), absence of NADPH (dark green line) and absence 
of substrate (light green line) are also shown. The major products are represented by roman 
letter (I-V) and the minor products are represented by alphabets (a-e). 
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It was found that the product peak III (RT 4.67 min) has similar retention time as 9α-OH-
progesterone (RT 4.70 min) whereas the peak ‘e’ (RT 4.09 min) showed similar movement 
with 11α-OH-progesterone (RT 4.10 min). The major product peak II (RT 2.66 min) can not 
be identified using the available standards as illustrated in Figure III. 5.  
 
 
 
Figure III. 5: HPLC chromatogram of CYP260A1 dependent progesterone conversion 
and comparison with the hydroxylated and dihydroxylated standard products. The 
chromatograms of control, progesterone only, (brown line) and the conversion (red line) are 
shown. The chromatogram peaks of the hydroxylated and dihydroxylated standard 
progesterone of 9α- (voilet line), 11α- (green line), 11α6β- (dark blue line), 15β11α- (pink 
line) and 15β-OH-progesterone (grey line) are overlaid with the conversion chromatogram. 
The inset illustrates the magnified view of the overlaid products parts. The product peak ‘e’ 
and peak III are shown to have similar RT as standard 11α- (green line) and 9α-OH-
progesterone (violet line), respectively. The negative controls, with absence of both 
CYP109D1 and NADPH (blue line), absence of NADPH (dark green line) and absence of 
substrate (light green line) during assay are also shown.  
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4. 4. 2. Conversion of DOC by CYP260A1 
CYP260A1 was also able to convert DOC with the reconstituted heterologous redox partners. 
The product profiles varied depending on the incubation time of the in vitro assay. 
Aldosterone and corticosterone were used as standards to compare the RT of the DOC 
products. The applied HPLC conditions were able to separate the standards (aldosterone and 
corticosterone) and the substrate DOC within less than 10 min (Figure III. 6). The substrate 
peak, DOC, has a RT of 7.40 min. the standards, aldosterone and corticosterone, have RT 
values of 1.81 and 3.27 min, respectively.  
 
 
Figure III. 6: HPLC separation of aldosterone, corticosterone and DOC standards. The 
chromatograms were recorded with an isocratic solvent system consisting of 
acetonitrile/water (40:60) at a flow rate of 1 ml/min on a C18 reverse phase column. The 
aldosterone (blue line), corticosterone (red line) and DOC (brown line) are shown. 
 
During 1 hr incubation of the in vitro assay for DOC conversion, one major product (peak II 
at 2.42 min), one minor product (peak I at 1.80 min), and some very minor products (peak a, 
b, c, d, e and f at 2.03, 2.12, 2.28, 3.54, 5.00 and 5.20 min, respectively) were obtained 
(Figure III. 7). The major product (peak II) could not be identified whereas the peak I showed 
similar movement (RT 1.80 min) as aldosterone (RT 1.81 min). 
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Figure III. 7: HPLC chromatogram of DOC conversion by CYP260A1. The substrate 
DOC (brown line) and its conversion products (green line) are shown. Aldosterone (blue line) 
and corticosterone (red line) are used as standard. The inset illustrates the magnified view of 
the product peaks. The products peak I and II as well as peaks a-f are illustrated.  
 
4. 4. 2. 1. Time dependence of DOC conversion by CYP260A1 
Time dependent DOC hydroxylation by CYP260A1 was also carried out. Each of the 
independent in vitro assays was stopped after 6, 15, 30, 45 and 60 min and was measured by 
HPLC. During successive increment of the incubation time from 5 min to 60 min of the in 
vitro assay, the substrate, DOC, peak was gradually diminished and after 60 min it was almost 
vanished (Figure III. 8). During this time, the abundance of the product peaks has increased, 
but the product patterns were remaining the same.  
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Figure III. 8: HPLC chromatogram of time dependent DOC conversion by CYP260A1. 
Time dependent in vitro conversion of DOC was carried out and was measured by HPLC. The 
product obtained after 5 (pink line), 15 (blue line), 30 (green line), 45 (red line) and 60 min 
(black line) incubation of the assay are shown. The control substrate, DOC only (brown line) 
is also shown. The minor and major products, peak I and II are also illustrated. The down-
arrow denotes the decrement of the DOC and the up-arrow denotes the increment of the 
product abundance during time interval.  
 
The product patterns of the DOC were changed when the incubation time of the in vitro assay 
was increased to more than 1 hr, during which the main product peak II (RT 2.42 min) was 
gradually shifted to the peak I (RT 1.80 min) (Figure III. 9). After 2 hr of incubation, a single 
major product peak I (RT 1.80 min) was obtained and the former major peak II (RT 2.42 min) 
obtained at 1 hr of incubation was almost lost. On comparison with the standard, it has been 
found that the movement of the peak I has almost similar RT with that of standard aldosterone 
(RT 1.81 min) (Figure III. 10), which could be a poly or dihydroxylation from the peak II to I.  
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Figure III. 9: HPLC chromatogram of CYP260A1 dependent DOC conversion after 1 hr 
30 min of incubation. The substrate DOC (brown line) and its conversion (black line) are 
shown. Aldosterone (blue line) and corticosterone (red line) are used as standards. The inset 
illustrates the magnified view of the product peaks. The products peak I and II as well as 
peaks a-b are shown.  
 
 
 
Figure III. 10: HPLC chromatogram of CYP260A1 dependent DOC conversion after 2 
hr of incubation. The substrate DOC (brown line) and its conversion (black line) are shown. 
The aldosterone (blue line) and corticosterone (red line) are used as standards. The inset 
illustrates the magnified view of the product peaks. The products peak I and II as well as 
peaks a-d are shown.  
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4. 5. Conversion of nootkatone by CYP260A1 
4. 5. 1. Selection of nootkatone as a substrate  
The screening hits also guided that some of the sesquiterpenoid could also be a potential 
substrate for CYP260A1. The sesquiterpenes related compounds have several important 
functions in bacterial life cycle, and their alcohol, aldehyde and ketone derivatives are 
biologically active or precursors to other biological metabolites (Fraga, 2004). Due to this, all 
21 P450s of the So ce56 were aligned (Appendix VIII. C) and a unrooted phylogenetic tree 
was constructed with the well characterized P450, like P450ditQ from Pseudomonas 
abietaniphila BKME-9 and P450tdtD from Pseudomonas diterpeniphila which are involved 
in the metabolism of terpenoids (Smith et al, 2004), and CYP226 from Burkholderia 
xenovorans LB400 involved in diterpenes catabolism (Smith et al, 2007) (Figure III. 11 ). It 
was found that CYP260A1 shows 40.5% similarity (24.7% identity) to P450ditQ , 42% 
similarity (25.8% identity) to tdtD and 39.1% similarity (23.4% identity) to CYP226 from B. 
xenovorans LB400. In these reference, one of the sesquiterpenes, nootkatone, was selected as 
a potential substrate for CYP260A1.  
 
 
Figure III. 11: The unrooted tree of So ce56 CYPome with CYP226 of Burkholderia 
xenovorans LB400, CYPDitQ of Pseudomonas abietaniphila BKME-9 and CYPtdtD of 
Pseudomonas diterpeniphila. Only CYP260 families of So ce56 are in same clan with that of 
CYP226, CYPDitQ and CYPtdtD (cluster of pink branches). The bar on the right corner 
indicates 0.2 amino aicd substitution per amino acid for the branch length.  
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4. 5. 2. Binding of nootkatone to CYP260A1 
Nootkatone (NK) was able to induce a high spin shift. This was further used to determine the 
apparent dissociation constant (KD) and the maximum absorbance shift (Amax) obtained at the 
saturation with the nootkatone. The KD and Amax were calculated to be 7.87 (± 3.16) µM and 
2.27 (± 0.19) µM, respectively with the correlation coefficient of 0.99 (Figure III. 12). This 
showed that the nootkatone binds firmly with CYP260A1 and could acts as a good substrate. 
 
A B  
 
Figure III. 12: Type I binding spectra of CYP260A1 with nootkatone. Varying 
concentrations of nootkatone (dissolved in DMSO) were added to a solution of CYP260A1 
(10 µM) in 10 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol (v/v). The 
plot of the absorbance change vs. concentration of the substrate was fitted to a quadratic 
equation (in Sigma Plot), and apparent dissociation constant (KD) and the maximum 
absorbance shift (Amax) obtained at the saturation with the nootkatone were calculated. A. 
Difference spectra of CYP260A1 with nootkatone. Difference spectra, with the starting 
spectrum subtracted from the subsequent traces. The concentrations of nootkatone added were 
2.5 (black line), 5.0 (red line), 7.5 (green line), 10.0 (blue line), 12.5 (pink line), 15.0 (grey 
line),17.5 (brown line), 20.0 (dark green line), 30.0 (purple line) and 50.0 (dark grey) µM. B. 
Plot of absorbance change vs. concentration of nootkatone (from part A). Each of the 
titration was performed for three times. The mean values and their standard deviations of the 
difference between absorption maxima and minima were calculated. The points were fitted to 
a quadratic equation and yielded KD and Amax were 7.87 (± 3.16) µM and 2.27 (± 0.19), 
respectively, with a correlation coefficient of 0.99. 
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4. 5. 3. Conversion of nootkatone 
CYP260A1 can convert nootkatone (NK) into two major and some minor products after 
reconstitution with heterologous redox partners, Adx and AdR. During HPLC analysis, the 
substrate and the products were eluted within 30 min from the column. The substrate peak 
was obtained at 29.35 min. During 1 hr incubation of the in vitro assay, two major products 
(peak III and peaks IV at 1.77 min and 4.70 min, respectively) and two minor products (peak I 
and II at 1.22 and 1.59 min, respectively) were observed (Figure III. 13). Time dependent in 
vitro assays were done from 15 min to 2 hr but the product patterns were not changed (Figure 
III. 14). 
 
Figure III. 13: HPLC chromatogram of nootkatone conversion by CYP260A1. The 
chromatograms were recorded at 240 nm after HPLC separation with an isocratic system 
consisting of acetonitrile/water 40:60 at a flow rate of 1 ml/min on a C18 reverse phase 
column. The applied method was able to separate the products (red line) and the substrate, 
nootkatone, (brown line). The inset illustrates the magnified view of the product peaks I-IV.  
 
 
 
 
Figure III. 14: HPLC chromatogram of time dependent conversion of nootkatone by 
CYP260A1. The substrate nootkatone (brown line) and its conversion at 15 (black line), 30 
(red line), 45 (blue line), 60 min (green line) and 2 hr (purple line) are shown. The insets 
illustrates the magnified view of the product peaks I-IV. 
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4. 5. 4. GC-MS of nootkatone conversion 
During HPLC measurement, due to absence of the authentic standards of nootkatone 
derivatives, the product peaks were not assigned. Therefore, the conversion was also 
measured by GC-MS and mass spectra were obtained. The MS of peak III at 1.77 min and 
peak IV at 4.70 min were measured and their mass spectra were illustrated in Figure III.18 
and Table III. 4. The total mass of the peak III was 234 which suggested the possible 
hydroxylation or epoxidation. The product peak IV has the mass value 232 corresponding to a 
possible oxygenated product. It was further found that peak I (RT 1.22 min) was nonspecific 
and peak II (1.59 min) was the regioisomer of peak III (Figure III.15).  
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Figure III. 15: MS data of the product of nootkatone conversion. MS data of A. Peak III 
and B. Peak IV are shown. 
 
Table III. 4: Possible hydroxylation, epoxidation or oxidation of nootkatone by 
CYP260A1. The possible hydroxylation and epoxidation sites for nootkatone with respect to 
the total mass value are shown.  
 
Illustration of nootkatone structure  
The possible total mass value (m/z) of 234 could 
be due to hydroxylation or epoxidation 
1. hydroxylation could be at position 3, 6, 7,  
    8 or 9 (the potential hydroxylation position  
    at 15 would be m/z of 220.31) 
2. epoxidation at 1 and 10 or 13 and 14 (the  
    double epoxidation would reveal m/z of 
    250.33).  
3. Possible total mass value (m/z) of 232 could  
    be due to oxidation at 3, 6, 8 or 9. 
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5. Discussion 
CYP260A1 is one of the novel P450s family members found in Sorangium cellulosum So 
ce56. Though the heterologous proteins Adx and AdR were identified as electron transfer 
partners (Chapter I), the substrates of this P450 were not known. Three approaches were 
implemented to explore potential substrates. Firstly, the genomic informations of the adjacent 
and neighboring genes of CYP260A1 were analyzed but all the proximal genes encoded for 
hypothetical proteins (Chapter I). As a result, the genomic informations were not sufficient 
enough to predict a putative substrate. Secondly, a compound-library consisting of 17,000 
substances was screened and potential hits were identified. As a last approach, CYP260A1 
was aligned to find the closest homologues of well characterized sesquiterpenoid converting 
P450s to get a hint on a potential substrate.  
 
5. 1. Substrate screening and conversion of analogues compound. 
Type I and Type II substrate binding modes have been extensively studied demonstrating 
spectral changes in the heme−Soret absorption band (Schenkman, et al.1967; Kumaki et al, 
1978; Roberts et al, 2005). The screening of the compound library carried out during this 
study enabled us to find potential substrates (Type I binding ligands) and inhibitors (Type II 
binding ligands). As we are focused on finding some potential substrates, only Type I hits 
were considered. Unfortunately, most of the hits have a complex structure and were not 
natural substances. Nevertheless, the chemical structure of the screening hits enabled us to 
search for analogous compounds having some potential physiological or biotechnological 
application. The structure analogues of the Type I binding ligands were searched (Table III. 
3), and steroids (progesterone and DOC) were selected. CYP260A1 was able to hydroxylate 
both the steroids. Concerning the steroid hydroxylating bacterial cytochrome P450s, only very 
few bacteria has been described so far, among which 15β-hydroxylase (CYP106A2) from B. 
megaterium ATCC 13368 has been extensively studied (Lisurek, et al, 2004; Kang, et al, 
2004; Virus and Bernhardt, 2008). Several other steroid hydroxylases like CYP163A2 from 
Streptomyces roseochromogenes (Berrie et al., 1999, 2001), CYP105D1 of Streptomyces 
griseus (Taylor et al., 1999) and Arthrobacter simplex (Kominek et al, 1993) have also been 
described.  
 
5. 2. Microbial conversion of progesterone and 11-deoxycorticosterone (DOC) 
Progesterone and 11-deoxycorticosterone (DOC) are important steroids having direct 
pharmaceutical implications. DOC is a precursor molecule for the production of aldosterone. 
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The major pathway for the aldosterone production is in the adrenal glomerulosa zone of the 
adrenal gland in mammals. It is produced from progesterone via 21-hydroxylation, 11-
hydroxylation as well as 18-hydroxyltion and 18-oxidation (Figure III. 16) (Smith et al., 
2008).  
 
Figure III. 16: Conversion of DOC to aldosterone. 
 
There are several published reports concerning the microbial conversion of progesterone and 
DOC. Most of the progesterone converting enzymes are from filamentous fungus. P450 
mediated conversions of progesterone are shown in Bacillus sp., Mycobacterium sp. and 
Streptomyces sp.. The details of progesterone and DOC conversion in bacteria and fungus are 
illustrated in Table III. 5-6.  
 
Table III. 5: Summary of literature data on progesterone conversion in (a) bacteria and 
(b) fungus. 
a. Bacterial progesterone conversion 
Organism/enzyme Product Reference 
Bacillus megaterium ATCC 
13368,  
15β-Hydroxylase (CYP106A2) 
15β-OH-Progesterone 
11α-OH-Progesterone 
9α-OH-Progesterone 
6β-OH-Progesterone 
Berg et al., 1976 
Lisurek et al., 2004 
Kang et al., 2004 
Bacillus thermoglucosidasium 
Strain 12060 
cytochrome P450 
6β-OH-Progesterone 
6α-OH-Progesterone 
Androstenedion 
Sideso et al., 1998 
Bacillus stearothermophilus 
cytochrome P450 
20α-OH-Progesterone 
6β-OH-Progesterone 
6α-OH-Progesterone 
9,10-Seco-20α-OH-Progesteron 
6β,20α-DiOH-Progesterone 
Al-Awadi et al., 
2001, 2002 
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6α,20α-DiOH-Progesterone 
5α-Pregnen-3,6,20-trione 
6-Dehydroprogesterone 
 
Caldariella acidophila 4-Pregnen-3,6,20-trione 
5α-Pregnan-3,6,20-trione 
20α-OH-4-pregnen-3-one 
6β-OH-Progesterone 
6α-OH-Progesterone 
De Rosa et al., 
1981 
Mycobacterium smegmatis 17α-OH-Progesteron Jenkins et al., 2004 
Streptomyces rosepchromogenes  
strain 10984 
Progesterone-16α-Hydroxylase 
16α-OH-Progesterone  
2β,16α-DiOH-Progesterone 
Berri et al., 1999, 
2001 
Pseudomonas sp. Androsta-1,4-dien-3,17-dione 
17β-Hydroxyandrosta-1,4-diene-3-
on 
Dhar and Samanta., 
1993 
Rhododcoccus rhodochrous 
Baeyer-Villager-Monoxygenase 
Testosteronacetate Miyamoto et al., 
1995 
 
b. Fungal progesterone conversion 
Organism/enzyme Product Reference 
Acremonium strictum PTCC 5282 
 
15α-OH-Progesterone 
7β,15β-DiOH-Progesterone 
6β,11α-DiOH-Progesterone 
11α,15β-DiOH-Progesterone 
6β,11α,17α-TriOH-Progesterone 
11α,15β,17α-TriOH-Progesterone 
7β,15β,17α-TriOH-Progesterone 
Yoshihama, 1993 
Faramarzi et al., 
2003 
 
Aspergillus fumigatus 
 
11α-OH-Progesterone 
15β-OH-Progesterone 
7β-OH-Progesterone 
7β,15β-DiOH-Progesterone 
11α,15β-DiOH-Progesterone 
Smith et al., 1994 
Apergillus ochraceus  11α-OH-Progesterone Samanta et al., 
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cytochrome P450  1987 
Cochliobolus lunatus M118 
cytochrome P450 
11β-OH-Progesterone 
11β,14α-DiOH-Progesterone 
7α,14α-DiOH-Progesterone 
11-keto-14α-OH-Progesterone 
Vita et al., 1994 
Fusarium culmorium 15α-OH-Progesterone  
12β,15α-DiOH-Progesterone 
Kolek et al., 1998 
Mortierella isabellina 14α-OH-Progesterone Holland et al., 
1992, 95 
Mucor piriformis 
14α-Hydroxylase 
14α-OH-Progesterone 
5β,14α-DiOH-Progesterone 
6β,14α-DiOH-Progesterone 
7α,14α-DiOH-Progesterone 
7β,14α-DiOH-Progesterone 
Madyastha and 
Joseph, 1993, 1996 
Phycomyces blakesleeanus 7α-OH-Progesterone 
15β-OH-Progesterone 
6β-OH-Progesterone 
14α-OH-Progesterone 
15α-OH-Progesterone 
Smith et al., 1991 
Ahmed et al., 1995 
Penicillium decumbens 
ATCC10436 
15α-OH-Progesterone Holland et al., 
1995 
Rhizopus nigricans  
cytochrome P450 
11α-OH-Progesterone 
6β,11α-DiOH-Progesterone 
11α-OH-5α-pregnan-3,20-dione 
Kim and Kim, 
1991 
Trichophyton mentagrophyton 15α-OH-Progesterone 
11α-OH-Progesterone 
1-Dehydroprogesterone 
Clemons et al., 
1989 
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Table III. 6: Summary of literature data on DOC conversion in (a) bacteria and (b) 
fungi. 
a. Bacterial DOC conversion 
Organism/enzyme Product Reference 
Achromobacter 
kashiwasakiensis 
6β-OH-RSS (RSS:11-deoxycortisol) 
 
Tsuda et al., 1959 
 
Bacillus sp. 
 
6β-OH-RSS 
15α -OH-RSS 
14-OH-RSS 
Mahato and Garai, 
1986 
Bacillus megaterium ATCC 
13368; CYP106A2 
15β-OH-RSS 
6 β-OH-RSS 
11α-OH-RSS 
Virus and Bernhardt, 
2008 
Mycobaacterium smegmatis Prednisolon 
 
Ghanem and Yusef, 
1992 a and b. 
 
b. Fungal DOC conversion 
Organism/enzyme Product Reference 
Apergillus fumatus 
 
17α,21-Dihydroxy-5α-pregn-1-en-
3,20-dione 
17α, 20α,21-Trihydroxy-5α-pregn-1-
en-3-dione 
6β, 17α,21-Trihydroxypregn-4-en-
3,20-dione 
15β, 17α,21-Trihydroxypregn-5α-
pregnan-3,20-dione 
Garai and Mahato, 
1992 
 
Beauveria bassiana 11α-OH-RSS (Epihydrocortison) Zeng and Zhang, 1992 
Cunninghamella elegans 11α-OH-RSS (Epihydrocortison) 
11β-OH-RSS (Cortisol) 
Dlugonski et al., 1991 
Curvularia lunata 11β-OH-RSS (Cortisol) Zuidweg et al., 1962 
Hormodendrum olivaceum 15α-OH-RSS 
 
Bernstein et al., 1960 
Allen et al., 1961 
Spicaria simplicissima 15β-OH-RSS 
 
Bernstein et al., 1960 
Allen et al., 1961 
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5. 3. Triterpenoids and their biosynthesis in myxobacteria 
Triterpenes belong to a large group of compounds and are arranged in a four or five ring 
configuration of 30 carbons. They are assembled from a C5 isoprene unit through the 
cytosolic mevalonate pathway to make a C30 compound. It has been published that the 
triterpenoids function as an important pharmaceutical compounds and showed antimicrobial 
(Chen et al, 2008; Yadava and Jharbade, 2008; Horiuchi et al., 2007; Ovenden et al., 2005), 
antiviral (Wu et al., 2007) and cytotoxic (Zhang et al., 2008; Sogno et al, 2009) activities.  
 
The triterpenoid lipids like steroids are synthesized in almost all eukaryotic cells and are use 
to control the fluidity and flexibility of their cell membranes (Ourisson and Nakatani, 1994). 
In mammals, steroid hormones are mainly being synthesized in the adrenal and sexual glands 
(Bernhardt, 2006) and play an important role as glucocorticoids, mineralocorticoids and sex 
hormones. Whereas, bacteria rarely synthesize such compounds but frequently replace them 
with a different class of triterpenoids, the pentacyclic hopanoids as building blocks in their 
membranes (Ourisson et al., 1987; Kannenberg and Poralla, 1999). The biosynthesis of 
hopanoids and steroids starts from squalene, a linear precursor that is formed by condensation 
of six isopentenyl units. The biosynthetic steps giving rise to the cyclic products belong to the 
most complicated reactions in nature catalysed by one single protein, squalene-hopene cyclase 
(Shc), and different forms of (S)-2,3-oxidosqualene cyclases (Osc). The latter type of enzyme 
is responsible for the formation of the protosteryl cation, the first cyclization product of (S)-2, 
3-oxidosqualene (Figure III. 17) (Michal, 1999). A variety of further reactions leads to 
different cyclic triterpenes, which are the precursors of membrane sterols, such as the 
zoosterine cholesterol, the mycosterine ergosterol (both derived from lanosterol) and the 
phytosterine sitosterol (derived from cycloartenol).  
 
It has been shown that the steroids are found in other bacterial species like, Methylococcus 
capsulatus (Bird et al., 1971) for physiological regulations. The myxobacteria like, 
Nannocystis excedens and Polyangium sp. have also been shown to produce steroids (Kohl et 
al., 1983) that have rarely been found in prokaryotes. There are also several reports on the 
existence of steroids in other myxobacteria (Kohl et al., 1983). Interestingly, Bode et al., 
(2003), reported that myxobacteria Stigmatella aurantiaca also produce cycloartenol, the 
well-known first cyclization product of steroid biosynthesis in plants and algae. The 
physiological role of CYP260A1 in Sorangium cellulosum So ce56 is not know but the steroid 
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hydroxylase activity of CYP260A1 speculates to have some important role during its complex 
life cycle. 
 
 
Figure III. 17: Steroid biosynthesis in myxobacteria. All steroids except for cholesterol 
(shown in brackets) have been isolated from different myxobacterial strains. 
 
5. 4. Biotechnological application of CYP260A1  
A variety of steroids are widely used as anti-inflammatory, diuretic, anabolic, contraceptive, 
antiandrogenic, progestational, and anticancer agents. So nowadays, the multi-step 
combinations of chemical and biochemical processes are used in the industrial production of 
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steroids (Farnandes et al., 2003). The immediate shortfall of chemical synthesis are regarding 
the hazard, cost and time. Microorganisms or their isolated enzymes became a cheap and 
efficient alternative. The importance of microbial biotechnology in the production of steroid 
drugs and hormones was realized for the first time in 1952 when Murray and Peterson of 
Upjohn Company patented the process of 11α-hydroxylation of progesterone by a Rhizopus 
sp (Murray and Peterson, 1952). The 11α-, 11β-, and 16α-hydroxylations are now exclusively 
achieved in the steroid industry by microbial transformations. The other hydroxylations that 
seem to have potential for industrial exploitation are 9α- and 14α-hydroxylations. 14α-
hydroxyandrost-4-ene-3,17-dione is a useful intermediate for the preparation of hormones. 
14α-hydroxyandrost-4-ene-3,6,17-trione possess androgen activity and are useful inhibitors 
for breast cancer cells (Yoshioka et al., 1994). The detailed study of the microbial 
biotransformations of steroids concerning the hydroxylation and C-C cleavage was reviewed 
before (Mahato and Garai, 1997; Donova et al., 2005; Malaviya and Gomes, 2008 ). 
 
Concerning this, as CYP260A1 of So ce56 was hydroxylating the steroids, the potential 
biotechnological importance was more pronounced. Beside this, as the biosynthesis of steroid 
pathway in myxobacteria has already been shown, the steroid hydroxylation with CYP260A1 
could have some important physiological significance too. Furthermore, CYP260A1 was also 
able to convert nootkatone into potentially hydroxylated and/or epoxidated products. This 
gives a new insight to study the conversion of several other sesquiterpenes, having some 
pharmaceutical and biotechnological applications. The importance of novel P450, 
CYP260A1, needs further exploration.  
 
6. Outlook 
The novel myxobacterial cytochrome P450 CYP260A1 from Sorangium cellulosum So ce56 
was found to be a potential steroid hydroxylase and sesquiterpene converter. These 
preliminary results give a new insight for the novel bacterial P450 for the conversion of 
several other steroids and terpenoids having some pharmaceutical and biotechnological 
applications. The physiological role of CYP260A1 during the life cycle of So ce56 for steroid 
hydroxylation, the less predominated in bacterial system, could potentially be a new insight 
for further studies.  
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APPENDIX I 
A. INSTRUMENTS 
Instrument Characteristics Company 
FPLC Äkta prime  
Electrophoresis unit  Bio-Rad 
Autoclave  LVSA 50/70 Zirbus IMM 20 
Balance  
 
KB 600-2 
SBA 62 
SBC 31 
Kern 
Scaltec 
Scaltec 
Centrifuge 
  
Pico Fuge HF-120 
3K30 (rotors 19776, 12153) 
2K15 (rotor 12148) 
Avanti J-20 
Himac CP75β (Ultra-centrifuse) 
Stratgene 
Sigma  
Sigma  
Beckman Coulter 
Hitachi 
CD-spectrometer  Jasco 715  
Electroporator  EasyjecT Prima Equibio 
FPLC Äkta prime  
Freezer Revco Ultima II  
Forma Scientific  
Thermo Scientific 
Thermo Scientific 
Gel dryer  Model 583 Bio-Rad 
HPLC system  PU-2080Plus Intelligent HPLC-
Pump, AS-2050 Intelligent Sampler, 
DG-2080-53 3-Line Degasser, 
LG-2080-02 Ternary-Gradient Unit, 
LC-Net II/ADC, 
UV-2075Plus Intelligent UV/VIS-
Detector 
Jasco 
Incubator  Heraeus 
Incubation shaker Multitron II 
Innova "4230" 
Infors HT 
New Brunswick 
Scientific 
Microwave oven  Siemens 
Peltier thermal cycler DNA Engine Biorad 
pH meter 766 Calimatic Knick 
Power supply unit PowerPac 300 
ECPS 3000/150 
Bio-Rad 
Pharmacia 
SDS gel electrophoresis unit Mighty Small II Hoefer 
SpeedVac  UniEquip Univapo 
Thermocycler  MJ Research 
Thermomixer  5436 Eppendorf 
Ultrasonic desintegrator USD-30 Emich Ultraschall 
UV/VIS Spectrophotometer UV-2100 
UV-2101 PC 
Shimadzu 
Vortex VF2 VF2 IKA RLabortechnik 
   
 B. CHEMICALS 
All commercially obtained materials used in this work were of the finest quality available 
purchased from the companies listed below: 
Amersham Pharmacia Biotech 
Bio-Rad Laboratories 
BioTez GmbH 
Biozym GmbH 
Clontech Laboratories GmbH 
Difco Laboratories 
Dulbeco 
Fluka AG 
Gibco/BRL GmbH 
Invitrogen BV 
Kodak 
Merck 
MWG Biotech GmbH 
New England Biolabs 
Promega 
Qiagen 
Roche Molecular Biochemicals 
Serva GmbH & Co KG 
Sigma-Aldrich 
Stratagene 
 
C. ENZYMES 
Bioline 
Stratagene Ltd, Cambridge, UK 
New England Biolabs 
Boehringer  
CLONTECH Laboratories  
MBI Fermentas  
Promega Corporation 
 
C. KITS 
 
Purpose Characteristics Company 
Plasmid DNA purification NucleoBond AX 100 Macherey-Nagel  
PCR clean-up Gel 
extraction 
NucleoSpin Extract II Macherey-Nagel 
Protein quantification BC Assay Uptima 
 
D. COLUMN MATERIALS FOR PROTIEN PURIFICATION 
Affinity chromatography: Talon® Resin, Metal affinity resin, Clontech 
Size exclusion chromatography: Superdex-75, GE Healthcare. 
 
E. CONSUMABLES 
Amersham Pharmacia Biotech 
Fisher Scientific 
Falcon 
 Machery-Nagel GmbH & Co KG 
Millipore 
Carl Roth GmbH 
Qiagen GmbH 
 
APPENDIX II 
 
II. 1. BUFFERS AND COMMONLY USED SOLUTIONS 
a. Buffer for chemical competent cell preparation 
TFP buffer 
A B 
1M 
CH3COOK 
3 ml 1M MnCl2 5 ml 
1M KCl 10 ml 
1M CaCl2 1 ml 
Glycerol 12 ml  
Fill water up to 80 ml 
and set pH to 6.1  
autoclave separately 
Mix A and B and adjust the final volume of 100 ml. filter 
sterilize and stored at 4°C. 
 
II. 2. Common Buffers 
a. Sodium phospate buffer (50 mM, pH 7.4) 
1M Na2HPO4 46.6 ml 
1M NaH2PO4 3.4 ml add d/w up to 1000 ml 
b. Potassium phosphate buffer (40 mM, pH 7.3) 
1M K2HPO4 40 ml 
1M KH2PO4 10 ml add d/w up to 1000 ml 
c. Potassium phosphate buffer (10 mM, pH 7.4) 
1M K2HPO4 8.4 ml 
1M KH2PO4 1.6 ml add d/w up to 1000 ml 
 
II.3. BUFFERS AND SOLUTIONS FOR AGAROSE GEL ELECTROPHORESIS 
10 x TAE Buffer 
 
Tris base 242.28 g  
EDTA-Na 18.61 g 
Acetic acid 60.05 ml 
 pH 8.5 ± 0.2 Add  
d/w up to 1000 ml 
10 x Loading buffer 
Bromophenol 
blue 
2.5 mg 
Xylencyanole 2.5 mg 
Glycerol 300 µl 
add d/w up to 1 ml 
 
  
 
 
 
 
APPENDIX III 
 
1. Buffers and solutions for polyacrylamide gel electrophoresis 
 
separating gel Final acrylamide concentration Stock solutions 
10% 12% 15% 
4 x LT   3.75 ml 3.75 ml 3.75 ml 
10% APS  75 µl 75 µl 75 µl 
dest.H2O ad 15 ml ad 15 ml ad 15 ml 
30% AA/Bis  5.0 ml 6.0 ml 7.5 ml 
TEMED 7.5 µl 7.5 µl 10 µl 
 
stacking gel Stock solutions 5% acrylamide concentration 
4 x UT 2.5 ml 
10% APS 50 µl 
Dest.H2O ad 10 ml 
30% AA/Bis 1.6 ml 
TEMED 5 µl 
 
4 x Buffer for 
separating gel (LT) 
1.5 M Tris/Cl, pH=8,8 
0.4% SDS 
4 x Buffer for 
stacking gel (UT) 
0.5 M Tris/Cl, pH=6,8 
0.4% SDS 
2 x SDS loading 
buffer  
125 mM Tris/Cl, pH=6.8 
20% Glycerol 
4% SDS 
β-mercaptoethanol 10% 
Bromphenol blue 0.004% 
Staining solution  0.1% Coomassie Brilliant Blue G-250  
40% Methanol 
10% Acetic acid 
Destaining 
solution  
25% Methanol 
10% Acetic acid 
 
2. Buffers and solutions for protein purification 
 
A. PMSF stock - 100 mM PMSF in isopropanol 
 
B. Cell lysis buffer (Buffer A) 
50 mM Sodium phosphate buffer, pH 8.0 
300 mM NaCl 
20% Glycerin 
10 mM imidazole 
50 x TARE Buffer [Tris/Acetate/reduced EDTA, pH 8.0] 
Tris 24.1 g 
Acetic acid 5.7 ml 
5 mM EDTA 1 ml 
2M 
Tris/Acetate, 
pH 8.0 
 Add d/w up to 100 ml 
 C. Buffer for affinity chromatography 
i. Equilibrium buffer (Buffer B)  
50 mM Sodium phosphate             
buffer, pH 8.0 
300 mM NaCl 
20% Glycerin 
20 mM imidazole 
ii. Elution buffer (Buffer C) 
50 mM Sodium phosphate buffer, pH 
8.0 
300 mM NaCl 
20% Glycerin 
150 mM imidazole 
D. Buffer for size exclusion chromatography (Buffer D) 
Potassium phosphate buffer (10 mM, pH 7.4) containing 20% glycerol. 
E. Buffer E  
10mM potassium phosphate buffer, pH 7.4 containing 20% glycerol and 3 mM 
DTT. 
 
APPENDIX IV 
 
1. Culture media 
i. TB media 
A 
 
Bacto tryptone 12 g 
Bacto yeast 
extract 
24 g 
Glycerin 4 ml 
Add d/w up to 900 ml and 
autoclave it 
B 
 
KH2PO4 2.31 g 
K2HPO4 12.54 g 
Add d/w up to 100 ml 
and autoclave it 
Mix solution A and B for use  
 
ii. SOC Medium 
 
Trypton 2% 
Yeast extract 0.5%  
NaCl 10 mM  
KCl 2.5 mM  
MgCl2 10 mM  
Adjust pH 7.0, autoclave, add 20mM glucose and filter sterilize by 0.22-micron filter. 
 
  
2. ANTIBIOTICS AND OTHERS 
                                          
Antibiotics Stock solution Solvent Working conc. 
Ampicillin 100 mg/ml water 100 µg/ml 
Kanamycin 50 mg/ml water 50 µg/ml 
Chloramphenicol 50 mg/ml ethanol 50 µg/ml 
 
APPENDIX V 
1. Vector map of pET17b 
 
 2. Vector map of pCWori+. The vector map with three promotors (lacUV5, tac1 and tac2) 
and multiple coloning site (EcoRI, XbaI, SalI, PstI and HindIII are shown. The P450 inserts 
of So ce56 having same restriction sites are shown in same color. Each P450 shown in green, 
black and purple has XbaI, EcoRI and HindIII sites, respectively, at C-terminal after hexa-
histidine tag..  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX VI 
Mass spectra of A. apo-mass, and B. holo-mass of CYP109C1, CYP109C2, CYP109D1, 
CYP260A1, CYP264A1, CYP264B1 and CYP266A1 of So ce56 are shown. The mass of 
the P450s was measured in collaboration with Aurélie Même, Laboratoire de Dynamique et 
Structure Moléculaire par Spectrométrie de Masse, Institut de Chimie, Starsbourg, France. 
Mass spectrometric studies were performed in the positive ion mode using an ESI-TOF 
(Time-of-flight) mass spectrometer (microTOF, Bruker Daltonics, Bremen, Germany).  
 
Each peak on the spectrum shows the corresponding P450 mass with different state of charge, 
for example, in the spectrum of CYP109C1 (O7380AM), the peak at 916.98 Da 
corresponding to the P450 with 50 charges (50 protons on the protein). As the abscissa of the 
spectrum is in m/z, the real mass of the protein is obtained by multiplying the mass 916.98 by 
50. Software coupled with the system calculates the real mass for each peak according to its 
state of charge and calculates the average mass for all the peaks.  
 
A. Mass spectra (apo- mass) of different P450s of So ce56 (Table I. 14 in text) 
 
 
  
 
B. Mass spectra (holo- mass) of different P450s of So ce56 (Table I. 14 in text) 
 
  
APPENDIX VII 
 
A. SCREENING RESULTS FOR CYP109C1 
 
CYP109C1 Type I hits Compound code (Chem_Div nos)/ 
Remarks 
 31649, C074-0114  (also for CYP260A1)  
Type I- Primary screening 
Type I- 1st validation 
Type II- Clear  with concentration dependent  
validation 
 32245, 5701-2503 
Type I- Primary screening 
Type II- 1st validation 
Type I- Clear  with concentration dependent  
validation 
 33152, 7406-0023  
(also for CYP260A1) 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 33160, 7746-0008 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 33629, 8006-6674 
Type II- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 34062, 8012-8381 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 34355, 8012-8982 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 
 
 
 
 
 
 
 35049, 8016-2764 
Type II- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 35443, E545-0590 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 35444, C047-0116 
Type II- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 35447, E545-0637 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 35449, E545-0638 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 36880, C499-0591 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 37517, C499-0591 
(also forCYP109C2 and CYP266A1) 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 37518, C800-0101 
Type II- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
 
 38786, E213-1274 
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear  with concentration dependent  
validation 
CYP109C1 Type II hits 
 
Compound code/Remarks 
 
 31305, 7395-3009 
Type II- Primary screening 
TypeII- 1st validation 
Not Clear  with concentration dependent  
validation 
 31632, 5451-0327 
Type II- Primary screening 
TypeII- 1st validation 
Not 100% Clear  with concentration 
dependent  validation 
 
 33182, 7462-0037 
(also for CYP109C2, CYP260A1 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 33202, 7462-0046 
(also for CYP109C2, CYP260A1 and 
CYP266A1)  
Type II- Primary screening 
Not clear with 1st validation 
Type II- Clear with concentration dependent  
validation 
 33463, D155-0026  
(also for CYP109C2, CYP260A1 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 33469, D155-0050 
(also for CYP109C2, CYP260A1 and 
CYP266A1)  
Type II- Primary screening 
Not clear with concentration dependent  
validation 
 
 34218, 8013-4052 
(also for CYP109C2, CYP260A1 and 
CYP266A1)  
Type II- Primary screening 
Not clear in 1st validation 
Type II- Clear with concentration dependent  
validation 
 35863, C169-0140 
(also for CYP260A1)  
Type II- Primary screening 
Not clear in 1st validation 
Type II- Clear with concentration dependent  
validation 
 35933, C169-0144 
(also for CYP109C2, CYP260A1 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear in 1st validation 
Type II- Clear with concentration dependent  
validation 
 2371-0057 
Type II- Primary screening 
Type II- Clear in 1st validation 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
B. SCREENING RESULTS FOR CYP109C2 
CYP109C2 Type I hits Compound code/Remarks 
 31358, 5089-1245 
(also for CYP266A1) 
Type I- Primary screening 
Not clear with concentration dependent  
validation 
 31649, 5451-0327 
(also for CYP266A1) 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 34168, 8013-0849 
Type II- Primary screening 
Type II- in first validation 
Type I- Clear  with concentration dependent  
validation 
 35086, 8017-2885 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 35449, E545-0638 
Type I- Primary screening 
Not clear in first validation 
Type I- Clear  with concentration dependent  
validation 
 35862, C169-0253 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 37517, C499-0591 
(also for CYP266A1 and CYP260A1) 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
CYP109 Type II hits 
 
Compound code/Remarks 
 31506, 5149-0173 
Type II- Primary screening 
Not clear with concentration dependent  
validation 
 
 
 
N
O
NC
 
 
 38219, C721-0718 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation but not 100% sure 
 
 
 31518, D097-0031 
Type II- Primary screening 
Not clear with concentration dependent  
validation 
 31632, 5451-0327 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation  
 31892, 5436-1027 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation  
 32628, C276-0392 
Type II- Primary screening 
Not clear with concentration dependent  
validation 
 
 
 32873, 6257-0356 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation  
 33182, 7462-0037 
(also for  CYP109C1 and CYP266A1) 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation  
 33202, 7462-0046 
(also for CYP109C1, CYP266A1 and 
CYP260A1)  
Type II- Primary screening 
Type II- Clear  with concentration  validation 
 33463, D155-0026  
(also for CYP109C1, CYP266A1 and 
CYP260A1)  
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 
  33469, D155-0050 
(also for CYP109C1, CYP266A1 and 
CYP260A1)  
Type II- Primary screening 
Type II- Clear  with concentration dep. Val.  
 34218, 8013-4052 
(also for CYP109C1, CYP266A1 and 
CYP260A1)  
Type II- Primary screening 
Type II- Clear  with conc. Dep. Val. 
 34484, 8015-3948 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 35124, 8016-9750 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 35444, C047-0116 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 35820, 8012-4720 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 35822, C119-0040 
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 37518, C800-0101  
(CYP260A1)  
Type II- Primary screening 
TypeII- 1st validation 
Type II- Clear  with concentration dependent  
validation 
 40120, K815-0059 
(also for CYP266A1)  
Type II- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 
 
C. SCREENING RESULTS FOR CYP260A1 
CYP260A1 Type I hits 
 
Compound code/Remarks 
 N062-0006 
Type I- Primary screening 
Type I- Clear with validation 
 
 N045-0002 
Type I- Primary screening 
Type I- Clear with validation 
 
 R092-0022 
Type I- Primary screening 
Type I- Clear with validation 
 
 31649, C074-0114 
(also for CYP109C2  and CYP266A1)  
Type I- Primary screening 
Not clear with concentration dependent  
validation 
 
 33152, 7406-0023  
 (also for CYP109C1  )  
Type I- Primary screening 
Not clear in 1st validation 
 
 33160, 7746-0008 
Type I- Primary screening 
Not clear with concentration dependent  
validation 
 
 
 
 
 
 
 
 33780, 8016-0529 
Type I- Primary screening 
Not 100% clear with concentration 
dependent  validation for Type I 
 
 33883, E938-0001 
Type I- Primary screening 
Not 100% clear with concentration 
dependent  validation for Type I 
 
 34218, 8013-4052 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type I- Clear with concentration dependent  
validation 
 
 34286, 8013-6360 
Type II- Primary screening 
Type I- Clear with concentration dependent  
validation 
 
 
 34723, 8015-0565 
Type I- Primary screening 
Type I- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 36260, K511-0020 
Type I- Primary screening 
Type I- Clear with concentration dependent  
validation 
 
 37517, C499-0591 
(CYP266A1)  
Type I- Primary screening 
Not clear in 1st validation 
Type I- Clear with concentration dependent  
validation but not 100% sure 
 
 37633, C614-0577 
Type II- Primary screening 
Type II- 1st validation  
Type I- Clear with concentration dependent  
validation but not 100% sure 
 
 37880, C652-0093 
Type I- Primary screening 
Type I- Clear with concentration dependent  
validation but not 100% sure 
 
 
CYP260A1 Type II hits 
 
Compound code/Remarks 
 31132, 4588-0118 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 31359, 4984-3625 
Type II- Primary screening 
Not clear with concentration dependent  
validation 
. 
 
 31472, 5183-0085 
Type II- Primary screening 
Type II- 1st validation 
Type II- Clear with concentration dependent  
validation 
 
 31632, 5451-0327 
Type II- Primary screening 
Type II- 1st validation 
Type II- Clear with concentration dependent  
validation 
 
 32990, 6550-0046 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 33182, 7462-0037 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 33202, 7462-0046 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 33463, D155-0026 
(also for CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 33469, 8008-4502 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- 1st validation 
Type II- Clear with concentration dependent  
validation 
 
 34103, 8012-7514 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Not clear with concentration dependent  
validation 
 
 35081, 8016-3010 
Type II- Primary screening 
Type I- Clear with concentration dependent  
validation 
 
 35108, 8017-4048 
Type II- Primary screening 
Not clear 1st validation 
Type I- Clear with concentration dependent  
validation 
 
 35448, C047-1182 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 35450, C047-1207 
(also for CYP266A1) 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 35863, C169-0140 
(also for CYP109C1) 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 
 
  
 35933, C169-0144 
Type II- Primary screening 
Type II- Not clear 1st validation 
Type II- with concentration dependent  
validation but not 100% sure 
 
 37518, C800-0101 
(CYP109C1) 
Type II- Primary screening 
Type II- with concentration dependent  
validation but not 100% sure 
 
 37635, C614-0578 
Type II- Primary screening 
Type II- with concentration dependent  
validation but not 100% sure 
 
 
 
 
D. SCREENING RESULTS FOR CYP266A1 
Screening hits for CYP266A1  
CYP266A1 Type I hits 
 
Compound code/Remarks 
 31021, 4373-3072 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 31358, 5089-1245  
(also for CYP109C2 
Type I- Primary screening 
Not clear  with concentration dependent  
validation 
 
 31649, C074-0114 
(CYP109C2 and CYP260A1) 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 31655, 5237-0515 
Type I- Primary screening 
Not clear  with concentration dependent  
validation 
 
 35862, C169-0253 
Type I- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 36386, C240-0165 
Type I- Primary screening 
Type II- Clear  with concentration dependent  
validation 
 
 
 
 
 
 
 37517, C499-0591 
(also for CYP109C2 and CYP260A1) 
Type I- Primary screening 
Not 100% clear  with concentration 
dependent  validation 
 
 39394, K261-0593 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 24650 – 8012-0674 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 24025 – C361-2424 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 24027 – C361-2436 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 25722 – 8006-1508 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 25979 – 4334-1827 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 25943 – 2922-2951 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 
 30373 – 3793-2107 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 25101 – 3769-2011 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 1563-0004 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
 N050-0003 
Type I- Primary screening 
Type I- Clear  with concentration dependent  
validation 
 
CYP266A1 Type II hits  Compound code/Remarks 
 
 31632, 5451-0327 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 33182, 7462-0037  
(also for CYP109C1, and CYP109C2)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 33202, 7462-0046 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 
 33463, D155-0026 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 33469, D155-0050 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 34286, 8013-6360 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 34218, 8013-4052 
(also for CYP109C1, CYP109C2 and 
CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 35049, 8016-2764 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 35444, C047-0116 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 35450, C047-1207 
(also for CYP266A1)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 
 
 35613, C066-3765 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 35820, C119-0038 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 36261, C200-3873 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 36293, K310-0067 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 36293, K310-0067 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 39637, K216-1373 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
 
  
 
 
 
 40120, K815-0059 
(also for CYP109C2)  
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 25051 – 5509-0020 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 29543 – 3442-0170 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 24247 – 8003-6142 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 26844 – 8017-8439 
Type II- Primary screening 
Type II- Clear with concentration dependent  
validation 
 
 
 
 
 
 
D. Representative Type I binding spectra for the hits of CYP260A1 during screening. 
During screening only major shifts was considered. The represented Type I hits are shown 
with the peak maxima at 390 nm. The ligands 25796 (black line with yellow box), 25800 
(pink line with pink box), 25826 (brown line with solid brown circle), 26173 (blue line with 
blue bar) and 26267 (red line with blue mark) are shown. The serial number assigned for each 
spectrum represents the Chem-Div library number. The screening was done in 384 wells 
micro titer plate in an automated pipette robot Cyclone ALH 3000 Workstation as described 
in ‘Methods’ (Chapter I. 3. 2. 8). The screening was done with 1.5 µM of CYP260A1 and 0.5 
µM of ligands in 50 µl assay buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 20% glycerin, 
0.05% Tween-20 and 1 mM DTT). The wavelength of 350-450 nm with an interval of 10 nm 
was fixed with Tecan-Safire plate-photometer and the absorbance of the substances were 
recorded and analyzed.   
 
 
 
APPENDIX VIII 
A. Alignment of P450s of So ce56 with known fatty acid hydroxylases. The amino acid 
sequences of the fatty acid hydroxylating P450s [CYP102A1 from Bacillus megaterium; 
P450BioI (CYP107H1), CYP102A2, CYP102A3 and CYP152A1 from Bacillus subtilis, 
CYP152A from Clostridium acetobutylicum, CYP105D5 from Streptomyces coelicolor A(3)2 
and P450foxy from Fusarium oxysporum] were accessed from EMBL database. They were 
aligned in Clustwl W2. A tree was generated to find out the relatedness of So ce56 with 
known fatty acids  
 
  
  
  
   
  
B. The amino acid sequences of the fatty acid hydroxylating P450s [CYP102A1 from 
Bacillus megaterium; P450BioI (CYP107H1), CYP102A2, CYP102A3 and CYP152A1 from 
Bacillus subtilis, CYP152A from Clostridium acetobutylicum, CYP105D5 from Streptomyces 
coelicolor A(3)2 and P450foxy from Fusarium oxysporum] were accessed from EMBL 
database. They were aligned with CYP109 family of So ce56 in Clustwl W2. A tree was 
generated to find out the relatedness of CYP109 family of So ce56 with that of known fatty 
acids hydroxylase P450s. 
 
 
 
C. Alignment of P450s of So ce56 with known terpenoid hydroxylases. The amino acid 
sequences of terpenoid hydroxylating P450s [CYPtdtD(CYP226A3)  from Pseudomonas 
diterpeniphila, CYPDitQ from Pseudomonas abietaniphla, and CYP226A1  from Burkholderia 
xenovorans] were accessed from EMBL database. They were aligned with P450s of So ce56 
in Clustwal W2. A unrooted tree was generated to find out the relatedness of So ce56 P450s 
with those P450s. 
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